Cancer evidence library
Prostate Cancer
PubMed-indexed evidence for localized, advanced, metastatic, and treatment-resistant prostate cancer.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Living evidence synopsis
What the current PubMed collection shows.
Alexandria currently organizes 661 non-retracted PubMed-indexed records for Prostate Cancer. The structured collection includes 10 guideline or consensus records, 104 evidence syntheses/systematic reviews/meta-analyses, and 92 randomized or phase III studies. 214 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 466 of 661 included records.
Evidence data
Research landscape
Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.
Publication activity
Latest 12 represented yearsRecords by publication year
1
2016
1
2017
1
2019
4
2020
8
2021
9
2022
5
2023
12
2024
36
2025
584
2026
Evidence composition
Study designs
Transparency
Conflict-of-interest reporting
Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.
Abstract result signals
Extracted result direction
Reported outcomes
Numerical results extracted from PubMed abstracts
Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.
Non-pooled ratio measures
Reference = 1.0
Hazard, risk, and odds ratios reported in abstracts
0.250.51.02.04.0
View extracted numerical results 60
| Publication | Outcome | Measure | Reported value | Source |
|---|---|---|---|---|
| Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.European urology oncology · 2026 | not_reported | Hazard Ratio | 2.1 p = 0.01 | PMID 39613566 |
| Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.European urology oncology · 2026 | not_reported | Hazard Ratio | 0.6 95% CI 0.1–2.4 p = 0.45 | PMID 39613566 |
| Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.European urology oncology · 2026 | not_reported | Hazard Ratio | 2.0 95% CI 1.1–3.64 p = 0.007 | PMID 39613566 |
| Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer.European urology oncology · 2026 | not_reported | Odds Ratio | 60.0 | PMID 40335398 |
| Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer.European urology oncology · 2026 | not_reported | Percentage Comparison | 53.0percent vs 44.0percent p = 0.01 | PMID 40335398 |
| Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer.European urology oncology · 2026 | not_reported | Percentage Comparison | 51.0percent vs 39.0percent p = 0.01 | PMID 40335398 |
| Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis.European urology oncology · 2026 | not_reported | Hazard Ratio | 0.42 95% CI 0.21–0.82 | PMID 40645821 |
| Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis.European urology oncology · 2026 | not_reported | Hazard Ratio | 0.53 95% CI 0.3–0.93 | PMID 40645821 |
| Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis.European urology oncology · 2026 | not_reported | Hazard Ratio | 0.58 95% CI 0.41–0.83 | PMID 40645821 |
| Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial.European urology · 2026 | not_reported | Odds Ratio | 3.0 | PMID 40685282 |
| Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.European urology oncology · 2026 | not_reported | Odds Ratio | 160.0 | PMID 41033927 |
| Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.European urology oncology · 2026 | adverse events | Percentage Comparison | 65.4percent vs 30.2percent | PMID 41033927 |
| Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.European urology oncology · 2026 | not_reported | Hazard Ratio | 1.9 p = 0.02 | PMID 41033927 |
| Enhancing Prostate Cancer Screening Literacy Through Shared Decision-Making: Results of a Randomized Trial in a Vulnerable Population.Urology practice · 2026 | not_reported | Odds Ratio | 5.811 95% CI 1.885–17.909 P = .002 | PMID 41223063 |
| Enhancing Prostate Cancer Screening Literacy Through Shared Decision-Making: Results of a Randomized Trial in a Vulnerable Population.Urology practice · 2026 | not_reported | Odds Ratio | 4.384 95% CI 1.566–12.278 P = .002 | PMID 41223063 |
| Enhancing Prostate Cancer Screening Literacy Through Shared Decision-Making: Results of a Randomized Trial in a Vulnerable Population.Urology practice · 2026 | not_reported | Odds Ratio | 5.33 95% CI 1.749–16.246 P = .002 | PMID 41223063 |
| Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.The Journal of urology · 2026 | not_reported | Percentage Comparison | 58.0percent vs 58.0percent P < .001 | PMID 41270377 |
| Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.The Journal of urology · 2026 | not_reported | Percentage Comparison | 30.0percent vs 30.0percent P < .001 | PMID 41270377 |
| Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.The Journal of urology · 2026 | not_reported | Percentage Comparison | 62.0percent vs 74.0percent P = .023 | PMID 41270377 |
| Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.The Journal of urology · 2026 | not_reported | Percentage Comparison | 34.0percent vs 48.0percent P = .023 | PMID 41270377 |
| Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.The Journal of urology · 2026 | not_reported | Percentage Comparison | 39.0percent vs 56.0percent P = .023 | PMID 41270377 |
| Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.The Journal of urology · 2026 | not_reported | Percentage Comparison | 25.0percent vs 34.0percent P = .023 | PMID 41270377 |
| Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Prostate cancer and prostatic diseases · 2026 | not_reported | Odds Ratio | 1.17 P = 0.009 | PMID 41298852 |
| Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Prostate cancer and prostatic diseases · 2026 | not_reported | Odds Ratio | 1.2 P = 0.009 | PMID 41298852 |
| Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Prostate cancer and prostatic diseases · 2026 | not_reported | Odds Ratio | 0.79 P = 0.009 | PMID 41298852 |
| Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Prostate cancer and prostatic diseases · 2026 | not_reported | Odds Ratio | 0.94 P = 0.009 | PMID 41298852 |
| Prostate MRI learning curves: establishing training benchmarks for radiology and urology trainees.European radiology · 2026 | not_reported | Odds Ratio | 1.24 | PMID 41402568 |
| Prostate MRI learning curves: establishing training benchmarks for radiology and urology trainees.European radiology · 2026 | not_reported | Odds Ratio | 2.01 | PMID 41402568 |
| Prostate MRI learning curves: establishing training benchmarks for radiology and urology trainees.European radiology · 2026 | not_reported | Odds Ratio | 0.82 | PMID 41402568 |
| Prostate MRI learning curves: establishing training benchmarks for radiology and urology trainees.European radiology · 2026 | not_reported | Odds Ratio | 0.61 | PMID 41402568 |
| Prostate MRI learning curves: establishing training benchmarks for radiology and urology trainees.European radiology · 2026 | not_reported | Percentage Comparison | 88.0percent vs 89.9percent | PMID 41402568 |
| Prostate MRI learning curves: establishing training benchmarks for radiology and urology trainees.European radiology · 2026 | not_reported | Percentage Comparison | 84.6percent vs 90.0percent | PMID 41402568 |
| [18F]-Fluciclovine or [68Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial.European urology · 2026 | not_reported | Percentage Comparison | 84.0percent vs 73.0percent p = 0.01 | PMID 41412908 |
| Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial.European urology · 2026 | not_reported | Hazard Ratio | 1.03 95% CI 0.75–1.41 p = 0.87 | PMID 41494929 |
| Subcutaneous local anaesthetic after transperineal prostate biopsy under general anaesthesia: a randomised trial.BJU international · 2026 | not_reported | Odds Ratio | 20.0 | PMID 41502396 |
| Subcutaneous local anaesthetic after transperineal prostate biopsy under general anaesthesia: a randomised trial.BJU international · 2026 | not_reported | Percentage Comparison | 34.1percent vs 10.6percent | PMID 41502396 |
| Impact of image-guided radiation therapy with intraprostatic seeds on long-term toxicity in prostate cancer patients undergoing risk-adapted intensification therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 | adverse events | Hazard Ratio | 0.66 95% CI 0.46–0.95 p = 0.021 | PMID 41533295 |
| Impact of image-guided radiation therapy with intraprostatic seeds on long-term toxicity in prostate cancer patients undergoing risk-adapted intensification therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 | adverse events | Hazard Ratio | 0.88 p = 0.053 | PMID 41533295 |
| Impact of image-guided radiation therapy with intraprostatic seeds on long-term toxicity in prostate cancer patients undergoing risk-adapted intensification therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 | adverse events | Percentage Comparison | 13.0percent vs 18.0percent p = 0.053 | PMID 41533295 |
| Impact of image-guided radiation therapy with intraprostatic seeds on long-term toxicity in prostate cancer patients undergoing risk-adapted intensification therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 | adverse events | Hazard Ratio | 1.98 95% CI 1.3–2.59 p = 0.002 | PMID 41533295 |
Research transparency
Funding and conflicts of interest
Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.
NCI NIH HHS158
NHLBI NIH HHS40
NIH HHS38
National Natural Science Foundation of China12
National Cancer Institute (NCI)12
National Institutes of Health (NIH)11
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)7
NIA NIH HHS7
View records with declared financial or industry relationships 12
Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.
A.R.B. declares grants outside this work from Prostate Cancer UK (including for the TRANSFORM trial of prostate cancer screening), NIHR, Breast Cancer Research Foundation, MRC, Cancer Research UK; Royalties from Cancer Research UK; Consulting fees from QM Innovation (Median Technologies) and Kings College London Talent Bank (NHS Galleri trial). M.R. declares grants outside this work from Cancer Research UK, Public Health England, and the UK National Screening Committee; fees for attendance and travel cost reimbursement at advisory board and other meetings organised by Hologic. P.S. declares grants outside this work from Yorkshire Cancer Research (IMProVE trial of prostate cancer screening), Cancer Research UK, NIHR. P.S. is a paid member of the scientific advisory board for GRAIL. G.F. reports research funding outside this work from NIHR, Cancer Research UK, and Prostate Cancer Research. R.G. reports grants outside this work from Prostate Cancer UK (including for the TRANSFORM trial of prostate cancer screening), NIHR, Yorkshire Cancer Research. A.J.V. is named on the patent for the statistical model that has been licensed and commercialised as the 4Kscore by OPKO Diagnostics, receives royalties from sales of this test, and owns stock options in OPKO.
PMID 42015666 · 2026Dissecting histological transformation.
Declaration of interests A.M.L. owns equity in, is Chief Executive Officer of, and serves on the Board of Directors of Manarola Therapeutics, a company focused on the development and commercialization of functional genomics technologies.
PMID 41896034 · 2026Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models.
Drs Han, Lonard, and Dacso are founding members of a new non-public company, called CoRegen, Inc. Laboratory research support exists for Drs Han, Lonard, and Dacso from CoRegen. Dr Gilad is a paid consultant by and disclose an equity position in CoRegen, Inc.
PMID 41772940 · 2026Nonprostate Cancer Deaths Best Predict Long-Term Survival in Men Aged ≤59 Years Treated With Low Dose Rate Brachytherapy With or Without Supplemental Therapies: A Mandate for Health Enhancement.
Peter Orio: consulting for Teleflex Inc and Theragenics Corp. Grgur Mirić: consultant for Theragenics. Robert Galbreath: none. Shalini Moningi: none. Ryan Fiano: none. Kent Wallner: none. Martin King: grants or contracts: Bayer (research), Teleflex (research), and AstraZeneca (research); payment or honoraria: Bayer and Pfizer; support for attending meetings: Bayer; participation on a Data Safety Monitoring Board or Advisory Board: Teleflex.
PMID 42438566 · 2026Salvage Stereotactic Body Radiation Therapy for Locally Recurrent Prostate Cancer: Quality-of-Life Outcomes From a Prospective Clinical Trial.
Disclosures Baris Turkbey received royalties from the National Institutes of Health; multiple patents in AI (details available on request); cooperative research and development agreements with NVIDIA and Philips. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PMID 41173140 · 2026PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trial.
Declarations. Ethical approval and consent to participate: This prospective study was approved by the ethics committee of Institut Jules Bordet (CE3400) and conducted in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants. Consent to publish: The authors affirm that human research participants provided informed consent for publication of the images in Figure(s) 3 and 4. Competing interests: GNM received travel grants from AstraZeneca. RS served as advisory board member for BMS (paid), Roche (paid), Astra Zeneca (paid), Daichii Sankyo (paid), Exact Sciences, Case45 (unpaid). RS has received research funding by Roche, Puma, Merck, BMS. RS is member of an advisory group to the Belgian Government on reimbursement of assays in genomics and pathology. RS is co-Chair of The International Immuno-Oncology Biomarker Working Group ( www.tilsinbreastcancer.org ). RS has no financial conflicts of interests related to the current work or assays presented. The remaining authors do not have any conflict of interest to disclose. Clinical trial number: ClinicalTrials.gov identifier: NCT06059469 registered on May 30, 2022.
PMID 41309999 · 2026Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.
S.Z. reports personal fees from GLG and Guidepoint consulting and has received consulting fees from Pfizer and Aptitude Health; H.M.B has consulting or advisory roles from Endocyte, Celgene, Idera, Myovant Sciences, Novocure, Ipsen, Caris MPI, Incyte, Guardant Health. Speakers’ Bureau for Guardant Health. Research Funding from Spirita Oncology (Inst), Novocure (Inst), AstraZeneca (Inst), JSI (Inst), Incyte (Inst), Qurient (Inst), HiFiBiO Therapeutics (Inst), Revolution Health Care (Inst), Elevation Oncology (Inst), Dragonfly Therapeutics (Inst), Zelbio (Inst), BMS (Inst), Mirati Therapeutics (Inst), Strategia (Inst); R.M. is a shareholder and employee of Convergent Therapuetics. J.D.S. is a shareholder and employee of Tagworks Pharmaceuticals and received consulting fees and stock ownership from Repare Therapuetics. D.P.P. has received honoraria from Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche, Seattle Genetics, and UroGen; and has received research grants/funding from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche, Sanofi Aventis, and Seattle Genetics. O.S. has consulting fees from Abbvie, Abdera, Actinium Pharmaceuticals, Ambryx, Actithera, AdvanCell, Amgen, ARTBIO, Arvinas, AstraZeneca, Bayer, Clarity Pharmaceuticals, Convergent, Curium, Fusion, ITM Isotope Technologies Munich, JNJ, Lantheus, Mariana, Merck, Metis, Molecular Partners, Norroy, NorthStar, Novartis, Nuclidium, Pfizer, Sanofi, Swiss Rockets, Telix, and stock or stock options in AbbVie, Abbot, Abdera, AdvanCell, ARTBIO, Clarity Pharmaceuticals, Convergent, Fusion, Lilly, Pfizer, Ratio, and Telix; M.J.M has advisory relationships with Lantheus, Convergent, Z-Alpha, Flare Therapeutics, Fusion Pharmaceuticals, Transtherabio, Arvinas, Exelixis, Amgen, Wren Laboratories, Isotopia, Actinium Pharmaceuticals, Advancelle, Molecular Partners, Artbio.
PMID 41591990 · 2026Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial.
Conflict of Interest Disclosures: Dr Yadalam reported grants from the US National Heart, Lung and Blood Institute of the National Institutes of Health during the conduct of the study. Dr van Assen reported grants from Pfizer during the conduct of the study and grants from Cleerly and Siemens Healthineers outside the submitted work. Dr De Cecco reported grants from Bayer during the conduct of the study and grants from Cleerly, Elucid, and Siemens outside the submitted work. Dr Mandawat reported grants from Pfizer and personal fees from Sumitomo during the conduct of the study. No other disclosures were reported.
PMID 41706486 · 2026Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.
Conflict of Interest Disclosures: Dr Sushentsev reported receiving personal fees from Lucida Medical Ltd outside the submitted work. Dr Colling reported receiving grants from MDXHealth Commercial, UK Research and Innovation, and NHSX (for the ARTICULATE PRO study) outside the submitted work; serving as coauthor of the 2024 RCPath (UK) prostate cancer pathology reporting guidelines; receiving partial salary from the National Health Service; receiving a stipend from Clarendon; and working previously with PathLAKE and PathLAKE+. Dr Verrill reported receiving grants from the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research Centre during the conduct of the study and serving as principal investigator of the ARTICULATE PRO study and working previously with PathLAKE and PathLAKE+ outside the submitted work. Dr Seibert reported receiving grants from GE Healthcare and Blue Earth Diagnostics; receiving personal fees from Varian Medical Systems, MJH Life Sciences, GE Healthcare, Blue Earth Diagnostics, and Cortechs.ai; receiving nonfinancial support from Quibim; and receiving stock options for advisory board participation from Cortechs.ai outside the submitted work. Dr Bryant reported receiving grants from Cancer Research UK, The Urology Foundation, and the NIHR Health Technology Assessment outside the submitted work. Dr Donovan reported receiving grants from the NIHR during the conduct of the study. Dr Neal reported receiving grants from Cancer Research UK during the conduct of the study. Dr Hamdy reported receiving grants from the NIHR (PROTECT trial chief investigator) during the conduct of the study and receiving personal fees from Intuitive Surgical, Recordati, Pfizer, and Ipsen outside the submitted work. No other disclosures were reported.
PMID 41100113 · 2025Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial.
Conflict of Interest Disclosures: Dr Petit reported grants from Fondation de France during the conduct of the study. Dr Delouya reported personal fees from Astellas, grants from Atellas as a research payment to institution, personal fees from Bayer, Janssen, Ter Sera, and Tolmar, expenses paid to attend conference from Tolmar, personal fees from AbbVie, Knights Therapeutics, and Pfizer during the conduct of the study; personal fees from Astellas, grants from Astellas to institution, personal fees from Bayer, Janssen, Ter Sera, and Tolmar, conference fees from Tolmar, personal fees from AbbVie, Knights therapeutics, and Pfizer outside the submitted work. Dr Barkati reported personal fees from TerSera, nonfinancial support from Tolmar, and Knight Therapeutics for travel support, personal fees from AbbVie, Sumitomo, and Astellas outside the submitted work. Dr Beauchemin reported personal fees from Tersera outside the submitted work. Dr Nguyen Huynh reported grants from AbbVie, from TerSera, Tolmar, and Knight Therapeutics outside the submitted work. Dr Keu reported personal fees, generally honoraria and lectures. Dr Juneau reported personal fees from Novartis and Bayer outside the submitted work. Dr Menard reported nonfinancial support from Lantheus for in-kind radiotracer provision, grants from Siemens/Varian, and AbbVie-Caro during the conduct of the study. No other disclosures were reported.
PMID 41037308 · 2025Explainable artificial intelligence in prostate cancer treatment recommendation: A decision support system for oncological expert panels.
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors state that these relationships did not influence the design, conduct, analysis, interpretation, or reporting of the present study. Gregor Duwe: reports no serving advisory role; receiving honoraria or travel expenses from Johnson & Johnson Corporation, Merck KGaA and Boston Scientific Corporation; receiving grant from the German Federal Ministry of Research, Technology and Space (grant number: 16SV9053). Dominique Mercier: reports no serving advisory role, honoraria or travel expenses; receiving grant from the German Federal Ministry of Research, Technology and Space (grant number: 16SV9053). Verena Kauth: reports no serving advisory role; receiving honoraria or travel expenses from LAWG Deutschland e.V.; receiving grants or funds from Sanofi-Aventis Deutschland GmbH; receiving grant from the German Federal Ministry of Research, Technology and Space (grant number: 16SV9053). Kerstin Moench: reports no serving advisory role, honoraria or travel expenses; receiving grant from the German Federal Ministry of Research, Technology and Space (grant number: 16SV9053). Vikas Rajashekar: reports no serving advisory role, honoraria or travel expenses; receiving grant from the German Federal Ministry of Research, Technology and Space (grant number: 16SV9053). Markus Junker: reports no serving advisory role, honoraria or travel expenses; receiving grant from the German Federal Ministry of Research, Technology and Space (grant number: 16SV9053). Axel Haferkamp: reports no serving advisory role; receiving honoraria or travel expenses from Astellas Pharma Inc. and Ipsen Pharma; receiving grant from the German Federal Ministry of Research, Technology and Space (grant number: 16SV9053). Andreas Dengel: reports no serving advisory role, honoraria or travel expenses; receiving grant from the German Federal Ministry of Research, Technology and Space (grant number: 16SV9053). . Thomas Höfner: reports serving advisory roles for Pfizer, Astra-Zeneca, Astellas Pharma Inc., MSD Bristol Myers Squibb; receiving honoraria or travel expenses from Pfizer, Astra-Zeneca, MSD, Johnson & Johnson Corporation and Ferring; receiving grant from the German Federal Ministry of Research, Technology and Space (grant number: 16SV9053). All remaining authors have no declaration of interest.
PMID 42235465 · 2026Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Andrew J. Armstrong . Consulting or Advisory Role: Bayer, Pfizer, Astellas Scientific and Medical Affairs Inc, AstraZeneca, Merck, Bristol Myers Squibb, Janssen, Novartis, Exelixis, Myovant Sciences, GoodRx, Cytogen, Precede Bio, Sumitomo Pharma Oncology, Boundless Bio. Research Funding: Bayer (Inst), Pfizer (Inst), Novartis (Inst), Janssen Oncology (Inst), Astellas Pharma (Inst), Bristol Myers Squibb (Inst), Merck (Inst), AstraZeneca (Inst), Bristol Myers Squibb (Inst), Amgen (Inst), Syntrix Biosystems (Inst), Pathos (Inst). Patents, Royalties, Other Intellectual Property: Circulating Tumor Cell Novel Capture Technology (Inst). Travel, Accommodations, Expenses: Astellas Scientific and Medical Affairs Inc. Michael J. Morris . Employment: Memorial Sloan-Kettering Cancer Center. Stock and Other Ownership Interests: Doximity. Consulting or Advisory Role: Lantheus Medical Imaging, Convergent Therapeutics, Z-Alpha, Flare Therapeutics, Fusion Pharmaceuticals, Transtherabio, Arvinas, Exelixis, Mashup Media, Amgen, Molecular Partners, Wren Laboratories, Isotopia, Actinium Pharmaceuticals, Soffinova, Advancelle, ARTbio, Bristol Myers Squibb, AbbVie. Research Funding: Janssen (Inst), Novartis (Inst), Astellas Pharma (Inst), AstraZeneca (Inst). Patents, Royalties, Other Intellectual Property: Telix Pharmaceuticals (Inst). Travel, Accommodations, Expenses: APCCC, Memorial Sloan-Kettering Cancer Center, AbbVie. Uncompensated Relationships: Bayer, Janssen Oncology, Novartis, Amgen, Halda Therapeutics. Wassim Abida . Honoraria: Roche, Medscape, Aptitude Health, Clinical Education Alliance, OncLive/MJH Life Sciences, touchIME, Pfizer, theMedNet, Prostate Cancer Foundation. Consulting or Advisory Role: Clovis Oncology, Janssen, ORIC Pharmaceuticals, Daiichi Sankyo, AstraZeneca/MedImmune, Pfizer, Laekna Therapeutics, MOMA Therapeutics, Endeavor BioMedicines, K36 Therapeutics, Boundless Bio, Tolmar, DualityBio, IDEOlogy Health. Research Funding: AstraZeneca (Inst), Zenith Epigenetics (Inst), Clovis Oncology (Inst), ORIC Pharmaceuticals (Inst), Epizyme (Inst), Nuvation Bio (Inst), Merus (Inst), TransThera Biosciences (Inst), MOMA Therapeutics (Inst). Uncompensated Relationships: Nuvation Bio. Rahul R. Aggarwal . Consulting or Advisory Role: Pfizer, Merck, Amgen, Alessa Therapeutics, Exelixis, Bayer, Tersera, BioXcel Therapeutics, Janssen, Novartis, AstraZeneca, Boxer Capital, EcoR1 Capital, PCCTC, MJH Life Sciences, Flare Therapeutics, Research to Practice, Guidepoint Inc, Slingshot Insights, Harpoon Therapeutics, Washington Research Foundation, Curio Science. Research Funding: Zenith Epigenetics (Inst), Novartis (Inst), Xynomic Pharma (Inst), Janssen (Inst), Merck (Inst), Amgen (Inst), AstraZeneca (Inst). Expert Testimony: University of Utah Health. Travel, Accommodations, Expenses: DAVA Oncology. Emmanuel S. Antonarakis . Consulting or Advisory Role: Sanofi, Janssen Biotech, Merck, AstraZeneca, Lilly, Bayer (Inst), Amgen, Blue Earth Diagnostics, Curium Pharma, Foundation Medicine, Tempus, AIkido Pharma, Z-Alpha, AADi, Corcept Therapeutics, Hookipa Pharma, Menarini Silicon Biosystems, Pfizer, Tango Therapeutics. Research Funding: Astellas Pharma (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), MacroGenics (Inst), Merck (Inst), Orion Health (Inst). Patents, Royalties, Other Intellectual Property: Co-inventor of a biomarker technology that has been licensed to Qiagen. Gerhardt Attard . Honoraria: Janssen, Astellas Pharma, Janssen (I). Consulting or Advisory Role: Janssen-Cilag, Veridex, Ventana Medical Systems, Astellas Pharma, Medivation, Novartis, Millennium, Abbott Laboratories, ESSA, Bayer, Pfizer, AstraZeneca, Ferring, Amgen, Blue Earth Therapeutics, Merck, Merck Serono, Novartis, Veracyte. Speakers' Bureau: Janssen, Astellas Pharma, Takeda, Sanofi, Ventana Medical Systems, Ipsen, AstraZeneca, Ferring, Sandoz. Research Funding: Janssen (Inst), Astellas Pharma (Inst), Novartis, Blue Earth Therapeutics, Veracyte. Patents, Royalties, Other Intellectual Property: I am on The ICR rewards to inventors list of abiraterone acetate, listed as an inventor on patent related to blood biomarkers (UCL, Cancer Research Horizons), listed as an inventor on docetaxel predictive biomarker (Veracyte). Travel, Accommodations, Expenses: Janssen, Astellas Pharma, Medivation, Ventana Medical Systems, Abbott Laboratories, Bayer, ESSA, Janssen (I), Astellas Pharma (I), Pfizer, Ferring, AstraZeneca, Novartis, Arvinas, Sanofi, Propella Therapeutics, Orion Clinical, Amgen, Bristol Myers Squib (I), Merck Serono. Other Relationship: Institute of Cancer Research. Himisha Beltran . Consulting or Advisory Role: AstraZeneca, Pfizer, Daiichi Sankyo, Bayer, Sanofi, Merck, Novartis. Research Funding: Bristol Myers Squibb Foundation (Inst), Daiichi Sankyo (Inst), Novartis (Inst), Circle Pharma (Inst). Travel, Accommodations, Expenses: Janssen Oncology. Alan Bryce . Employment: City of Hope. Leadership: City of Hope. Honoraria: Pfizer, Janssen, Novartis, Verity Pharmaceuticals, Astellas Pharma, Bayer, Pfizer, Janssen Oncology, Lilly, Lantheus Medical Imaging, MOMA Therapeutics, Tolmar, Pfizer, AstraZeneca. Consulting or Advisory Role: Astellas Pharma. Research Funding: Provectus Biopharmaceuticals. Travel, Accommodations, Expenses: Pfizer (Inst), Bayer, Pfizer, Tolmar. Michael A. Carducci . Honoraria: Remedica. Consulting or Advisory Role: Pfizer, Acrivon Therapeutics, AstraZeneca, Amgen. Heather H. Cheng . Consulting or Advisory Role: Janssen Oncology. Research Funding: Sanofi (Inst), Janssen (Inst), Clovis Oncology (Inst), Phosplatin Therapeutics (Inst). Patents, Royalties, Other Intellectual Property: UpToDate. Open Payments Link: https://openpaymentsdata.cms.gov/physician/746939. Delphine L. Chen . Honoraria: GE Healthcare. Research Funding: Telix Pharmaceuticals (Inst), United Imaging (Inst). Patents, Royalties, Other Intellectual Property: WO 201503526 A1 Mach RH, Chu W, Zhou D, Michel LS, Chen DL. Radiolabeled tracers for poly(adp-ribose)polymerase-1 (PARP-1), methods and uses therfor. Travel, Accommodations, Expenses: GE Healthcare. Kim N. Chi . Honoraria: Janssen, Astellas Pharma, Bayer, AstraZeneca, Roche, Merck, POINT Biopharma, Amgen, BMS GmbH & Co. KG, Novartis, Pfizer. Consulting or Advisory Role: Astellas Pharma, Janssen, Amgen, Bayer, AstraZeneca, Roche, POINT Biopharma, Merck, BMS GmbH & Co. KG. Research Funding: Janssen (Inst), Astellas Pharma (Inst), Bayer (Inst), Sanofi (Inst), Bristol Myers Squibb (Inst), Merck (Inst), Roche (Inst), AstraZeneca (Inst), Novartis (Inst), Pfizer (Inst), ESSA (Inst). Daniel S. Childs . Employment: Mayo Clinic. Honoraria: Targeted Oncology, IntrinsiQ, MJH Life Sciences, International Centers for Precision Oncology Foundation, Curio Science, DAVA Oncology, IDEOlogy Health, Mashup Media. Consulting or Advisory Role: Janssen Biotech (Inst), Novartis (Inst), Abdera Therapeutics (Inst), Johnson & Johnson/Janssen (Inst). Research Funding: Janssen Biotech (Inst), Novartis (Inst). Travel, Accommodations, Expenses: Prostate Cancer Foundation. William Dahut . Leadership: Dexcom (I). Stock and Other Ownership Interests: Dexcom (I). Louise Emmett . Consulting or Advisory Role: Clarity Pharmaceuticals, Advancell, Astellas Pharma, Novartis. Speakers' Bureau: Janssen Oncology, MundiPharma, Astellas Pharma (Inst), Novartis. Research Funding: Novartis (Inst), PCF (Inst), Clarity Pharma (Inst), Telix Pharmaceuticals (Inst). Travel, Accommodations, Expenses: Advancell. Karim Fizazi . Honoraria: Janssen (Inst), Astellas Pharma (Inst), Bayer (Inst), Novartis (Inst). Consulting or Advisory Role: Janssen Oncology (Inst), Bayer (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), Pfizer (Inst), Daiichi Sankyo Europe GmbH (Inst), MSD (Inst). Travel, Accommodations, Expenses: Janssen, MSD, AstraZeneca, Pfizer, Bayer, Novartis. Andrei Gafita . Consulting or Advisory Role: Novartis, Blue Earth Diagnostics, Lilly, Nucs AI. Speakers' Bureau: Novartis. Daniel J. George . Leadership: Capio BioSciences. Stock and Other Ownership Interests: Pfizer, BMS. Honoraria: Bayer, OncLive, Pfizer, UroToday, Axess Oncology, Janssen Oncology, Millennium Medical Publishing, Novartis, AstraZeneca, Eisai, IDEOlogy Health, Merck, Astellas Pharma, Sumitomo, Candel Therapeutics. Consulting or Advisory Role: Bayer, Pfizer, Astellas Pharma, Janssen, Merck Sharp & Dohme, AstraZeneca, Michael J. Hennessy Associates, Physicans' Education Resource, Novartis, Candel Therapeutics. Research Funding: Exelixis (Inst), Janssen Oncology (Inst), Novartis (Inst), Pfizer (Inst), Astellas Pharma (Inst), Bristol Myers Squibb (Inst), Bayer (Inst), Merck (Inst), Corvus Pharmaceuticals (Inst), Bayer (Inst), AstraZeneca (Inst), Convergent Therapeutics (Inst). Expert Testimony: Exelixis. Travel, Accommodations, Expenses: Exelixis, Pfizer, Novartis, Bayer, Merck. Ken Hermann . Leadership: Aktis Oncology, Pentixapharm. Stock and Other Ownership Interests: SOFIE, Aktis Oncology, AdvanCell, Convergent Therapeutics, NVision, Yellowbird Diagnostics, Radiopharm Theranostics. Consulting or Advisory Role: Novartis, Bain Capital, Bayer, Advanced Accelerator Applications, Amgen, BTG, IPSEN, ITG (Inst), ROTOP Pharmaka (Inst), Siemens Healthineers, GE Healthcare, Boston Scientific, Fusion Pharmaceuticals, Immedica, Molecular Partners, Debiopharm Group, AstraZeneca, Janssen Oncology, Radiopharm Theranostics, Telix Pharmaceuticals. Michael S. Hofman . Consulting or Advisory Role: Janssen, MSD, Novartis (Inst), Advancell (Inst), Bicycle Therapeutics, Sanofi, AstraZeneca (Inst). Research Funding: Bayer (Inst), Novartis (Inst), Isotopia (Inst), ITM Isotope Technologies Munich (Inst). Travel, Accommodations, Expenses: Novartis, Debiopharm Group (Inst), GE Healthcare (Inst). Thomas Hope . Stock and Other Ownership Interests: RayzeBio, Curium Pharma, Utter Therapeutics, AdvanCell. Honoraria: GE Healthcare, Cardinal Health. Consulting or Advisory Role: Ipsen, Curium Pharma, Blue Earth Diagnostics, Bayer, ITM Isotope Technologies Munich, Lantheus Medical Imaging, Sanofi, AstraZeneca, Molecular Partners, Novartis, Bristol Myers Squibb Company. Research Funding: GE Healthcare (Inst), Philips Healthcare (Inst), Advanced Accelerator Applications (Inst), Clovis Oncology (Inst), Lantheus Medical Imaging (Inst), Janssen Oncology (Inst), Telix Pharmaceuticals (Inst), Novartis (Inst), Bayer (Inst). Travel, Accommodations, Expenses: GE Healthcare. Maha Hussain . Honoraria: Medscape, Targeted Oncology, AstraZeneca, Great Debates and Updates, Clinical Care Options, Novartis, Bayer, Research to Practice, Academic CME, AstraZeneca, Bayer. Consulting or Advisory Role: Bayer, AstraZeneca, GlaxoSmithKline, Convergent Therapeutics, Novartis, Tango Therapeutics, J&J, BMS, AbbVie. Research Funding: Genentech (Inst), Pfizer (Inst), PCCTC (Inst), AstraZeneca (Inst), Bayer (Inst), Arvinas (Inst). Patents, Royalties, Other Intellectual Property: TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753 US 8,185,186 (US patent number), Systems and methods for tissue imaging (issued patent), EP 08745653.9 (EP application number), Systems and methods for tissue imaging (pending), CA 2683805 (Canadian application number), Systems and methods for tissue imaging (pending) US 13/362,500 (US application number), Systems and Methods for Tissue Imaging (continuation application of US 8,185,186); TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671, Application Filed on: 5/2/2011; TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No./Patent No. 11764665.4-1464 Application No./Patent No. 11764656.2-1464 Application Filed on: 26/9/2011. Travel, Accommodations, Expenses: Bayer. Open Payments Link: https://openpaymentsdata.cms.gov/physician/146932. W. Kevin Kelly . Honoraria: Janssen Oncology, Amgen. Consulting or Advisory Role: Bayer, Janssen Oncology, Amgen, Fusion Pharmaceuticals. Research Funding: Novartis (Inst), Janssen Oncology (Inst), Bayer (Inst), Exelixis (Inst), Seagen (Inst), Endocyte (Inst), Amgen (Inst), BioClin Therapeutics (Inst), Sarah Cannon Research Institute (Inst), Roche (Inst), Regeneron (Inst). Travel, Accommodations, Expenses: Janssen Oncology. Elizabeth Kessler . Honoraria: Astellas Scientific and Medical Affairs Inc. Research Funding: Bristol Myers Squibb (Inst), Pfizer (Inst), Merck Serono (Inst), Lilly (Inst), Johnson & Johnson/Janssen (Inst). Phillip H. Kuo . Honoraria: Novartis, Lilly, Global Medical Solutions, GE Healthcare, Telix Pharmaceuticals, Blue Earth Diagnostics. Consulting or Advisory Role: Blue Earth Diagnostics, Novartis, Invicro, Bayer, Fusion Pharmaceuticals, GE Healthcare, Attralus, dGenThera, Lilly, Global Medical Solutions, Perceptive, Life Molecular Imaging, Merck, Navidea, Radionetics, Telix Pharmaceuticals, United Imaging, AstraZeneca, Cubresa, Perceptive, Lantheus Medical Imaging, Siemens. Speakers' Bureau: GE Healthcare, Novartis, Lilly. Research Funding: GE Healthcare (Inst), Blue Earth Diagnostics (Inst). Patents, Royalties, Other Intellectual Property: Motion correction system for brain/head imaging. Travel, Accommodations, Expenses: GE Healthcare, Invicro, Perceptive, Telix Pharmaceuticals, Novartis, AstraZeneca, Lantheus Medical Imaging, Bayer, Lilly, Global Medical Solutions, Perceptive. Joshua Lang . Leadership: EOLAS Diagnostics, INC. Consulting or Advisory Role: Sanofi, Janssen, Pfizer/Astellas, Gilead Sciences, Arvinas, Pfizer/Myovant, 4D Pharma, AstraZeneca, Pfizer, MacroGenics, Foundation Medicine, Daiichi Sankyo/Astra Zeneca. Research Funding: Medivation (Inst), Agensys (Inst), GlaxoSmithKline (Inst), Immunomedics (Inst), Bristol Myers Squibb (Inst), Janssen (Inst), Gilead Sciences (Inst), Arvinas (Inst). Patents, Royalties, Other Intellectual Property: I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available. Glenn Liu . Employment: AIQ Solutions. Leadership: AIQ Solutions. Stock and Other Ownership Interests: AIQ Solutions. Research Funding: Johnson & Johnson (Inst), Novartis (Inst), Madison Vaccines, Inc, Pfizer. Patents, Royalties, Other Intellectual Property: I have patent pending titled “System and method for evaluation of disease burden” which provides a novel method to identify and quantitate treatment response (Inst). Travel, Accommodations, Expenses: Janux Therapeutics. Catherine H. Marshall . Honoraria: Tempus, OncLive/MJH Life Sciences. Consulting or Advisory Role: McGraw-Hill Education, Dendreon, Bayer, Obseva, Pfizer. Research Funding: AstraZeneca (Inst). Patents, Royalties, Other Intellectual Property: McGraw Hill—Textbook Royalties. Travel, Accommodations, Expenses: Bayer, DAVA Pharmaceuticals. Alicia K. Morgans . Employment: Dana-Farber Cancer Institute. Stock and Other Ownership Interests: Vertex (I). Honoraria: Janssen, AstraZeneca, Astellas Scientific and Medical Affairs Inc, Bayer, Advanced Accelerator Applications, Exelixis, Pfizer, Merck, Telix Pharmaceuticals, Curium Pharma, MacroGenics, Sumitomo Pharma Oncology, Novartis, Tolmar, Lantheus Medical Imaging. Consulting or Advisory Role: AstraZeneca, Bayer, Astellas Pharma, Advanced Accelerator Applications, Novartis, Lantheus Medical Imaging, Merck, Sumitomo Pharma Oncology, Johnson & Johnson/Janssen. Research Funding: Bayer, AstraZeneca, Astellas Scientific and Medical Affairs Inc, Myovant Sciences, Pfizer, Sumitomo Pharma Oncology, Bristol Myers Squibb Foundation, Exact Sciences. Travel, Accommodations, Expenses: Novartis, AstraZeneca, Pfizer, Astellas Pharma, Bayer. Rana R. McKay . Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion Therapeutics, Calithera Biosciences, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seagen, Telix Pharmaceuticals, Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, AstraZeneca, Myovant Sciences, Precede Bio. Research Funding: Bayer (Inst), Tempus (Inst), AstraZeneca (Inst), Exelixis (Inst), Bristol Myers Squibb (Inst), Oncternal Therapeutics (Inst), Artera (Inst). David Nanus . Honoraria: Genentech. Consulting or Advisory Role: AstraZeneca, Janssen Scientific Affairs. Research Funding: Novartis (Inst), Boehringer Ingelheim (Inst), Zenith Epigenetics (Inst), AstraZeneca (Inst), Immumedics (Inst), Janssen (Inst), Clovis Oncology (Inst), Pfizer (Inst), Exelixis (Inst), Sagimet Biosciences (Inst). Peter Nelson . Consulting or Advisory Role: Janssen Oncology, Astellas Pharma, Bristol Myers Squibb, Pfizer, AstraZeneca, Genentech. Research Funding: Janssen Oncology, Auron, Inc (Inst). Expert Testimony: Venable. Channing Paller . Consulting or Advisory Role: Dendreon, Omnitura, Exelixis, AstraZeneca, Janssen Oncology, Pfizer, Bayer. Research Funding: Lilly (Inst). Travel, Accommodations, Expenses: Bayer. Zachery R. Reichert . Consulting or Advisory Role: Janssen Oncology. Research Funding: AstraZeneca (Inst), Incyte (Inst). Expert Testimony: Huff Bowell Bailey. Charles J. Ryan . Honoraria: Janssen Oncology, Bayer, Pfizer, Novartis. Consulting or Advisory Role: ORIC Pharmaceuticals, VIR Biotechnology, Tolmar. Other Relationship: Lilly, ArsenalBio, Bayer. A. Oliver Sartor . Stock and Other Ownership Interests: Lilly, AbbVie, Cardinal Health, United Health Group, Clarity Pharmaceuticals, Convergent Therapeutics, Telix Pharmaceuticals, Abbott Laboratories, BioNTech SE, ARTbio, Curadh, Advancell, Actithera, Asta, Abdera Therapeutics, NVision, Ratiopharm, Azurna. Honoraria: Lantheus Medical Imaging, Intellisphere, Clarity Pharmaceuticals, Advancell, Telix Pharmaceuticals, Sanofi, Pfizer, AstraZeneca, Ratiopharm, Actinium Pharmaceuticals, Convergent Therapeutics, Point Therapeutics. Consulting or Advisory Role: Bayer, Sanofi, AstraZeneca, Pfizer, Astellas Pharma, Novartis, Clarity Pharmaceuticals, Fusion Pharmaceuticals, Isotopen Technologien, Janssen, Point Biopharma, Telix Pharmaceuticals, Amgen, Ratiopharm, Advancell, Lantheus Medical Imaging, ARTbio, Actinium Pharmaceuticals, Convergent Therapeutics, Abdera Therapeutics, Alpha9, Curium Pharma, Curdah, Merck, Modex, Norroy, Nucleus Radiopharma, Precede Bio, Progenics, Swiss Rockets, Wren Laboratories, Actithera, X-Cancer Software, NVision, Johnson & Johnson/Janssen, Syneos Health, NorthStar, Full Life. Research Funding: Bayer (Inst), AstraZeneca (Inst), Janssen, Lantheus Medical Imaging (Inst), Novartis (Inst), Amgen (Inst). Expert Testimony: Sanofi. Travel, Accommodations, Expenses: Bayer, Sanofi, Lantheus Medical Imaging. Heiko Schöder . Patents, Royalties, Other Intellectual Property: Memorial Sloan Kettering, my employer, has received royalty payments from Telix Pharmaceuticals (Inst). Lawrence H. Schwartz . Consulting or Advisory Role: Bristol-Myers Squibb/Celgene, Merck. Research Funding: Merck Sharp & Dohme (Inst), Boehringer Ingelheim (Inst). Patents, Royalties, Other Intellectual Property: Varian Medical Systems. Nima Sharifi . Consulting or Advisory Role: Astellas Pharma. Patents, Royalties, Other Intellectual Property: A patent application has been filed by Cleveland Clinic for a method of steroid-dependent disease treatment based on HSD3B1. Nima Sharifi is a co-inventor on this patent application. Walter M. Stadler . Stock and Other Ownership Interests: Fortress Biotech. Consulting or Advisory Role: CVS Caremark, AstraZeneca, Pfizer, Merck, Treadwell Therapeutics, Aveo, Xencorp. Research Funding: Bayer (Inst), Bristol Myers Squibb (Inst), Boehringer Ingelheim (Inst), Exelixis (Inst), Novartis (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), Pfizer (Inst), Merck (Inst), Millennium (Inst), Janssen (Inst), Johnson & Johnson (Inst), AstraZeneca (Inst), AbbVie (Inst), X4 Pharma (Inst), Clovis Oncology (Inst), Eisai (Inst), Seagen (I), Tesaro (Inst), Corvus Pharmaceuticals (Inst), Astellas Medivation (Inst), Amgen (Inst), Xencor (Inst). Expert Testimony: Sandoz, Apotex, US Dept of Justice. Other Relationship: UpToDate, American Cancer Society. Mark Stein . Stock and Other Ownership Interests: Rafael Holdings. Consulting or Advisory Role: Exelixis, Johnson & Johnson/Janssen, GI Innovation. Research Funding: Bristol Myers Squibb (Inst), Lilly (Inst), Xencor (Inst), Regeneron (Inst), Bicycle Therapeutics (Inst), AstraZeneca (Inst), Telix Pharmaceuticals (Inst), Exelixis (Inst), ARTBIO (Inst), Johnson & Johnson/Janssen (Inst), DualityBio (Inst). Cora N. Sternberg . Consulting or Advisory Role: Bayer, Pfizer, Incyte, Merck, UroToday, Bristol Myers Squibb/Medarex, Janssen Oncology, Tolmar, MJH Life Sciences, Cantor Fitzgerald, Duality Biologics, Aptitude Health, Curio Science, MJH Healthcare Holdings, LLC, AbbVie, Novartis, Bicycle Therapeutics. Travel, Accommodations, Expenses: Merck. Russell Z. Szmulewitz . Consulting or Advisory Role: Merck, Amgen, Janssen Oncology, Sanofi, Novartis, Eisai, Bayer. Research Funding: AbbVie (Inst), Astellas Pharma (Inst), Janssen Oncology (Inst), Merck (Inst), Novartis (Inst), Progenics (Inst), Bayer (Inst), Nurix (Inst), Janux Therapeutics (Inst). Patents, Royalties, Other Intellectual Property: Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer. Travel, Accommodations, Expenses: DAVA Oncology. Scott T. Tagawa . Stock and Other Ownership Interests: Convergent Therapeutics. Consulting or Advisory Role: Medivation, Astellas Pharma, Dendreon, Janssen, Genentech, Endocyte, Immunomedics, Karyopharm Therapeutics, AbbVie, Tolmar, QED Therapeutics, Amgen, Sanofi, Pfizer, Clovis Oncology, Novartis, Genomic Health, POINT Biopharma, Blue Earth Diagnostics, Seagen, AIkido Pharma, 4D Pharma, Clarity Pharmaceuticals, Gilead Sciences, Telix Pharmaceuticals, Bayer, Myovant Sciences, Convergent Therapeutics, Hookipa Pharma, Merck, Daiichi Sankyo, Regeneron, TransThera Biosciences, Bicycle Therapeutics, Ambrx, Exelixis, Boston Scientific, General Electric, Lantheus Medical Imaging, Abdera Therapeutics, Biohaven Pharmaceuticals, Lilly. Research Funding: Lilly (Inst), Sanofi (Inst), Janssen (Inst), Astellas Pharma (Inst), Progenics (Inst), Millennium (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), Dendreon (Inst), Rexahn Pharmaceuticals (Inst), Bayer (Inst), Genentech (Inst), Newlink Genetics (Inst), Inovio Pharmaceuticals (Inst), AstraZeneca (Inst), Immunomedics (Inst), Novartis (Inst), AVEO (Inst), Boehringer Ingelheim (Inst), Merck (Inst), Stem CentRx (Inst), Karyopharm Therapeutics (Inst), AbbVie (Inst), Medivation (Inst), Endocyte (Inst), Exelixis (Inst), Clovis Oncology (Inst), POINT Biopharma (Inst), Ambrx (Inst), Clarity Pharmaceuticals (Inst), Telix Pharmaceuticals (Inst), Janux Therapeutics (Inst), AIQ Solutions (Inst). Patents, Royalties, Other Intellectual Property: Patent Royalty from Immunomedics/Gilead. Travel, Accommodations, Expenses: Sanofi, Immunomedics, Amgen, Merck, Astellas Pharma, Telix Pharmaceuticals, Lantheus Medical Imaging, General Electric. Uncompensated Relationships: ATLAB Pharma, Phosplatin Therapeutics. Alexandra O. Sokolova . Honoraria: AstraZeneca, CELC-G, Astellas Pharma, Dava Oncology, Bayer. Research Funding: Janssen Oncology (Inst), AstraZeneca (Inst), Novartis (Inst), Regeneron (Inst). Travel, Accommodations, Expenses: Lantheus Medical Imaging, AstraZeneca. Alex W. Wyatt . Honoraria: Janssen, AstraZeneca, Merck, Pfizer, Bayer. Research Funding: ESSA (Inst), Tyra Biosciences (Inst), Promontory Therapeutics (Inst). Evan Y. Yu . Consulting or Advisory Role: Bayer, Merck, Johnson and Johnson, AstraZeneca, Tolmar, Lantheus Medical Imaging, Astellas Pharma, Novartis. Research Funding: Dendreon (Inst), Merck (Inst), Blue Earth Diagnostics (Inst), Bayer (Inst), Lantheus Medical Imaging (Inst), Tyra Biosciences (Inst), Pfizer (Inst). Susan Halabi . Employment: ASCO. Consulting or Advisory Role: J&J, Sanofi, Bristol Myers Squibb, CG Oncology, BeiGene. Howard I. Scher . Honoraria: Physicans' Education Resource. Consulting or Advisory Role: Janssen Research & Development, Bayer, Promontory Therapeutics, AIQ Global, Novartis. Research Funding: Janssen (Inst), AIQ Solutions (Inst), Biodesix (Inst), Astrin Biosciences (Inst). Patents, Royalties, Other Intellectual Property: Elucida Oncology—Intellectual Property Rights. Travel, Accommodations, Expenses: WIRB-Copernicus Group, Prostate Cancer Foundation, Bayer, Promontory Therapeutics, Epic Sciences, Biodesix. No other potential conflicts of interest were reported.
PMID 41744290 · 202601
Current Standard-of-Care Sources
Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
PMID 41744290Prescription of PARP inhibitors (iPARP) in metastatic castration-resistant prostate cancer: a position paper of the Spanish Association of Urology (AEU) and its Uro-Oncology Group (GUO).
Actas urologicas espanolas · 2026
PMID 41500457NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026
PMID 42134408Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026).
The Journal of urology · 2026
PMID 41744286The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease.
Scandinavian journal of urology · 2026
PMID 42012147[Genitourinary Oncology Committee of Chinese Anti-Cancer Association (CACA-GO) guideline for prostate cancer for patients (2025 edition)].
Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026
PMID 41876195ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride.
American journal of clinical oncology · 2026
PMID 40851434Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).
The Journal of urology · 2026
PMID 41988960Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer.
Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia · 2026
PMID 42102633Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management.
The Journal of urology · 2026
PMID 42095477Latin American Consensus for the Diagnosis and Treatment of Metastatic Castration-Sensitive Prostate Cancer.
Clinical genitourinary cancer · 2026
PMID 41963237Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
PMID 4166788602
Highest-Priority Research
Magnetic Resonance Imaging-Based Artificial Intelligence in Predicting Prostate Cancer Biochemical Recurrence: Systematic Review and Meta-Analysis.
Journal of medical Internet research · 2026
BACKGROUND: Artificial intelligence (AI) has emerged as a promising tool for prostate cancer (PCa) risk stratification and outcome prediction. However, current studies often lack multicenter external validation, have limited sample sizes, present significant intermodel variability, and face overfitting concerns. OBJECTIVE: This study aimed to comprehensively evaluate the diagnostic performance of magnetic resonance imaging (MRI)-based AI models in predicting biochemical recurrence (BCR) of PCa. METHODS: Systematic searches were conducted in the PubMed, Embase, Web of Science, and Cochrane Library databases up to January 13, 2026. Studies were included that involved participants diagnosed wit…
PMID 42412916Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
PURPOSE: The continuous development of new imaging approaches, molecular phenotyping, genetic subtypes, prognosis assessments, and effective therapies across a range of disease states has created a need to redefine terminology and best practices for clinical trial conduct in patients with advanced prostate cancer. METHODS: We convened an international expert committee of diverse working groups, the Prostate Cancer Working Group 4 (PCWG4), between 2016 and 2025. Our objective was to formulate updated criteria based on emerging evidence and clinical trial data in a biomarker context to provide guidance for clinical trial design, eligibility, and end point assessments for patients with advanced…
PMID 41744290Prescription of PARP inhibitors (iPARP) in metastatic castration-resistant prostate cancer: a position paper of the Spanish Association of Urology (AEU) and its Uro-Oncology Group (GUO).
Actas urologicas espanolas · 2026
In recent months, restrictions have been proposed on the prescription of PARP inhibitors (iPARP) by urologists in metastatic castration-resistant prostate cancer (mCRPC). The Spanish Association of Urology (AEU), its Uro-Oncology Group (GUO), and the presidents of the Regional Urology Associations consider these limitations unjustified from clinical, organizational, legal, or professional perspectives. They unduly restrict the exercise of competencies recognized in the interdisciplinary management of prostate cancer, in line with the training, experience, and current regulations of the specialty. This document argues, from scientific, clinical, and legal standpoints, that urologists are qual…
PMID 41500457NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.
PMID 42134408Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026).
The Journal of urology · 2026
PURPOSE: The recommendations discussed on the early detection of prostate cancer provide a framework to facilitate clinical decision-making in the implementation of prostate cancer screening and follow-up. MATERIALS AND METHODS: The Early Detection of Prostate Cancer Guideline was reviewed in 2025 and updated through the AUA amendment process. This process involved reviewing and integrating newly published literature into the previously established Guideline. The methodologist updated the original Guideline search strategy to systematically search Ovid MEDLINE and Embase for new evidence published between November 2022 and December 2024. RESULTS: The Early Detection of Prostate Cancer Amendm…
PMID 41744286The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease.
Scandinavian journal of urology · 2026
OBJECTIVE: This article presents a summary of the 2025 Swedish prostate cancer guidelines, focusing on recurrence after local treatment, metastatic disease, and castration-resistant prostate cancer. RESULTS: The 2025 Swedish guidelines introduce several important updates. Prostate specific membrane antigen (PSMA)-PET/CT is recommended only when PSA exceeds 0.2 µg/L, and reporting should follow the defined PSMA-RADS-scale. PSMA-PET/CT is preferred over lymph-node dissection for staging. A strong recommendation is issued for radiotherapy to the primary tumour in all oligometastatic men with a life expectancy > 5 years, whereas metastasis-directed therapy is restricted to clinical trials. Syste…
PMID 42012147[Genitourinary Oncology Committee of Chinese Anti-Cancer Association (CACA-GO) guideline for prostate cancer for patients (2025 edition)].
Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026
Prostate cancer is a relatively common malignant tumor in the genitourinary system of elderly men, posing a heavy burden to the public health. In order to disseminate the knowledge of early screening and diagnosis of prostate cancer, effectively promote the prevention and treatment of prostate cancer in China, and improve patients' cognition of prostate cancer,the Genitourinary Oncology Committee of Chinese Anti-Cancer Association organized a panel of experts to formulate the "Genitourinary Oncology Committee of China Anti-Cancer Association (CACA-GO) guideline for prostate cancer for patients (2025 edition)", with the aim of enhancing the understanding of prostate cancer diagnosis and treat…
PMID 41876195ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride.
American journal of clinical oncology · 2026
OBJECTIVES: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The document represents an update of the radium-223 therapy practice parameter developed by the societies in 2019. METHODS: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website ( https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards ) by the Committee on Practice Parameters-Nuclear…
PMID 40851434Impact of frailty on overall survival and complications in patients with prostate cancer: a systematic review and meta-analysis.
International urology and nephrology · 2026
PURPOSE: The current systematic review and meta-analysis was designed to assess if the presence of frailty had an adverse impact on overall survival (OS) and complication rates of patients with prostate cancer. METHODS: Two reviewers explored the PubMed, Web of Science, Embase, and Scopus databases until January 3rd, 2026, for studies examining the impact of frailty on OS and complications in patients with prostate cancer. Data on OS were pooled as a hazard ratio (HR), while short-term mortality and complications were pooled as odds ratios (OR) in a random-effects model. RESULTS: 13 studies with 173,378 patients were included. Pooled analysis showed that the presence of frailty was associate…
PMID 41712034Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).
The Journal of urology · 2026
PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2022 publication of this Guideline via the AUA Amendment process. The resulting 2026 Guideline Amendment addresses updated recommendations to provide a clinical framework for the evaluation and management of clinically localized prostate cancer. MATERIALS AND METHODS: In 2025, this Guideline was reviewed via the AUA ULR process, which identified 29 studies for full-text review that were published between July 1, 2021 and December 5, 2024. An additional 8 studies were identified reviewing artificial intelligence (AI) as it relates to…
PMID 41988960Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer.
Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia · 2026
With the approval of PARP inhibitors (PARPi), both as monotherapy and in combination with androgen receptor signalling inhibitors (ARSi), for metastatic castration-resistant prostate cancer (mCRPC) and their rapid development in earlier disease settings, there is an urgent need to integrate homologous recombination repair (HRR) testing into daily clinical practice to identify patients who may benefit from these therapies and to improve patient management. Alterations in HRR genes are found in approximately 15-30% of patients with mCRPC and are associated with poor prognosis. In addition, some alterations are hereditary; therefore, testing also has implications for the identification of hered…
PMID 42102633Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management.
The Journal of urology · 2026
PURPOSE: This Guideline covers the treatment of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). The summary presented herein represents Part II of the three-part series dedicated to Management of LUTS attributed to BPH. Please refer to Parts I and III for additional information on this topic. MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews through January 2025. Update searches were conducted on December 15, 2025. Literature searches were limited to studies of medical therapies published since 2009 and surgica…
PMID 4209547703
Latest Research — Last 24 Months
2026
2026
Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
Clinical genitourinary cancer · PMID 41966893
2026
The Radical Prostatectomy Versus Brachytherapy for the Management of Low- and Intermediate-Risk Prostate Cancer: A Meta-Analysis of Observational Studies Focusing on Oncological Outcomes.
Asian Pacific journal of cancer prevention : APJCP · PMID 41569192
2026
The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.
Human vaccines & immunotherapeutics · PMID 41672480
2026
2026
Feasibility and Safety of Same-say Discharge after Robot-assisted Radical Prostatectomy: A Systematic Review and Meta-analysis.
European urology focus · PMID 42331644
2026
Comparison of the effects of exercise-based interventions on cardiometabolic health and fatigue in men with prostate cancer receiving androgen deprivation therapy: A network meta-analysis.
Asia-Pacific journal of oncology nursing · PMID 42022295
2026
Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology- and European Randomized Study of Screening for Prostate Cancer-based strategies.
International journal of cancer · PMID 41741956
2026
2026
2026
Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer.
European urology focus · PMID 41826123
2026
Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy.
The Prostate · PMID 42542970
2026
2026
2026
Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · PMID 41587107
04
Treatment Options Studied in the PubMed Collection
These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.
moderate-confidence evidence
radiotherapy
46 linked PMIDs30622 reported cumulative sample signal
- Research status
- mostly neutral
- Outcomes represented
- reported clinical outcomes, overall survival, quality of life, progression-free survival, recurrence, adverse events, metastasis-free survival, mortality
- Populations represented
- general population; PSA; localized prostate cancer; localized; PSA; localized prostate cancer; localized; metastatic; localized; locally advanced; advanced
- Mechanism
- Targeted radionuclide therapy (TRT) delivers ionizing radiation directly to cancer cells through radio molecules that bind tumor-associated targets 56.8% prescribe an LHRH agonist and 74.6% for 24 months
limited evidence
radical prostatectomy
45 linked PMIDs112686 reported cumulative sample signal
- Research status
- mostly neutral
- Outcomes represented
- reported clinical outcomes, recurrence, biochemical recurrence, quality of life, progression-free survival, overall survival, adverse events, recurrence-free survival
- Populations represented
- general population; PSA; localized prostate cancer; localized; metastatic; locally advanced; advanced; localized
- Mechanism
- Focal therapy has emerged as a treatment strategy designed to address these limitations by selectively targeting only the clinically significant cancer within the prostate, thereby aiming to achieve a balance between oncological control and functional preservation
preliminary evidence
Prostate-Specific Antigen
38 linked PMIDs450780 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, adverse events, recurrence, overall survival, biochemical recurrence, mortality, quality of life, progression-free survival
- Populations represented
- PSA; general population; metastatic castration-resistant prostate cancer; metastatic; PSA; metastatic; PSA; metastatic castration-resistant prostate cancer; advanced; metastatic; PSA; localized prostate cancer; localized; metastatic; PSA
- Mechanism
- ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) that combines AR antagonism and degradation via N-terminal domain binding, additionally targeting AR splice variants PSMA is indirectly modulated by androgen signalling through the androgen receptor (AR) pathway and has been observed to undergo transient upregulation following treatment with AR targeting agents, such as darolutamide, particularly in patients with castration-resistant PCa
preliminary evidence
androgen deprivation therapy
29 linked PMIDs32018 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, quality of life, biochemical recurrence, recurrence, progression-free survival, recurrence-free survival, adverse events
- Populations represented
- general population; PSA; metastatic; localized prostate cancer; high-risk localized prostate cancer; localized; locally advanced; advanced; localized prostate cancer; localized; metastatic; PSA; metastatic castration-sensitive prostate cancer; metastatic; PSA; homologous recombination repair
- Mechanism
- These findings highlight the role of TAM-derived miR-142-5p in regulating NED and suggest that targeting the RERG/Ras/ERK axis may provide a novel therapeutic approach for NEPC However, prognosis remains poor for some patients despite second-generation androgen receptor antagonist-based doublet therapy
preliminary evidence
Androgen Antagonists
27 linked PMIDs47002 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence, adverse events, progression-free survival, quality of life, biochemical recurrence, overall survival, metastasis-free survival
- Populations represented
- general population; metastatic; PSA; localized prostate cancer; high-risk localized prostate cancer; localized; locally advanced; advanced; localized prostate cancer; localized; metastatic; PSA
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
abiraterone
17 linked PMIDs49439 reported cumulative sample signal
- Research status
- mostly neutral
- Outcomes represented
- reported clinical outcomes, quality of life, overall survival, progression-free survival, adverse events, radiographic progression-free survival, recurrence, PSA response
- Populations represented
- metastatic; metastatic castration-resistant prostate cancer; metastatic; general population; first-line; second-line; metastatic castration-resistant prostate cancer; metastatic; homologous recombination repair; metastatic castration-sensitive prostate cancer; metastatic; PSA; homologous recombination repair
- Mechanism
- These effects are mediated through dual regulatory functions of DNA methyltransferase 1(DNMT1): RON-mediated regulation of the canonical methyltransferase activity of DNMT1, which inhibits receptor-interacting protein kinase 3(RIPK3) expression, leading to increased cellular survival with impaired RIPK3/MLKL-involved cell death signaling Here, we tested whether 3β-HSD1 maintains androgen receptor (AR) signaling by back-converting the inactive metabolite 3β-androstanediol (3β-diol) to DHT, and whether it similarly oxidizes the abiraterone metabolite 3β-OH-5α-abiraterone (3β-OH-5α-Abi) to 3-keto-5α-Abi, a weak AR agonist
preliminary evidence
Glutamate Carboxypeptidase II
17 linked PMIDs2985 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence, overall survival, progression-free survival, response rate, adverse events, biochemical recurrence, quality of life
- Populations represented
- metastatic; general population; metastatic castration-resistant prostate cancer; metastatic; metastatic; PSA; PSA
- Mechanism
- PSMA is indirectly modulated by androgen signalling through the androgen receptor (AR) pathway and has been observed to undergo transient upregulation following treatment with AR targeting agents, such as darolutamide, particularly in patients with castration-resistant PCa Primary attention was paid to small-molecule conjugates targeting both prostate-specific membrane antigen (PSMA) and gastrin-releasing receptor (GRPr), as these two receptors are the most common targets in the development of heterobivalent (HBV) radiopharmaceuticals for the treatment of PC
preliminary evidence
enzalutamide
16 linked PMIDs39635 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, quality of life, progression-free survival, overall survival, mortality, adverse events, radiographic progression-free survival
- Populations represented
- advanced; general population; metastatic castration-sensitive prostate cancer; metastatic; PSA; metastatic; metastatic castration-resistant prostate cancer; metastatic
- Mechanism
- Polo-like kinase 1 (PLK1) is an established therapeutic target in cancer; however, ATP-competitive kinase inhibitors have shown limited clinical success because of toxicity, acquired resistance, and incomplete inhibition of non-catalytic PLK1 functions Targeting the Polo-box domain (PBD), which regulates PLK1 localization and substrate recognition, represents an alternative therapeutic strategy but has been hindered by the lack of selective, cell-active small molecules
moderate-confidence evidence
Antineoplastic Agents
15 linked PMIDs20712 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, progression-free survival
- Populations represented
- general population; advanced; first-line
- Mechanism
- Talazoparib is a poly(ADP-ribose) polymerase inhibitor approved for the treatment of breast and prostate cancer Unintended inhibition of its homologous isoforms AKR1C1 and AKR1C2 may cause off-target effects and is therefore highly undesirable
preliminary evidence
Antigens, Surface
15 linked PMIDs2976 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- recurrence, reported clinical outcomes, overall survival, progression-free survival, response rate, adverse events, biochemical recurrence, quality of life
- Populations represented
- general population; metastatic; metastatic castration-resistant prostate cancer; metastatic; metastatic; PSA; PSA
- Mechanism
- PSMA is indirectly modulated by androgen signalling through the androgen receptor (AR) pathway and has been observed to undergo transient upregulation following treatment with AR targeting agents, such as darolutamide, particularly in patients with castration-resistant PCa Primary attention was paid to small-molecule conjugates targeting both prostate-specific membrane antigen (PSMA) and gastrin-releasing receptor (GRPr), as these two receptors are the most common targets in the development of heterobivalent (HBV) radiopharmaceuticals for the treatment of PC
preliminary evidence
FOLH1 protein, human
14 linked PMIDs11837 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- recurrence, reported clinical outcomes, overall survival, quality of life, progression-free survival, response rate, adverse events, biochemical recurrence
- Populations represented
- general population; metastatic; metastatic castration-resistant prostate cancer; metastatic; metastatic castration-resistant prostate cancer; metastatic; PSA; metastatic; PSA; PSA
- Mechanism
- PSMA is indirectly modulated by androgen signalling through the androgen receptor (AR) pathway and has been observed to undergo transient upregulation following treatment with AR targeting agents, such as darolutamide, particularly in patients with castration-resistant PCa Primary attention was paid to small-molecule conjugates targeting both prostate-specific membrane antigen (PSMA) and gastrin-releasing receptor (GRPr), as these two receptors are the most common targets in the development of heterobivalent (HBV) radiopharmaceuticals for the treatment of PC
preliminary evidence
Radiopharmaceuticals
13 linked PMIDs12129 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, quality of life, progression-free survival, response rate, adverse events
- Populations represented
- metastatic; general population; metastatic castration-resistant prostate cancer; metastatic; metastatic; PSA; metastatic castration-resistant prostate cancer; metastatic; PSA
- Mechanism
- Primary attention was paid to small-molecule conjugates targeting both prostate-specific membrane antigen (PSMA) and gastrin-releasing receptor (GRPr), as these two receptors are the most common targets in the development of heterobivalent (HBV) radiopharmaceuticals for the treatment of PC Importantly, [177Lu]Lu-2 achieved high tumor uptake, reaching 8.35%ID/g at 24 h post-injection, indicating effective tumor targeting and prolonged retention
preliminary evidence
Biomarkers, Tumor
12 linked PMIDs1986 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, progression-free survival, radiographic progression-free survival, recurrence, biochemical recurrence
- Populations represented
- general population; PSA; metastatic castration-resistant prostate cancer; metastatic; localized prostate cancer; high-risk localized prostate cancer; localized; locally advanced; advanced; metastatic castration-resistant prostate cancer; metastatic; homologous recombination repair
- Mechanism
- Mechanistically, SRRT enhanced STAT3 phosphorylation, and activation of STAT3 by colivelin partially reversed the suppressive effects of SRRT silencing, indicating that SRRT promotes PC progression through activation of the STAT3 signaling pathway The study was to explore the influence of lncSPATA8-AS1 on PCa and its molecular mechanism of action
moderate-confidence evidence
docetaxel
10 linked PMIDs49565 reported cumulative sample signal
- Research status
- mostly neutral
- Outcomes represented
- overall survival, reported clinical outcomes, progression-free survival, adverse events, radiographic progression-free survival
- Populations represented
- metastatic; advanced; first-line; metastatic castration-resistant prostate cancer; metastatic; general population
- Mechanism
- However, prognosis remains poor for some patients despite second-generation androgen receptor antagonist-based doublet therapy Mechanistically, GLUL-driven metabolic reprogramming reshaped bioenergetic and redox homeostasis and was tightly coupled to pro-survival signaling activation, forming a coordinated metabolism-signaling network that supports chemoresistance
preliminary evidence
Radioisotopes
8 linked PMIDs9281 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, reported clinical outcomes, quality of life
- Populations represented
- metastatic castration-resistant prostate cancer; metastatic; metastatic; metastatic castration-resistant prostate cancer; metastatic; PSA; PSA; metastatic castration-resistant prostate cancer; advanced; metastatic; PSA
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
apalutamide
7 linked PMIDs18728 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- progression-free survival, overall survival, mortality, adverse events, quality of life
- Populations represented
- metastatic castration-sensitive prostate cancer; metastatic; PSA; metastatic
- Mechanism
- However, prognosis remains poor for some patients despite second-generation androgen receptor antagonist-based doublet therapy
preliminary evidence
darolutamide
7 linked PMIDs17940 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- recurrence, overall survival, mortality
- Populations represented
- general population; metastatic
- Mechanism
- PSMA is indirectly modulated by androgen signalling through the androgen receptor (AR) pathway and has been observed to undergo transient upregulation following treatment with AR targeting agents, such as darolutamide, particularly in patients with castration-resistant PCa However, prognosis remains poor for some patients despite second-generation androgen receptor antagonist-based doublet therapy
limited evidence
MicroRNAs
6 linked PMIDs— reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence, biochemical recurrence
- Populations represented
- general population
- Mechanism
- The study was to explore the influence of lncSPATA8-AS1 on PCa and its molecular mechanism of action Mechanistically, lncSPATA8-AS1 affects the expression of EPHB2 by interacting with miR-653-5p, thereby regulating the malignant biological behavior of PCa
05
Conflicting Research
higher-confidence evidence
44 studiesradiotherapy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 31null: 7benefit: 3harm: 3
higher-confidence evidence
37 studiesradical prostatectomy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
null: 9unknown: 25harm: 3
higher-confidence evidence
36 studiesProstate-Specific Antigen · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: PSA. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 26null: 5mixed: 1benefit: 3harm: 1
higher-confidence evidence
20 studiesandrogen deprivation therapy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 18null: 1harm: 1
higher-confidence evidence
13 studiesAndrogen Antagonists · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 10benefit: 1null: 1harm: 1
higher-confidence evidence
13 studiesAndrogen Antagonists · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 11null: 1harm: 1
higher-confidence evidence
12 studiesradical prostatectomy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: PSA. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
null: 4mixed: 1unknown: 6benefit: 1
higher-confidence evidence
9 studiesProstate-Specific Antigen · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
harm: 2unknown: 6benefit: 1
higher-confidence evidence
9 studiesDocetaxel · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 7null: 1harm: 1
higher-confidence evidence
8 studiesradiotherapy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: PSA. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 6null: 1mixed: 1
higher-confidence evidence
7 studiesandrogen deprivation therapy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: PSA. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 5null: 1benefit: 1
higher-confidence evidence
5 studiesenzalutamide · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
null: 2benefit: 1unknown: 2
06
Failed or Negative Trials
Metformin Active Surveillance Trial in Low-Risk Prostate Cancer.
randomized controlled trial · 2025 · PMID 41166665
Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy.
phase 3 clinical trial · 2026 · PMID 42127891
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.
randomized controlled trial · 2026 · PMID 42061373
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.
randomized controlled trial · 2026 · PMID 42161369
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.
randomized controlled trial · 2026 · PMID 41033927
Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility.
randomized controlled trial · 2026 · PMID 41778764
The effect of povidone-iodine-enhanced rectal enema on procedure-related infectious complications before transrectal ultrasound-guided prostate biopsy: A prospective randomized study.
randomized controlled trial · 2026 · PMID 42152336
Functional outcomes of hypothermic robot assisted radical prostatectomy using BELLOCOOL in a randomized controlled trial.
randomized controlled trial · 2025 · PMID 41291046
Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.
randomized controlled trial · 2026 · PMID 41896701
Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.
randomized controlled trial · 2025 · PMID 41100113
07
Emerging and Experimental Research
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).
randomized controlled trial · 2026 · PMID 42096662
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.
randomized controlled trial · 2026 · PMID 42319132
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.
randomized controlled trial · 2026 · PMID 42269655
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.
randomized controlled trial · 2026 · PMID 41649873
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.
randomized controlled trial · 2026 · PMID 42372744
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.
randomized controlled trial · 2026 · PMID 42493213
Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.
randomized controlled trial · 2026 · PMID 41927282
Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo.
randomized controlled trial · 2026 · PMID 42303538
Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.
randomized controlled trial · 2026 · PMID 42113507
Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.
phase 3 clinical trial · 2026 · PMID 41587107
08
Evidence Gaps
Detailed risk-of-bias assessment remains limited
PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care60 records
Rank112.0
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41744290
PURPOSE: The continuous development of new imaging approaches, molecular phenotyping, genetic subtypes, prognosis assessments, and effective therapies across a range of disease states has created a need to redefine terminology and best practices for clinical trial conduct in patients with advanced prostate cancer. METHODS: We convened an international expert committee of diverse working groups, the Prostate Cancer Working Group 4 (PCWG4), between 2016 and 2025. Our objective was to formulate updated criteria based …
Rank110.0
Prescription of PARP inhibitors (iPARP) in metastatic castration-resistant prostate cancer: a position paper of the Spanish Association of Urology (AEU) and its Uro-Oncology Group (GUO).
Actas urologicas espanolas · 2026 · PMID 41500457
In recent months, restrictions have been proposed on the prescription of PARP inhibitors (iPARP) by urologists in metastatic castration-resistant prostate cancer (mCRPC). The Spanish Association of Urology (AEU), its Uro-Oncology Group (GUO), and the presidents of the Regional Urology Associations consider these limitations unjustified from clinical, organizational, legal, or professional perspectives. They unduly restrict the exercise of competencies recognized in the interdisciplinary management of prostate cance…
Rank110.0
[Genitourinary Oncology Committee of Chinese Anti-Cancer Association (CACA-GO) guideline for prostate cancer for patients (2025 edition)].
Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 41876195
Prostate cancer is a relatively common malignant tumor in the genitourinary system of elderly men, posing a heavy burden to the public health. In order to disseminate the knowledge of early screening and diagnosis of prostate cancer, effectively promote the prevention and treatment of prostate cancer in China, and improve patients' cognition of prostate cancer,the Genitourinary Oncology Committee of Chinese Anti-Cancer Association organized a panel of experts to formulate the "Genitourinary Oncology Committee of Ch…
Rank110.0
Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer.
Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia · 2026 · PMID 42102633
With the approval of PARP inhibitors (PARPi), both as monotherapy and in combination with androgen receptor signalling inhibitors (ARSi), for metastatic castration-resistant prostate cancer (mCRPC) and their rapid development in earlier disease settings, there is an urgent need to integrate homologous recombination repair (HRR) testing into daily clinical practice to identify patients who may benefit from these therapies and to improve patient management. Alterations in HRR genes are found in approximately 15-30% o…
Rank110.0
Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management.
The Journal of urology · 2026 · PMID 42095477
PURPOSE: This Guideline covers the treatment of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). The summary presented herein represents Part II of the three-part series dedicated to Management of LUTS attributed to BPH. Please refer to Parts I and III for additional information on this topic. MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic …
Rank110.0
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).
The Journal of urology · 2026 · PMID 41988960
PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2022 publication of this Guideline via the AUA Amendment process. The resulting 2026 Guideline Amendment addresses updated recommendations to provide a clinical framework for the evaluation and management of clinically localized prostate cancer. MATERIALS AND METHODS: In 2025, this Guideline was reviewed via the AUA ULR process, which identified 29 studies…
Rank110.0
The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease.
Scandinavian journal of urology · 2026 · PMID 42012147
OBJECTIVE: This article presents a summary of the 2025 Swedish prostate cancer guidelines, focusing on recurrence after local treatment, metastatic disease, and castration-resistant prostate cancer. RESULTS: The 2025 Swedish guidelines introduce several important updates. Prostate specific membrane antigen (PSMA)-PET/CT is recommended only when PSA exceeds 0.2 µg/L, and reporting should follow the defined PSMA-RADS-scale. PSMA-PET/CT is preferred over lymph-node dissection for staging. A strong recommendation is is…
Rank110.0
ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride.
American journal of clinical oncology · 2026 · PMID 40851434
OBJECTIVES: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The document represents an update of the radium-223 therapy practice parameter developed by the societies in 2019. METHODS: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Paramete…
Rank110.0
Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026).
The Journal of urology · 2026 · PMID 41744286
PURPOSE: The recommendations discussed on the early detection of prostate cancer provide a framework to facilitate clinical decision-making in the implementation of prostate cancer screening and follow-up. MATERIALS AND METHODS: The Early Detection of Prostate Cancer Guideline was reviewed in 2025 and updated through the AUA amendment process. This process involved reviewing and integrating newly published literature into the previously established Guideline. The methodologist updated the original Guideline search …
Rank110.0
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 42134408
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients…
Rank100.0
Latin American Consensus for the Diagnosis and Treatment of Metastatic Castration-Sensitive Prostate Cancer.
Clinical genitourinary cancer · 2026 · PMID 41963237
The treatment of metastatic castration-sensitive prostate cancer (mCSPC) is complex, requiring strategies to prevent complications and improve survival outcomes. In resource-limited settings, it is essential to guide clinical practice to ensure patients receive the best available diagnostic and treatment options. This consensus aims to provide updated recommendations for the diagnosis and management of mCSPC in Latin America. This consensus was developed with the participation of clinical experts from multiple Lati…
Rank78.9
Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41667886
PURPOSE: We aimed to describe treatment patterns of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who progressed after receiving darolutamide in a real-world setting, and according to the standard clinical practice in Spain. METHODS: This was a multicenter, observational, retrospective study conducted at the urology and oncology departments of 17 Spanish hospitals that participated in the ARAMIS trial and its rollover study. RESULTS: 85 patients, with a median age of 76 years, were inclu…
Rank72.0
PURE-MRI: An international study assessing physician accuracy in delineating the prostate and urethra on prostate MRI.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 41412436
PURPOSE: Precise delineation of genitourinary structures during prostate cancer (PCa) care is critical to optimize treatment delivery while minimizing toxicity and injury. The Prostate and UREthra on MRI (PURE-MRI) study is an international, prospective study to assess physicians' accuracy segmenting prostate and urethra on MRI. METHODS: Physicians who diagnose or treat PCa were invited to contour prostate and urethra on patient cases using standard T2-weighted MRI (all planes). We compared these contours to refere…
Rank54.0
Smooth Muscle Disruptive Feature Defines Molecular Subtyping, Risk Stratification, and Metastatic Potential in Prostate Cancer.
Annals of surgical oncology · 2026 · PMID 41428021
BACKGROUND: Smooth muscle (SM) invasion represents a critical feature of prostate cancer (PCa) progression and metastasis. This study aimed to develop a SM-based molecular score for progression and metastasis forecasting for PCa. PATIENTS AND METHODS: A total of 952 patients with PCa with transcriptomic sequencing data and corresponding clinical information were included in this study to develop and validate a SM-related signature (SM score). SM-related molecular subtypes were identified on the basis of 35 smooth m…
Rank51.2
Whole-Slide Telepathology Grading of Prostate Cancer in Biopsies Using International Society of Urological Pathology Criteria: Interobserver and Intraobserver Concordance and Implications for Active Surveillance.
The Journal of urology · 2026 · PMID 41461080
PURPOSE: Subjectivity of prostate cancer (PCa) grading affects biomarker investigations, assessments of imaging, and treatment decisions, especially for active surveillance. We conducted the first telepathology concordance study of PCa needle biopsy grading using contemporary International Society of Urologic Pathology guidelines. METHODS: Whole slide images (n = 120) of PCa biopsy cases across grade groups (GGs) were examined by 11 urologic pathologists. Forty cases were blindly regraded, oversampling cases with l…
Rank50.2
Prostate MRI quality assessment using PI-QUAL version 2: Comparative analysis between 1.5 T and 3 T scanners and its association with T-staging agreement.
European journal of radiology · 2026 · PMID 41916137
PURPOSE: To assess prostate MRI image quality using Prostate Imaging Quality (PI-QUAL) version 2, to compare quality distributions between 1.5 T and 3 T MRI scanners, and to evaluate the association between image quality and concordance of MRI-based and pathological T-staging. MATERIALS AND METHODS: This retrospective study included 416 patients who underwent preoperative prostate MRI followed by radical prostatectomy between December 2021 and August 2024. MRI examinations were performed using one 1.5 T scanner and…
Rank49.8
Noninvasive Prediction of Perineural Invasion and Lymphovascular Invasion in Prostate Cancer Using bpMRI Radiomic Signatures.
Academic radiology · 2026 · PMID 41513575
OBJECTIVE: Perineural invasion (PNI) and lymphovascular invasion (LVI) are critical predictors of aggressive behavior and poor prognosis in prostate cancer (PCa), yet their diagnosis relies on postoperative histopathology. This study aims to develop a noninvasive radiomic model based on biparametric magnetic resonance imaging (bpMRI) for preoperative prediction of PNI and LVI. METHODS: A total of 256 patients with pathologically confirmed PCa who underwent radical prostatectomy were retrospectively enrolled. Patien…
Rank49.2
[A QUESTIONNAIRE SURVEYON TREATMENT SELECTION FOR PATIENTS WITH ADVANCED PROSTATE CANCER IN JAPAN].
Hinyokika kiyo. Acta urologica Japonica · 2026 · PMID 42374892
We conducted a web-based questionnaire survey targeting urologists in Japan on the real-world treatment selection for patients with advanced prostate cancer. The results were stratified by medical institution category and compared with those reported in the Advanced Prostate Cancer Consensus Conference 2024 (APCCC24). The survey included 124 urologists working at cancer centers/university hospitals (n＝48), public hospitals (n＝32), and general hospitals (n＝44). The proportion of respondents who selected triplet ther…
Rank48.8
Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.
European radiology · 2026 · PMID 41493546
OBJECTIVE: Indeterminate lesions on prostate-specific membrane antigen (PSMA)-PET are challenging to address. We aimed to develop, implement, and evaluate a multidisciplinary consensus algorithm that integrates existing interpretation systems with multimodality imaging and clinicopathological information for interpreting indeterminate bone and lymph node lesions on PSMA-PET. MATERIALS AND METHODS: This was a retrospective single-center study on a prospectively implemented algorithm. We included all consecutive pros…
Rank48.4
Inter-Vendor Variability of Perfusion Parameters Derived from Dynamic Contrast-Enhanced MRI in Patients with Prostate Cancer.
Tomography (Ann Arbor, Mich.) · 2026 · PMID 42506856
Purpose: To investigate the agreement on perfusion parameters derived from two different commercially available solutions for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with prostate cancer (PCa). Methods: A total of 50 patients (mean age, 71.6; range 56-86) who had undergone radical prostatectomy between December 2021 and September 2022 were included in this retrospective study. All patients had undergone DCE-MRI on a single 3T-MR scanner. Tumor segmentation on MR images was perform…
Rank48.4
[18F]Fluciclovine PET/CT versus [18F]DCFPyL PET/CT in patients with biochemical recurrence of prostate cancer after robot-assisted radical prostatectomy: a prospective, single-center, single-arm, comparative imaging trial.
European journal of nuclear medicine and molecular imaging · 2026 · PMID 41762267
PURPOSE: The current EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines recommend radiolabeled prostate-specific membrane antigen (PSMA), choline, or fluciclovine PET/CT at biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy. While studies compared [68Ga]Ga-PSMA-11 and [18F]Fluciclovine, data on 18F-labelled PSMA-ligands versus [18F]Fluciclovine in patients with low prostate-specific antigen (PSA) levels (< 2 ng/mL) are limited. This study compared the detection rates of [18F]Fluciclovine and [1…
Rank48.2
Efficacy and limitations of diffusion-weighted imaging with background suppression-based whole-body magnetic resonance imaging in high-risk prostate cancer staging: A retrospective study.
PloS one · 2026 · PMID 42490591
PURPOSE: To evaluate the diagnostic performance and limitations of whole-body magnetic resonance imaging (WB-MRI) using diffusion-weighted imaging with background body signal suppression (DWIBS) for staging high-risk prostate cancer (PCa) in comparison with conventional computed tomography (CT) and bone scintigraphy (BS). MATERIALS AND METHODS: This retrospective study included 38 patients with newly diagnosed high-risk PCa who underwent CT, bone scintigraphy (BS), and DWIBS, all performed within two months prior t…
Rank48.1
Diagnostic performance of PSMA PET/CT, multiparametric MRI, and combined imaging for local prostate cancer recurrence after radical prostatectomy.
Abdominal radiology (New York) · 2026 · PMID 41204951
OBJECTIVES: Approximately 20-50% of patients develop biochemical recurrence (BCR) of prostate cancer within 10 years following radical prostatectomy (RP). The accurate identification of recurrent disease is crucial for guiding salvage treatment decisions. While multiparametric MRI (mpMRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) are both utilized for detecting local recurrence, their combined diagnostic benefits remain unclear. This study seeks to evaluat…
Rank47.8
Generative Artificial Intelligence for Medical Summarization in Prostate Cancer: Comparative Evaluation by Physicians and Patient Advocates-A Pilot Study.
JCO clinical cancer informatics · 2026 · PMID 41926718
PURPOSE: The exponential growth of scientific publications presents increasing challenges for clinicians and patients seeking to access up-to-date medical information. Language models (LMs) have emerged as powerful tools for generating and summarizing scientific content, but their performance in oncology remains insufficiently characterized from both professional and patient perspectives. MATERIALS AND METHODS: We conducted a prospective, survey-based pilot study evaluating four LMs: Llama 3, Mistral Large 2, Gemma…
Rank47.7
Development of a prostate cancer survivorship care toolkit for Black men with clinical and contextual tailoring.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42489746
PURPOSE: Black men experience the highest prostate cancer (CaP) burden among all racial and ethnic groups, underscoring the urgent need for research to guide the development and implementation of culturally tailored strategies aimed at reducing disparities and improving health outcomes. Survivorship care resources are recommended to educate patients and provide them with better information about their cancer diagnosis, treatment, and follow-up care, thereby empowering them to be active participants in their own sur…
Diagnosis And Screening108 records
Rank110.0
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.
Nature genetics · 2025 · PMID 39930085
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10-8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) …
Rank108.5
Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 41966893
Circulating tumor DNA (ctDNA) is a minimally invasive biomarker that enables molecular profiling and prognostic stratification in cancer. This meta-analysis evaluated the prognostic significance of ctDNA in metastatic prostate cancer (mPC). PubMed, Web of Science and Scopus were searched from inception to September 15, 2025 for studies assessing ctDNA and survival in prostate cancer. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were extracted; when unavailable, HRs were reconstr…
Rank106.4
The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.
Human vaccines & immunotherapeutics · 2026 · PMID 41672480
Some immune checkpoint inhibitors (ICI) has been used for men with specific metastatic castration-resistant prostate cancer (mCRPC). However, inconsistent results of ICI for unselected mCRPC population raise concerns. The primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS), and the secondary outcomes included objective response rate (ORR). Individual patient data (IPD) were reconstructed from reported survival curve, and Kaplan-Meier method was used to evaluate the efficacy.…
Rank105.4
Integrative analysis of clinical and epigenetic biomarkers of mortality.
Aging cell · 2022 · PMID 35546478
DNA methylation (DNAm) has been reported to be associated with many diseases and with mortality. We hypothesized that the integration of DNAm with clinical risk factors would improve mortality prediction. We performed an epigenome-wide association study of whole blood DNAm in relation to mortality in 15 cohorts (n = 15,013). During a mean follow-up of 10 years, there were 4314 deaths from all causes including 1235 cardiovascular disease (CVD) deaths and 868 cancer deaths. Ancestry-stratified meta-analysis of all-ca…
Rank102.0
Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.
International journal of cancer · 2026 · PMID 42015666
Prostate cancer overdiagnosis is detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime. It is a major concern to policymakers due to its impact on quality of life. We used long-term follow-up data from the CAP randomised trial of a one-off screen, and English male competing mortality rates (2021-23), to estimate the impact of age on excess prostate cancer incidence within 15 years ('overdiagnosis') using competing-risks methods. In total, 2249 (1…
Rank100.0
Systematic Review of Genomic-Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence.
Cancer medicine · 2026 · PMID 41802997
BACKGROUND: Several genomic risk stratification tests are available to predict the risk of metastasis and mortality for prostate cancer patients at the time of diagnosis. However, the evidence supporting the clinical utility of genomic risk stratification tools is fragmented, posing challenges in assessing their real-world clinical impact and cost-effectiveness. OBJECTIVE: To review and summarise the clinical impact and health economic evidence of the four types of genomic risk stratification tests and to validate …
Rank100.0
Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology- and European Randomized Study of Screening for Prostate Cancer-based strategies.
International journal of cancer · 2026 · PMID 41741956
Prostate cancer (PC) screening reduces PC mortality but also causes burden such as overdiagnosis and unnecessary biopsies. The European Association of Urology (EAU) recently proposed a risk-adapted screening protocol incorporating prostate-specific antigen (PSA)-based intervals, a risk calculator (RC), and magnetic resonance imaging (MRI), though its long-term outcomes remain unquantified. We constructed the MIcrosimulation SCreening Analysis-PSA model by adapting the existing MIcrosimulation SCreening Analysis-PRO…
Rank85.0
Apalutamide-induced prostate-specific antigen response and its association with clinical outcomes in metastatic castration sensitive prostate cancer (Review).
Molecular and clinical oncology · 2026 · PMID 42534213
Prostate-specific antigen (PSA) kinetics in metastatic castration-sensitive prostate cancer (mCSPC) have been evaluated as prognostic markers in relation to clinical outcomes under apalutamide plus androgen deprivation therapy (ADT). A literature search was conducted via PubMed, Scopus and Google Scholar. Randomized controlled trials, post hoc analyses, and real-world and retrospective cohort studies were included. Early and deep PSA responses (for example, PSA50, PSA90, PSA ≤0.2 ng/ml, ultralow PSA) were found to …
Rank85.0
Pelvic lymph node dissection in prostate cancer: current evidence, controversies, and future directions.
Annals of medicine · 2026 · PMID 41999318
BACKGROUND: Pelvic lymph node dissection (PLND) remains controversial in the management of prostate cancer. Although it provides the most accurate pathological staging, its therapeutic value beyond staging has long been debated due to conflicting evidence and concerns regarding procedure-related morbidity. OBJECTIVE: To critically evaluate the contemporary role of PLND, particularly extended pelvic lymph node dissection (ePLND), in prostate cancer management in the context of modern imaging, risk stratification too…
Rank78.3
Fat quality, not quantity, linked to reduced risk of advanced and lethal prostate cancer in US populations: a large prospective multicenter study.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 · PMID 41562707
BACKGROUND: Epidemiological evidence on dietary fat intake and advanced prostate cancer (PCa) risk is limited and inconclusive; moreover, no prospective study has been conducted to investigate the association between fat quality and quantity and advanced and lethal PCa risk. METHODS: This prospective cohort included 49 424 men from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. The fat quality index (FQI) and low-fat diet score (LFDs) were used to evaluate the quality and quantity separately, w…
Rank76.0
Hematological Inflammation Markers in the Prediction of Clinically Significant Prostate Cancer and the Individualization of Biopsy Decisions for PI-RADS 3 Lesions: A Two-Center Retrospective Study.
The Prostate · 2026 · PMID 42314010
BACKGROUND: PI-RADS 3 lesions represent a diagnostic "gray zone" in which biopsy decision-making is particularly challenging, with reported clinically significant prostate cancer (csPCa) detection rates ranging from 13% to 50%. This study evaluated the predictive value of the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR)-alone and in combination with PSA density (PSAD) and PI-RADS score-for the detection of prostate cancer (PCa) and csPCa, wit…
Rank67.0
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534.
Investigational new drugs · 2026 · PMID 41774321
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) that combines AR antagonism and degradation via N-terminal domain binding, additionally targeting AR splice variants. In this study patients received ONCT-534 daily ranging from 40 to 1200 mg. The primary objectives were safety and dose-limiting toxicities (DLTs). Additional objectives included antitumor activity and AR signaling biomarkers. Adverse events (AEs) were assessed within the first 28 days for DLTs. Clinical activity was evaluated by PSA and r…
Rank56.2
Comprehensive Characterization of Metastatic Patterns and a Redefined Prognostic Framework in Metastatic Prostate Cancer.
The Prostate · 2026 · PMID 42263174
BACKGROUND: Metastatic prostate cancer (mPCa) exhibits highly complex metastatic patterns. Comprehensive evaluation of distinct metastatic patterns and their integrated prognostic impact remains lacking. METHODS: Patients with mPCa were identified from the Surveillance, Epidemiology, and End Results (SEER) database, and metastatic patterns were systematically characterized. Cancer-specific survival (CSS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using multivariable Cox regr…
Rank52.9
Prostate and colorectal cancer screening among sexual minority individuals assigned male at birth in Japan: Evidence from a national online survey.
Annals of epidemiology · 2026 · PMID 42263793
PURPOSE: To assess whether sexual and gender minority individuals assigned male at birth (SGM-AMAB) differ from heterosexual individuals in prostate and colorectal cancer screening participation and intention among age-eligible AMAB participants in Japan. METHODS: Using data from the 2023 JACSIS survey, we analyzed 9043 AMAB participants aged 40 years and older with available prostate and colorectal cancer screening information. Screening behavior was categorized as screened, intending to screen, or not screened. M…
Rank52.6
The prevalence and predictors of previous prostate cancer screening among men attending primary healthcare centers in Riyadh, Saudi Arabia.
Annals of medicine · 2026 · PMID 41830420
BACKGROUND: Early detection through screening is crucial for improving treatment outcomes and reducing disease burden. . This study investigates the predictors of previous prostate cancer screening among Saudi men attending primary healthcare centers (PHCs) in Riyadh, Saudi Arabia. METHODS: A cross-sectional study was conducted from March to July 2023, involving 6,177 men attending 48 PHCs in Riyadh, selected via multistage cluster sampling. Unadjusted and adjusted logistic regression analyses were performed to ide…
Rank51.0
Incorporating functional soft tissue deformations in AI model training for spatially accurate prostate cancer detection.
Magnetic resonance imaging · 2026 · PMID 42097246
PURPOSE: To increase performance and generalization ability of artificial intelligence prostate cancer detection systems by simulating physiological size changes of the bladder and rectum and, thereby, associated deformations of the prostate and its lesions. MATERIALS AND METHODS: This retrospective study included 1028 bi-parametric MRI examinations of men (age range: 40-90 years) performed between 2014 and 2019, divided into training/test sets (771/257). We integrated an 'anatomy-informed' transformation into the …
Rank51.0
Clinical pathological changes in prostate cancer patients after hormonal therapy: A single-center pilot study.
Biochemistry and biophysics reports · 2026 · PMID 42437084
BACKGROUND: Prostate cancer (PCa) remains a leading malignancy with variable prognosis, and while PSA is widely used for disease monitoring, it frequently lacks sufficient specificity. This study investigated plasma coagulation parameters, inflammatory cytokines, and molecular markers as complementary biomarkers in PCa patients undergoing hormonal therapy. METHODS: In a prospective single-center pilot study, patients with newly diagnosed PCa were evaluated alongside patients with benign prostatic hyperplasia (BPH) …
Rank50.9
Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors.
Journal of medical economics · 2026 · PMID 41915379
AIMS: The rapid development of therapies linked to molecular biomarkers has increased the importance of next-generation sequencing (NGS)-based tumor profiling to guide treatment decisions. Technology has enabled more comprehensive clinical testing; however, the optimal economic approach deserves investigation. This study evaluated the impact of testing using whole-exome, whole-transcriptome sequencing (WES/WTS) versus 50-gene panel tests from a US payer perspective. MATERIALS AND METHODS: A previously published Mic…
Rank50.6
NF-κB (p65, p50), IL-18, and IL-10 as Therapeutic Targets in Prostate Cancer and BPH: Molecular Insights into Inflammation-Driven Pathogenesis.
Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 41569207
BACKGROUND: Prostate cancer is a significant global health burden and is the second most commonly diagnosed malignancy among men. Chronic inflammation and environmental exposures, including occupational toxins, are increasingly recognized as key contributors to its development. Nuclear factor kappa B (NF-κB) subunits p65 and p50, along with the cytokines IL-18 and IL-10, are central mediators of inflammation, but remain understudied in the context of benign prostatic hyperplasia (BPH) and occupation-related risks. …
Rank50.4
Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria.
The Prostate · 2026 · PMID 42257571
BACKGROUND: While guidelines state that patients with NCCN favorable intermediate risk (FIR) prostate cancer (PCa) may consider active surveillance (AS), there is a relative lack of longer term follow up data informing AS inclusion criteria of patients with Grade Group (GG) 2 prostate cancer in the MRI era. Here we evaluate patient outcomes from a MRI-screened AS-eligible cohort of FIR GG2 PCa receiving radical prostatectomy (RP). METHODS: Patients with prostate MRI, NCCN FIR GG2 PCa (PSA < 10 ng/mL, ≤ cT2a, < 50% …
Rank50.4
Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model.
European urology focus · 2026 · PMID 41864782
BACKGROUND AND OBJECTIVE: Although the effects of 5-α-reductase inhibitors (5-ARIs) on prostate-specific antigen (PSA) have been well-studied, the effects on other kallikrein markers have not been firmly established. Accordingly, a statistical model based on blood measurements of four kallikreins-known commercially as the "4Kscore"-cannot be used for men taking 5-ARIs. We investigated how finasteride affects kallikrein markers and whether suitably adjusted marker levels could be used in the four-kallikrein model to…
Rank49.9
Diagnostic impact of interpretation criteria for [18F]PSMA-1007 PET/CT: Prospective comparison with CT and bone scan.
European journal of nuclear medicine and molecular imaging · 2026 · PMID 42168644
PURPOSE: The PSMA Reporting and Data System (PSMA-RADS) has been proposed to standardize the interpretation of PSMA-PET. However, its diagnostic performance has not been fully validated. This study aimed to determine the optimal interpretation criteria for PSMA-PET and to compare its diagnostic performance with conventional imaging. METHODS: This prospective study enrolled 284 patients across various disease stages who underwent [¹⁸F]PSMA-1007 PET/CT. Diagnostic performance was evaluated using different positivity …
Rank49.7
Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zone.
Adipocyte · 2026 · PMID 42231146
Periprostatic adipose tissue (PPAT) is a potential factor closely associated with prostate cancer (PCa) development. This study aimed to introduce normalized PPAT thickness, a novel imaging biomarker, as a PCa predictor for patients within the diagnostic 'double gray zone', defined as the combination of Prostate Imaging Reporting and Data System (PI-RADS) score 3 lesions and serum prostate-specific antigen (PSA) levels of 4-10 ng/mL. A total of 219 patients were retrospectively enrolled. PPAT thickness was measured…
Rank49.3
Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4-10 ng/mL.
The Prostate · 2026 · PMID 42262267
BACKGROUND: Prostate-specific antigen (PSA) is a widely used prostate cancer marker; however, its use is limited by its low specificity. Novel biomarkers are being explored to avoid unnecessary biopsies. A new prostate cancer marker, S2,3PSA, became eligible for insurance coverage in February 2024. MATERIAL AND METHODS: A total of 144 patients underwent S2,3PSA measurement prior to prostate biopsy at Asahikawa Kosei Hospital and Teine Keijinkai Hospital. PI-RADS score on MRI, PSA level, prostate volume (PV), and Gl…
Rank49.2
[18F]PSMA-1007 PET-Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42533777
OBJECTIVES: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is a sensitive imaging modality for detecting recurrent prostate cancer following definitive local therapy. However, evidence on 18F-labeled PSMA tracers in Japanese patients with biochemical recurrence (BCR) remains limited. The aim of this study was to examine the recurrence site distribution by [18F]PSMA-1007 PET in patients with BCR and identify factors associated with metastatic disease. METHODS: We retrospectively analyzed …
Evidence Syntheses65 records
Rank112.8
Magnetic Resonance Imaging-Based Artificial Intelligence in Predicting Prostate Cancer Biochemical Recurrence: Systematic Review and Meta-Analysis.
Journal of medical Internet research · 2026 · PMID 42412916
BACKGROUND: Artificial intelligence (AI) has emerged as a promising tool for prostate cancer (PCa) risk stratification and outcome prediction. However, current studies often lack multicenter external validation, have limited sample sizes, present significant intermodel variability, and face overfitting concerns. OBJECTIVE: This study aimed to comprehensively evaluate the diagnostic performance of magnetic resonance imaging (MRI)-based AI models in predicting biochemical recurrence (BCR) of PCa. METHODS: Systematic …
Rank110.0
Impact of frailty on overall survival and complications in patients with prostate cancer: a systematic review and meta-analysis.
International urology and nephrology · 2026 · PMID 41712034
PURPOSE: The current systematic review and meta-analysis was designed to assess if the presence of frailty had an adverse impact on overall survival (OS) and complication rates of patients with prostate cancer. METHODS: Two reviewers explored the PubMed, Web of Science, Embase, and Scopus databases until January 3rd, 2026, for studies examining the impact of frailty on OS and complications in patients with prostate cancer. Data on OS were pooled as a hazard ratio (HR), while short-term mortality and complications w…
Rank110.0
Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer.
Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia · 2026 · PMID 42102633
With the approval of PARP inhibitors (PARPi), both as monotherapy and in combination with androgen receptor signalling inhibitors (ARSi), for metastatic castration-resistant prostate cancer (mCRPC) and their rapid development in earlier disease settings, there is an urgent need to integrate homologous recombination repair (HRR) testing into daily clinical practice to identify patients who may benefit from these therapies and to improve patient management. Alterations in HRR genes are found in approximately 15-30% o…
Rank110.0
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.
Nature genetics · 2025 · PMID 39930085
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10-8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) …
Rank110.0
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).
The Journal of urology · 2026 · PMID 41988960
PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2022 publication of this Guideline via the AUA Amendment process. The resulting 2026 Guideline Amendment addresses updated recommendations to provide a clinical framework for the evaluation and management of clinically localized prostate cancer. MATERIALS AND METHODS: In 2025, this Guideline was reviewed via the AUA ULR process, which identified 29 studies…
Rank110.0
Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management.
The Journal of urology · 2026 · PMID 42095477
PURPOSE: This Guideline covers the treatment of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). The summary presented herein represents Part II of the three-part series dedicated to Management of LUTS attributed to BPH. Please refer to Parts I and III for additional information on this topic. MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic …
Rank109.7
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.
Targeted oncology · 2026 · PMID 42371314
BACKGROUND: Abiraterone (ABI) and enzalutamide (ENZA) are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, their safety and efficacy have not been directly compared in prospective clinical trials. OBJECTIVE: To directly compare their safety and efficacy in prospective clinical trials. PATIENTS AND METHODS: A systematic search was performed in PubMed, Embase, and Cochrane Library databases (CRD42024608496) on 24 June 2025. Eligibility criteria included studies on patients wit…
Rank109.4
Post-diagnosis physical activity in relation to mortality among prostate cancer survivors: a systematic review and meta-analysis.
Cancer causes & control : CCC · 2026 · PMID 42348026
BACKGROUND: Physical activity after cancer diagnosis may reduce mortality. However, systematic evidence for this association for men living with prostate cancer remains limited. METHODS: We searched PubMed, Embase, and CINAHL data bases from start to June 2025. Random-effects meta-analyses estimated summary hazard ratios (HRs) and 95% confidence intervals (CI) for all-cause mortality and prostate-cancer-specific mortality to assess the association between post-diagnosis physical activity, measured in metabolic equi…
Rank108.5
Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 41966893
Circulating tumor DNA (ctDNA) is a minimally invasive biomarker that enables molecular profiling and prognostic stratification in cancer. This meta-analysis evaluated the prognostic significance of ctDNA in metastatic prostate cancer (mPC). PubMed, Web of Science and Scopus were searched from inception to September 15, 2025 for studies assessing ctDNA and survival in prostate cancer. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were extracted; when unavailable, HRs were reconstr…
Rank107.9
Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer.
Seminars in nuclear medicine · 2026 · PMID 42225513
Prostate-specific membrane antigen (PSMA) PET has become a highly accurate imaging modality for prostate cancer (PCa), demonstrating superior diagnostic performance. However, substantial variability exists in imaging protocols beyond standard time-point acquisition, and the clinical value of these variations remains unclear. The aim of this study is to systematically review and compare PSMA PET protocols in PCa patients, focusing on detection rates and potential advantages, using extracted data from published studi…
Rank107.9
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.
Clinical genitourinary cancer · 2026 · PMID 42285797
PURPOSE: To systematically review and synthesize the evidence for Prolaris, a combined clinical risk (CCR) score that stratifies individual patient risk and provides a decision-making tool that impacts medical management across key decision points in the localized prostate cancer care continuum. PATIENTS AND METHODS: A systematic literature search was performed, and individual participant data (IPD) were collected where possible to perform a two-step IPD analysis. The primary endpoint was composite distant metastas…
Rank107.9
Transrectal vs transperineal prostate biopsy: a systematic review and meta-analysis.
BJU international · 2026 · PMID 41800666
OBJECTIVE: To compare transrectal ultrasonography (TRUS) and local anaesthetic transperineal (LATP) biopsy. METHODS: A systematic review of randomised control trials and prospective studies meeting eligibility criteria was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: A total of 12 studies with 8497 patients were included. LATP biopsy was performed in 3961 patients and TRUS biopsy in 4536. Patient characteristics were comparable in both grou…
Rank107.9
The impact of abiraterone and enzalutamide on hypokalemia incidence in patients with prostate cancer: a systematic review and meta-analysis.
BMC cancer · 2026 · PMID 42387420
OBJECTIVE: To systematically evaluate the incidence of hypokalemia associated with novel androgen receptor axis-targeted therapies (ARATs)-specifically abiraterone, enzalutamide, and their combination-in patients with advanced prostate cancer. METHODS: A comprehensive search of PubMed, Embase, and the Cochrane Library was conducted to identify published randomized controlled trials (RCTs). Risk of bias was assessed using the Cochrane Risk of Bias tool. A random-effects model was employed to pool risk ratios (RRs) a…
Rank107.9
Diagnostic Performance of Biparametric versus Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis: An Updated Systematic Review and Meta-analysis.
European urology · 2026 · PMID 41702800
BACKGROUND AND OBJECTIVE: Multiparametric magnetic resonance imaging (mpMRI) is the reference modality for detecting clinically significant prostate cancer (csPC). Biparametric MRI (bpMRI), which omits contrast, has emerged as a streamlined alternative. Recent studies have demonstrated the noninferiority of bpMRI to mpMRI for csPC detection in biopsy-naïve men. We performed an updated systematic review and meta-analysis of head-to-head studies comparing bpMRI and mpMRI for csPC detection, and conducted a noninferio…
Rank107.7
Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.
International journal of radiation oncology, biology, physics · 2026 · PMID 41663033
PURPOSE: The association between late toxicity and biochemical recurrence (BCR) after prostate radiation therapy is unclear. We set out to characterize the relationship between late gastrointestinal (GI) and genitourinary (GU) toxicity and BCR among patients receiving conventionally fractionated (CF) or moderately hypofractionated (MHF) prostate radiation therapy. METHODS AND MATERIALS: This was an individual patient data meta-analysis that identified randomized phase 3 trials of CF or MHF prostate radiation therap…
Rank107.5
The Radical Prostatectomy Versus Brachytherapy for the Management of Low- and Intermediate-Risk Prostate Cancer: A Meta-Analysis of Observational Studies Focusing on Oncological Outcomes.
Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 41569192
OBJECTIVE: This study aims to compare the oncological outcomes of radical prostatectomy (RP) and brachytherapy (BT) in patients with low- and intermediate-risk prostate cancer, and determine whether one treatment demonstrates superiority over the other. METHODS: A systematic literature search was conducted using databases, including PubMed, ScienceDirect, Google Scholar, EBSCO, and the Cochrane Library, to identify relevant clinical studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted, wit…
Rank107.3
Perirectal spacers and endorectal balloons in external beam radiotherapy for prostate cancer: a review of prospective studies.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026 · PMID 42171762
PURPOSE: Endorectal balloons (ERB) and perirectal spacers (RS) were developed to minimize rectal toxicity in prostate cancer radiotherapy. We conducted a review to assess available data. METHODS AND MATERIALS: Literature search was conducted on 20th May, 2025, using PubMed. Prospective studies and meta-analyses assessing the efficacy of ERB and PRS on rectal toxicity were included. Risk of bias was evaluated (MINORS and Cochrane Risk of Bias). Other relevant publications, guideline recommendations and cost-effectiv…
Rank107.3
Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis.
JAMA oncology · 2026 · PMID 42060279
IMPORTANCE: Standard-of-care management of radiorecurrent prostate cancer (PCa) involves systemic therapy; however, some patients seek to avoid the adverse events (AEs) that are associated with androgen-deprivation therapy (ADT). OBJECTIVE: To determine outcomes of local therapy without systemic therapy for radiorecurrent PCa. DATA SOURCES: MEDLINE, Embase, Web of Science Core Collection, and Google Scholar were searched from inception up to May 2025. No date or language filters were used. Data were analyzed from J…
Rank107.2
Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer Outside of Randomized Controlled Trials: A Systematic Review and Meta-Analysis of Prognostic Factors in Real-World Analyses.
Clinical genitourinary cancer · 2026 · PMID 42191465
We aimed to analyze prognostic factors for overall survival (OS) and progression-free survival (PFS) in real-world patients treated with androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPI) for metastatic hormone-sensitive prostate cancer (mHSPC). A systematic literature search was conducted in MEDLINE, Embase, and Web of Science in October 2025. Eligible studies examined prognostic factors for OS or PFS in patients with mHSPC receiving ARPI plus ADT using real-world data. To…
Rank107.1
Radiomics as a tool for predicting biochemical recurrence after total prostatectomy: a systematic review and meta-analysis.
International urology and nephrology · 2026 · PMID 41520314
PURPOSE: Biochemical recurrence (BCR) following radical prostatectomy (RP) remains a significant concern in prostate cancer (PCa) management, as it is associated with an increased risk of metastasis and disease progression. While conventional clinical and pathological prognostic factors are helpful in determining the prognosis, their accuracy remains suboptimal. Radiomics has been shown to be a promising tool for improving risk stratification and outcome prediction in PCa patients post-RP. This systematic review an…
Rank106.8
Artificial-intelligence models vs. radiologists in the detection of clinically significant prostate cancer on mpMRI: a meta-analysis.
European radiology · 2026 · PMID 41844851
OBJECTIVE: Multiparametric magnetic resonance imaging (mpMRI) detects clinically significant prostate cancer (csPCa, Gleason Grade Group ≥ 2) with high sensitivity but limited specificity and inter-reader variability. Artificial intelligence (AI), particularly convolutional neural networks (CNNs) and deep learning, may improve diagnostic consistency and accuracy. This meta-analysis compares AI systems and experienced radiologists in detecting csPCa using mpMRI. METHODS: We performed a systematic review and meta-ana…
Rank106.6
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for ARPI-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer: a pooled analysis of KEYNOTE-921 and CheckMate 7DX trials.
International urology and nephrology · 2026 · PMID 41741934
BACKGROUND: The optimal treatment strategy for androgen receptor pathway inhibitor (ARPI)-pretreated and chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) remains unclear. Chemotherapy has limited efficacy as a monotherapy in unselected mCRPC patients. In contrast, the addition of PD-1/PD-L1 inhibitors to chemotherapy (Chemo-IO) may enhance antitumor activity. We conducted a meta-analysis using data from phase 3 randomized controlled trials (RCTs), with the objective of assessing the compar…
Rank106.6
Single Port Extraperitoneal Versus Multiport Transperitoneal Radical Prostatectomy: A Systematic Review and Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 42108118
The emergence of extraperitoneal single-port robotic-assisted radical prostatectomy (RA-SPRP) as a minimally invasive surgical approach has prompted comparisons with the well-established multi-port transperitoneal technique (RA-MPRP). This study aims to systematically review and analyze perioperative, oncologic, and functional outcomes between RA-SPRP and RA-MPRP. A systematic review and meta-analysis were conducted following PRISMA guidelines and registered in PROSPERO (CRD420250648505). Databases including PubMed…
Rank106.5
Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.
Clinical nuclear medicine · 2026 · PMID 41945370
PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) tracers have reshaped prostate cancer (PC) imaging, supplementing non-PSMA options such as choline-based agents. However, direct comparative performance data across tracers remain scarce, leaving the optimal choice uncertain. We therefore conducted a systematic review and network meta-analysis (NMA) to assess detection rates (DRs) among PET tracers used for primary and biochemically recurrent PC. METHODS: Following PRISMA…
Rank106.4
The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.
Human vaccines & immunotherapeutics · 2026 · PMID 41672480
Some immune checkpoint inhibitors (ICI) has been used for men with specific metastatic castration-resistant prostate cancer (mCRPC). However, inconsistent results of ICI for unselected mCRPC population raise concerns. The primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS), and the secondary outcomes included objective response rate (ORR). Individual patient data (IPD) were reconstructed from reported survival curve, and Kaplan-Meier method was used to evaluate the efficacy.…
Landmark Evidence58 records
Rank110.0
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.
Nature genetics · 2025 · PMID 39930085
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10-8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) …
Rank110.0
Updated dose-response meta-analysis of sexual activity and prostate cancer risk.
BMC cancer · 2025 · PMID 41345847
BACKGROUND: This systematic review and meta-analysis aimed to update the evidence on how sexual activity factors, including frequency of intercourse, number of female sexual partners, age at first intercourse, and number of ejaculations and masturbations relate to prostate cancer. METHODS: We conducted a comprehensive search across PubMed, Web of Science, and Scopus up to October 19, 2025. We also reviewed existing study references for additional relevant research. To assess study consistency, we used I2 statistics…
Rank109.7
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.
Targeted oncology · 2026 · PMID 42371314
BACKGROUND: Abiraterone (ABI) and enzalutamide (ENZA) are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, their safety and efficacy have not been directly compared in prospective clinical trials. OBJECTIVE: To directly compare their safety and efficacy in prospective clinical trials. PATIENTS AND METHODS: A systematic search was performed in PubMed, Embase, and Cochrane Library databases (CRD42024608496) on 24 June 2025. Eligibility criteria included studies on patients wit…
Rank108.5
Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 41966893
Circulating tumor DNA (ctDNA) is a minimally invasive biomarker that enables molecular profiling and prognostic stratification in cancer. This meta-analysis evaluated the prognostic significance of ctDNA in metastatic prostate cancer (mPC). PubMed, Web of Science and Scopus were searched from inception to September 15, 2025 for studies assessing ctDNA and survival in prostate cancer. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were extracted; when unavailable, HRs were reconstr…
Rank107.9
A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer.
European urology · 2025 · PMID 39327114
BACKGROUND AND OBJECTIVE: Management of metastatic prostate cancer (mPCa) presents significant challenges. In this systematic review, meta-analysis, and meta-regression, the efficacy, safety, and quality of life (QoL) outcomes of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) utilising lutetium-177 ([177Lu]Lu-PSMA) and actinium-225 ([225Ac]Ac-PSMA) were assessed. METHODS: A detailed literature search across PubMed/Medline, EMBASE, Web of Science, Scopus, and Cochrane Library was condu…
Rank107.8
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis.
European urology oncology · 2026 · PMID 40645821
BACKGROUND AND OBJECTIVE: Metastatic hormone-sensitive prostate cancer (mHSPC) patients with visceral disease (VD) represent a high-risk subgroup associated with poor prognosis. Despite the introduction of treatment intensification strategies, the optimal systemic therapy for these patients remains unclear. This network meta-analysis (NMA) aims to evaluate the efficacy of the current therapeutic combinations in terms of overall survival (OS) in the subgroup of patients with VD. METHODS: A systematic review and NMA …
Rank107.5
The Radical Prostatectomy Versus Brachytherapy for the Management of Low- and Intermediate-Risk Prostate Cancer: A Meta-Analysis of Observational Studies Focusing on Oncological Outcomes.
Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 41569192
OBJECTIVE: This study aims to compare the oncological outcomes of radical prostatectomy (RP) and brachytherapy (BT) in patients with low- and intermediate-risk prostate cancer, and determine whether one treatment demonstrates superiority over the other. METHODS: A systematic literature search was conducted using databases, including PubMed, ScienceDirect, Google Scholar, EBSCO, and the Cochrane Library, to identify relevant clinical studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted, wit…
Rank107.3
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data.
European urology · 2025 · PMID 40571441
BACKGROUND AND OBJECTIVE: To better understand the role of hormone therapy (HT) with postoperative radiotherapy (RT) for nonmetastatic prostate cancer, the DADSPORT Collaboration planned a systematic review and meta-analysis of aggregate data from randomised controlled trials (RCTs). METHODS: RCTs evaluating HT with postoperative RT in people with nonmetastatic prostate cancer were identified. Methods were prespecified prior to results of recent trials being known (CRD42022325769). The primary outcome was overall s…
Rank107.0
Metabolic syndrome and risk of prostate cancer: a systematic review and meta-analysis.
Panminerva medica · 2022 · PMID 34859640
INTRODUCTION: Emerging evidence supports the hypothesis that metabolic syndrome is associated with cancer pathogenesis. In particular regarding prostate cancer, observational studies from various settings report different results. This systematic review and meta-analysis aimed to provide a quantitative estimate of the association between metabolic syndrome in prostate cancer, in particular Gleason Score >6, accounting for different study designs. EVIDENCE ACQUISITION: Systematic research of available literature in …
Rank106.9
Meta-Analysis of Transperineal and Transrectal Ultrasound-Guided Prostate Biopsy in the Detection of Prostate Cancer.
Archivos espanoles de urologia · 2024 · PMID 39632532
BACKGROUND: Transperineal (TP) biopsy is increasingly used as an alternative to standard transrectal (TR) biopsy for prostate cancer detection to reduce infection risks. However, evidence on comparative diagnostic accuracy remains inconclusive. The aim of this study was to perform an updated systematic review and meta-analysis of studies comparing prostate cancer detection rates between TP and TR ultrasound biopsies. METHODS: PubMed, EMBASE, Web of Science and other databases were searched for relevant studies up t…
Rank106.2
Effects of postoperative physical exercise rehabilitation on cardiorespiratory fitness, functional capacity and quality of life in patients with colorectal, breast, and prostate cancer - a systematic review and meta-analysis.
Journal of cancer research and clinical oncology · 2024 · PMID 39718582
PURPOSE: The reduced cardiorespiratory fitness (CRF) and functional capacity following surgical procedures and during cancer treatments is a major risk factor for morbidity and mortality among patients with cancer. We aimed to assess the impact of endurance and combined resistance exercise interventions during the postoperative rehabilitation period for patients with colorectal, breast, and prostate cancer. METHODS: A systematic search was conducted in MEDLINE Pubmed, Web of Science, and Cochrane Library until Octo…
Rank106.1
Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis.
Theranostics · 2025 · PMID 40093902
Rationale: Metastatic prostate cancer in the castration-resistant (mCRPC) setting remains challenging to treat. Prostate-specific membrane antigen (PSMA)-targeted alpha therapy (TAT) is emerging as a promising option. We aimed to systematically review the efficacy and safety of PSMA-TAT in patients with prostate cancer. Methods: A comprehensive search of PubMed/MEDLINE and EMBASE databases was conducted up to October 2024, adhering to the PRISMA guidelines. Selected studies were original research articles evaluatin…
Rank105.9
Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
The Prostate · 2025 · PMID 40719409
BACKGROUND: Patients with prostate cancer (PC) invading into the seminal vesicles (SV) constitute a specific subgroup of high-risk patients (staged as T3b) with a particularly high risk of disease recurrence, even when lymph node or distant metastases are absent (N0M0). The aim of the current systematic review and meta-analysis was to investigate efficacy of available treatments for men with PC invading the SV without metastasis. METHODS: A systematic review was performed according to the Cochrane guidance and repo…
Rank105.4
Integrative analysis of clinical and epigenetic biomarkers of mortality.
Aging cell · 2022 · PMID 35546478
DNA methylation (DNAm) has been reported to be associated with many diseases and with mortality. We hypothesized that the integration of DNAm with clinical risk factors would improve mortality prediction. We performed an epigenome-wide association study of whole blood DNAm in relation to mortality in 15 cohorts (n = 15,013). During a mean follow-up of 10 years, there were 4314 deaths from all causes including 1235 cardiovascular disease (CVD) deaths and 868 cancer deaths. Ancestry-stratified meta-analysis of all-ca…
Rank105.3
Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients.
BMC medicine · 2022 · PMID 35125113
BACKGROUND: Prostate-specific antigen (PSA) is a commonly used test to detect prostate cancer. Attention has mostly focused on the use of PSA in screening asymptomatic patients, but the diagnostic accuracy of PSA for prostate cancer in patients with symptoms is less well understood. METHODS: A systematic database search was conducted of Medline, EMBASE, Web of Science, and the Cochrane library. Studies reporting the diagnostic accuracy of PSA for prostate cancer in patients with symptoms were included. Two investig…
Rank105.0
Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
European journal of nuclear medicine and molecular imaging · 2025 · PMID 40705094
BACKGROUND: Lutetium-177 PSMA radioligand therapy ([¹⁷⁷Lu]Lu-PSMA-RLT) is an effective treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Prospective studies reported favourable efficacy and safety outcomes of up to 6 cycles of [¹⁷⁷Lu]Lu-PSMA. This study aimed to evaluate the efficacy and safety of [¹⁷⁷Lu]Lu-PSMA rechallenge therapy in patients with mCRPC who progressed after an initial course of [¹⁷⁷Lu]Lu-PSMA-RLT. METHODS: This systematic review followed the Preferred Repo…
Rank105.0
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
BJU international · 2022 · PMID 34171173
OBJECTIVES: To perform a systematic review and network meta-analysis to compare the efficacy and safety of currently available treatments for the management of metastatic hormone-sensitive prostate cancer (mHSPC), as there has been a paradigm shift with the use of next-generation androgen receptor inhibitors (ARIs) and docetaxel. METHODS: Multiple databases were searched for articles published before May 2020 according to the Preferred Reporting Items for Systematic Review and Meta-analysis extension statement for …
Rank105.0
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
European urology focus · 2023 · PMID 36058809
CONTEXT: Two recent randomized controlled trials (RCTs) reported overall survival benefit of triplet therapy (androgen receptor axis-targeted therapy agent [ARAT], docetaxel, and androgen deprivation therapy [ADT]) over that of doublet therapy (docetaxel and ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Ranking of therapy options and comparisons between triplet therapy and doublet ARAT and ADT therapy are scarce. OBJECTIVE: To rank therapy options (triplet vs doublet [docetaxel and ADT…
Rank104.8
Prevalence of prostate cancer in men with haematuria: a systematic review and meta-analysis.
BJU international · 2023 · PMID 36522728
OBJECTIVES: To investigate the prevalence of prostate cancer in men attending evaluation for haematuria, as this could help healthcare providers to determine whether men with haematuria should have prostate examinations performed. METHODS: The study was performed according to a pre-specified protocol uploaded to the International Prospective Register of Systematic Reviews (PROSPERO; CRD42022299383). A systematic search of MEDLINE, Ovid and Google Scholar was performed in December 2021. Two independent researchers e…
Rank104.1
HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis.
Brachytherapy · 2021 · PMID 33461894
PURPOSE: The effectiveness and safety of high dose brachytherapy as monotherapy (HDR-BRT-M) in prostate cancer is limited to retrospective studies. We performed a meta-analysis to summarize existing data and identify trends in biochemical recurrence-free survival (bRFS) and toxicity after HDR-BRT-M in patients with prostate cancer. METHODS AND MATERIALS: Retrospective, prospective, or randomized clinical trials were identified on electronical databases through June 2020. We followed the PRISMA and MOOSE guidelines.…
Rank104.0
Meta-Analysis of Body Concentration of Polychlorinated Biphenyls and Prostate Cancer.
Toxicology and industrial health · 2022 · PMID 36167526
Prostate Cancer (PCa) is the second most common hormone-sensitive neoplasm among men and the fifth cause of death due to malignancy in developed countries. Moreover, studies have shown the links between polychlorinated biphenyls (PCBs) and hormone-related cancers such as prostate cancer. Hence, we conducted a systematic review and meta-analysis to evaluate the potential relationship between the PCBs and developing PCa. In this meta-analysis study, the relevant databases such as Web of Science, PubMed, and Scopus we…
Rank103.6
PET/MRI in prostate cancer: a systematic review and meta-analysis.
European journal of nuclear medicine and molecular imaging · 2021 · PMID 32901351
AIM: In recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical, and functional imaging to be explored. The present systematic review and meta-analysis summarize the diagnostic information provided by PET/MRI in patients with prostate cancer (PCa). MATERIALS AND METHODS: A literature search was conducted in three different databases. The terms …
Rank103.0
Feasibility and Safety of Same-say Discharge after Robot-assisted Radical Prostatectomy: A Systematic Review and Meta-analysis.
European urology focus · 2026 · PMID 42331644
BACKGROUND AND OBJECTIVE: Same-day discharge (SDD) after robot-assisted radical prostatectomy (RARP) is increasingly adopted as a standard of care. This systematic review and meta-analysis assess the safety and effectiveness of SDD compared with conventional inpatient (IP) management. METHODS: A literature search was conducted in accordance with PRISMA guidelines using PubMed/MEDLINE, Embase, Web of Science, and Scopus databases up to February 2025, including only comparative studies reporting on SDD versus IP RARP…
Rank101.6
Longitudinal model-based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer.
European journal of clinical pharmacology · 2020 · PMID 31925454
PURPOSE: The aims of this longitudinal model-based meta-analysis (MBMA) were to indirectly compare the time courses of survival probabilities and to identify corresponding potential significant covariates across approved drugs in patients with castration-resistant prostate cancer (CRPC). METHODS: A systematic literature review for monotherapy studies in patients with CRPC was conducted up to August 8, 2018. The time courses of progression-free survival (PFS) and overall survival (OS) were fitted with parametric sur…
Rank100.9
Association of finasteride with prostate cancer: A systematic review and meta-analysis.
Medicine · 2020 · PMID 32282699
BACKGROUND: The Prostate Cancer Prevention Trial has shown a protective effect of finasteride on prostate cancer, but it also showed that finasteride can increase the risk of high-grade prostate cancer. Several studies have investigated the relationship between finasteride and prostate cancer, but these studies have shown inconsistent results. ETHICS: The protocol was approved by the institutional review board of each study center. Written informed consent will be obtained from all patients before registration, in …
Most Effective Evidence Supported Treatments68 records
Rank112.8
Magnetic Resonance Imaging-Based Artificial Intelligence in Predicting Prostate Cancer Biochemical Recurrence: Systematic Review and Meta-Analysis.
Journal of medical Internet research · 2026 · PMID 42412916
BACKGROUND: Artificial intelligence (AI) has emerged as a promising tool for prostate cancer (PCa) risk stratification and outcome prediction. However, current studies often lack multicenter external validation, have limited sample sizes, present significant intermodel variability, and face overfitting concerns. OBJECTIVE: This study aimed to comprehensively evaluate the diagnostic performance of magnetic resonance imaging (MRI)-based AI models in predicting biochemical recurrence (BCR) of PCa. METHODS: Systematic …
Rank110.0
Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer.
Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia · 2026 · PMID 42102633
With the approval of PARP inhibitors (PARPi), both as monotherapy and in combination with androgen receptor signalling inhibitors (ARSi), for metastatic castration-resistant prostate cancer (mCRPC) and their rapid development in earlier disease settings, there is an urgent need to integrate homologous recombination repair (HRR) testing into daily clinical practice to identify patients who may benefit from these therapies and to improve patient management. Alterations in HRR genes are found in approximately 15-30% o…
Rank110.0
Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management.
The Journal of urology · 2026 · PMID 42095477
PURPOSE: This Guideline covers the treatment of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). The summary presented herein represents Part II of the three-part series dedicated to Management of LUTS attributed to BPH. Please refer to Parts I and III for additional information on this topic. MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic …
Rank110.0
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).
The Journal of urology · 2026 · PMID 41988960
PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2022 publication of this Guideline via the AUA Amendment process. The resulting 2026 Guideline Amendment addresses updated recommendations to provide a clinical framework for the evaluation and management of clinically localized prostate cancer. MATERIALS AND METHODS: In 2025, this Guideline was reviewed via the AUA ULR process, which identified 29 studies…
Rank110.0
Impact of frailty on overall survival and complications in patients with prostate cancer: a systematic review and meta-analysis.
International urology and nephrology · 2026 · PMID 41712034
PURPOSE: The current systematic review and meta-analysis was designed to assess if the presence of frailty had an adverse impact on overall survival (OS) and complication rates of patients with prostate cancer. METHODS: Two reviewers explored the PubMed, Web of Science, Embase, and Scopus databases until January 3rd, 2026, for studies examining the impact of frailty on OS and complications in patients with prostate cancer. Data on OS were pooled as a hazard ratio (HR), while short-term mortality and complications w…
Rank109.7
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.
Targeted oncology · 2026 · PMID 42371314
BACKGROUND: Abiraterone (ABI) and enzalutamide (ENZA) are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, their safety and efficacy have not been directly compared in prospective clinical trials. OBJECTIVE: To directly compare their safety and efficacy in prospective clinical trials. PATIENTS AND METHODS: A systematic search was performed in PubMed, Embase, and Cochrane Library databases (CRD42024608496) on 24 June 2025. Eligibility criteria included studies on patients wit…
Rank108.5
Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 41966893
Circulating tumor DNA (ctDNA) is a minimally invasive biomarker that enables molecular profiling and prognostic stratification in cancer. This meta-analysis evaluated the prognostic significance of ctDNA in metastatic prostate cancer (mPC). PubMed, Web of Science and Scopus were searched from inception to September 15, 2025 for studies assessing ctDNA and survival in prostate cancer. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were extracted; when unavailable, HRs were reconstr…
Rank107.9
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.
Clinical genitourinary cancer · 2026 · PMID 42285797
PURPOSE: To systematically review and synthesize the evidence for Prolaris, a combined clinical risk (CCR) score that stratifies individual patient risk and provides a decision-making tool that impacts medical management across key decision points in the localized prostate cancer care continuum. PATIENTS AND METHODS: A systematic literature search was performed, and individual participant data (IPD) were collected where possible to perform a two-step IPD analysis. The primary endpoint was composite distant metastas…
Rank107.9
The impact of abiraterone and enzalutamide on hypokalemia incidence in patients with prostate cancer: a systematic review and meta-analysis.
BMC cancer · 2026 · PMID 42387420
OBJECTIVE: To systematically evaluate the incidence of hypokalemia associated with novel androgen receptor axis-targeted therapies (ARATs)-specifically abiraterone, enzalutamide, and their combination-in patients with advanced prostate cancer. METHODS: A comprehensive search of PubMed, Embase, and the Cochrane Library was conducted to identify published randomized controlled trials (RCTs). Risk of bias was assessed using the Cochrane Risk of Bias tool. A random-effects model was employed to pool risk ratios (RRs) a…
Rank107.7
Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.
International journal of radiation oncology, biology, physics · 2026 · PMID 41663033
PURPOSE: The association between late toxicity and biochemical recurrence (BCR) after prostate radiation therapy is unclear. We set out to characterize the relationship between late gastrointestinal (GI) and genitourinary (GU) toxicity and BCR among patients receiving conventionally fractionated (CF) or moderately hypofractionated (MHF) prostate radiation therapy. METHODS AND MATERIALS: This was an individual patient data meta-analysis that identified randomized phase 3 trials of CF or MHF prostate radiation therap…
Rank107.5
The Radical Prostatectomy Versus Brachytherapy for the Management of Low- and Intermediate-Risk Prostate Cancer: A Meta-Analysis of Observational Studies Focusing on Oncological Outcomes.
Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 41569192
OBJECTIVE: This study aims to compare the oncological outcomes of radical prostatectomy (RP) and brachytherapy (BT) in patients with low- and intermediate-risk prostate cancer, and determine whether one treatment demonstrates superiority over the other. METHODS: A systematic literature search was conducted using databases, including PubMed, ScienceDirect, Google Scholar, EBSCO, and the Cochrane Library, to identify relevant clinical studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted, wit…
Rank107.3
Perirectal spacers and endorectal balloons in external beam radiotherapy for prostate cancer: a review of prospective studies.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026 · PMID 42171762
PURPOSE: Endorectal balloons (ERB) and perirectal spacers (RS) were developed to minimize rectal toxicity in prostate cancer radiotherapy. We conducted a review to assess available data. METHODS AND MATERIALS: Literature search was conducted on 20th May, 2025, using PubMed. Prospective studies and meta-analyses assessing the efficacy of ERB and PRS on rectal toxicity were included. Risk of bias was evaluated (MINORS and Cochrane Risk of Bias). Other relevant publications, guideline recommendations and cost-effectiv…
Rank107.2
Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer Outside of Randomized Controlled Trials: A Systematic Review and Meta-Analysis of Prognostic Factors in Real-World Analyses.
Clinical genitourinary cancer · 2026 · PMID 42191465
We aimed to analyze prognostic factors for overall survival (OS) and progression-free survival (PFS) in real-world patients treated with androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPI) for metastatic hormone-sensitive prostate cancer (mHSPC). A systematic literature search was conducted in MEDLINE, Embase, and Web of Science in October 2025. Eligible studies examined prognostic factors for OS or PFS in patients with mHSPC receiving ARPI plus ADT using real-world data. To…
Rank107.1
Radiomics as a tool for predicting biochemical recurrence after total prostatectomy: a systematic review and meta-analysis.
International urology and nephrology · 2026 · PMID 41520314
PURPOSE: Biochemical recurrence (BCR) following radical prostatectomy (RP) remains a significant concern in prostate cancer (PCa) management, as it is associated with an increased risk of metastasis and disease progression. While conventional clinical and pathological prognostic factors are helpful in determining the prognosis, their accuracy remains suboptimal. Radiomics has been shown to be a promising tool for improving risk stratification and outcome prediction in PCa patients post-RP. This systematic review an…
Rank106.6
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for ARPI-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer: a pooled analysis of KEYNOTE-921 and CheckMate 7DX trials.
International urology and nephrology · 2026 · PMID 41741934
BACKGROUND: The optimal treatment strategy for androgen receptor pathway inhibitor (ARPI)-pretreated and chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) remains unclear. Chemotherapy has limited efficacy as a monotherapy in unselected mCRPC patients. In contrast, the addition of PD-1/PD-L1 inhibitors to chemotherapy (Chemo-IO) may enhance antitumor activity. We conducted a meta-analysis using data from phase 3 randomized controlled trials (RCTs), with the objective of assessing the compar…
Rank106.4
The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.
Human vaccines & immunotherapeutics · 2026 · PMID 41672480
Some immune checkpoint inhibitors (ICI) has been used for men with specific metastatic castration-resistant prostate cancer (mCRPC). However, inconsistent results of ICI for unselected mCRPC population raise concerns. The primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS), and the secondary outcomes included objective response rate (ORR). Individual patient data (IPD) were reconstructed from reported survival curve, and Kaplan-Meier method was used to evaluate the efficacy.…
Rank103.0
Feasibility and Safety of Same-say Discharge after Robot-assisted Radical Prostatectomy: A Systematic Review and Meta-analysis.
European urology focus · 2026 · PMID 42331644
BACKGROUND AND OBJECTIVE: Same-day discharge (SDD) after robot-assisted radical prostatectomy (RARP) is increasingly adopted as a standard of care. This systematic review and meta-analysis assess the safety and effectiveness of SDD compared with conventional inpatient (IP) management. METHODS: A literature search was conducted in accordance with PRISMA guidelines using PubMed/MEDLINE, Embase, Web of Science, and Scopus databases up to February 2025, including only comparative studies reporting on SDD versus IP RARP…
Rank102.8
Benefits and harms of antiresorptive therapy in men with non-metastatic prostate cancer on androgen deprivation therapy: A systematic review and meta-analysis of randomized controlled trials.
Metabolism: clinical and experimental · 2026 · PMID 42263846
BACKGROUND: Androgen deprivation therapy (ADT) is used as an adjuvant treatment in men with prostate cancer. It is associated with bone loss and increased fracture risk. In this systematic review and meta-analysis, we evaluated the effects of antiresorptives on bone health in men with non-metastatic prostate cancer (nmPCa) on ADT. METHODS: We searched four databases until October 14th 2024 for randomized controlled trials (RCTs) of antiresorptives in men with non-metastatic prostate cancer on ADT. FINDINGS: We incl…
Rank100.0
Immunotherapeutic strategies for castration-resistant prostate cancer: A systematic review of mechanisms, clinical advances and emerging approaches.
Molecular biology reports · 2026 · PMID 42455319
BACKGROUND: Despite the success of immunotherapy in other malignancies, castration-resistant prostate cancer (CRPC) remains a formidable challenge due to its immunosuppressive "cold" tumor microenvironment. This environment is characterized by low tumor mutational burden, sparse T-cell infiltration, and the dominance of immunosuppressive factors. This review aims to systematically examine recent advances, current challenges, and future directions in immunotherapy for CRPC, offering novel therapeutic perspectives fo…
Rank100.0
IgG4-related prostatitis: expanding the spectrum of IgG4-related disease. A systematic review.
Clinical and experimental rheumatology · 2026 · PMID 41562347
OBJECTIVES: Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory condition that may affect any organ. Prostatic involvement is uncommon and under-recognised. The presentation often mimics benign prostatic hyperplasia or prostate carcinoma, causing diagnostic uncertainty. This systematic review synthesises evidence on IgG4-related prostatitis, focusing on clinical manifestations, diagnostic approaches, treatment, and outcomes. METHODS: Following PRISMA 2020 guidelines, PubMed, Scopus, Web of S…
Rank100.0
Technical advancements in robot-assisted radical prostatectomy: systematic review and bibliometric analysis.
Journal of robotic surgery · 2026 · PMID 42474844
Robot-assisted radical prostatectomy has transformed the surgical management of localized prostate cancer, yet its research landscape remains incompletely mapped. We conducted a systematic review and bibliometric analysis of 578 articles and conference papers from Scopus and Web of Science (2005-2026), following PRISMA guidelines, and analyzed publication trends, geographic and institutional distribution, author networks, journal output, keyword co-occurrence, and thematic evolution. The results reveal exponential …
Rank100.0
Systematic Review of Genomic-Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence.
Cancer medicine · 2026 · PMID 41802997
BACKGROUND: Several genomic risk stratification tests are available to predict the risk of metastasis and mortality for prostate cancer patients at the time of diagnosis. However, the evidence supporting the clinical utility of genomic risk stratification tools is fragmented, posing challenges in assessing their real-world clinical impact and cost-effectiveness. OBJECTIVE: To review and summarise the clinical impact and health economic evidence of the four types of genomic risk stratification tests and to validate …
Rank100.0
Magnetic resonance-guided radiotherapy (MRgRT) and clinical outcomes: A systematic review.
Radiography (London, England : 1995) · 2026 · PMID 42361614
INTRODUCTION: Magnetic resonance-guided radiotherapy (MRgRT) offers potential advantages over conventional computed tomography-guided radiotherapy (CTgRT), however its impact on clinical outcomes remains unclear. METHODS: We systematically reviewed the clinical effectiveness and safety of MRgRT searching three databases and three trial registries through 9 December 2024. Comparative studies were assessed for risk of bias and the certainty of evidence was evaluated. An evidence and gap map was used to visualise avai…
Rank100.0
Diagnostic accuracy of PSMA-targeted radioguided surgery in prostate cancer at multiple anatomical levels: a systematic review and meta-analysis.
European journal of nuclear medicine and molecular imaging · 2026 · PMID 41888458
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (PSMA-RGS) is a promising intraoperative technique for improving lesion localization and surgical accuracy in prostate cancer (PCa), particularly in high-risk or recurrent cases. OBJECTIVE: To systematically evaluate the diagnostic performance of PSMA-RGS in PCa using multilevel meta-analysis. METHODS: Following PRISMA 2020 guidelines, we searched PubMed, Embase, and Web of Science for clinical studies published between January 2016 …
Rank100.0
The lived experience of active surveillance for prostate cancer: a systematic review and meta-synthesis.
Journal of cancer survivorship : research and practice · 2026 · PMID 39939565
PURPOSE: Prostate cancer is one of the most prevalent cancers worldwide. Active surveillance is a widely accepted treatment option for some localised prostate cancers. However, concerns have been raised about the experiences of men on this treatment given that almost 40% will discontinue without clinical indications. The objective of this review was to identify the lived experience of men on active surveillance. METHODS: A systematic review and meta-synthesis, according to PRISMA guidelines. Studies were included i…
New Research Last 24 Months214 records
Rank110.0
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.
Nature genetics · 2025 · PMID 39930085
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10-8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) …
Rank109.7
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.
Targeted oncology · 2026 · PMID 42371314
BACKGROUND: Abiraterone (ABI) and enzalutamide (ENZA) are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, their safety and efficacy have not been directly compared in prospective clinical trials. OBJECTIVE: To directly compare their safety and efficacy in prospective clinical trials. PATIENTS AND METHODS: A systematic search was performed in PubMed, Embase, and Cochrane Library databases (CRD42024608496) on 24 June 2025. Eligibility criteria included studies on patients wit…
Rank108.5
Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 41966893
Circulating tumor DNA (ctDNA) is a minimally invasive biomarker that enables molecular profiling and prognostic stratification in cancer. This meta-analysis evaluated the prognostic significance of ctDNA in metastatic prostate cancer (mPC). PubMed, Web of Science and Scopus were searched from inception to September 15, 2025 for studies assessing ctDNA and survival in prostate cancer. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were extracted; when unavailable, HRs were reconstr…
Rank107.5
The Radical Prostatectomy Versus Brachytherapy for the Management of Low- and Intermediate-Risk Prostate Cancer: A Meta-Analysis of Observational Studies Focusing on Oncological Outcomes.
Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 41569192
OBJECTIVE: This study aims to compare the oncological outcomes of radical prostatectomy (RP) and brachytherapy (BT) in patients with low- and intermediate-risk prostate cancer, and determine whether one treatment demonstrates superiority over the other. METHODS: A systematic literature search was conducted using databases, including PubMed, ScienceDirect, Google Scholar, EBSCO, and the Cochrane Library, to identify relevant clinical studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted, wit…
Rank106.4
The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.
Human vaccines & immunotherapeutics · 2026 · PMID 41672480
Some immune checkpoint inhibitors (ICI) has been used for men with specific metastatic castration-resistant prostate cancer (mCRPC). However, inconsistent results of ICI for unselected mCRPC population raise concerns. The primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS), and the secondary outcomes included objective response rate (ORR). Individual patient data (IPD) were reconstructed from reported survival curve, and Kaplan-Meier method was used to evaluate the efficacy.…
Rank103.4
Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.
European urology · 2026 · PMID 42521517
BACKGROUND AND OBJECTIVE: A recent individual patient data (IPD) meta-analysis of randomized trials found a limited overall survival (OS) and metastasis-free survival (MFS) benefit to the addition of hormonal therapy (HT) to postoperative radiotherapy for prostate cancer in patients with pre-radiotherapy prostate-specific antigen (PSA) ≤0.5 ng/ml. We evaluated whether the OS and MFS benefits of adding HT might be significantly modified by an increasing count of adverse pathological features (adverse feature count […
Rank103.0
Feasibility and Safety of Same-say Discharge after Robot-assisted Radical Prostatectomy: A Systematic Review and Meta-analysis.
European urology focus · 2026 · PMID 42331644
BACKGROUND AND OBJECTIVE: Same-day discharge (SDD) after robot-assisted radical prostatectomy (RARP) is increasingly adopted as a standard of care. This systematic review and meta-analysis assess the safety and effectiveness of SDD compared with conventional inpatient (IP) management. METHODS: A literature search was conducted in accordance with PRISMA guidelines using PubMed/MEDLINE, Embase, Web of Science, and Scopus databases up to February 2025, including only comparative studies reporting on SDD versus IP RARP…
Rank102.4
Comparison of the effects of exercise-based interventions on cardiometabolic health and fatigue in men with prostate cancer receiving androgen deprivation therapy: A network meta-analysis.
Asia-Pacific journal of oncology nursing · 2026 · PMID 42022295
OBJECTIVE: To compare the effects of exercise-based interventions on cardiometabolic health and fatigue in men with prostate cancer receiving androgen deprivation therapy (ADT). METHODS: A comprehensive search for Randomized controlled studies (RCTs) was performed in Pubmed, Embase, EBSCO, Web of science, Scopus, Cochrane library, Wanfang database, China National Knowledge Infrastructure (CNKI), VIP from their inception to May 2025. Meta-analysis and network meta-analysis was then conducted for each outcome using R…
Rank100.0
Systematic Review of Genomic-Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence.
Cancer medicine · 2026 · PMID 41802997
BACKGROUND: Several genomic risk stratification tests are available to predict the risk of metastasis and mortality for prostate cancer patients at the time of diagnosis. However, the evidence supporting the clinical utility of genomic risk stratification tools is fragmented, posing challenges in assessing their real-world clinical impact and cost-effectiveness. OBJECTIVE: To review and summarise the clinical impact and health economic evidence of the four types of genomic risk stratification tests and to validate …
Rank100.0
Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology- and European Randomized Study of Screening for Prostate Cancer-based strategies.
International journal of cancer · 2026 · PMID 41741956
Prostate cancer (PC) screening reduces PC mortality but also causes burden such as overdiagnosis and unnecessary biopsies. The European Association of Urology (EAU) recently proposed a risk-adapted screening protocol incorporating prostate-specific antigen (PSA)-based intervals, a risk calculator (RC), and magnetic resonance imaging (MRI), though its long-term outcomes remain unquantified. We constructed the MIcrosimulation SCreening Analysis-PSA model by adapting the existing MIcrosimulation SCreening Analysis-PRO…
Rank97.7
A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy.
European urology focus · 2026 · PMID 41760422
BACKGROUND AND OBJECTIVE: Erectile dysfunction (ED) following radical prostatectomy (RP) has a negative impact on quality of life. Herein, the aim was to assess the effectiveness of autologous adipose-derived regenerative cells (ADRCs) for treating ED after RP. METHODS: This was a randomized, double-blinded, placebo-controlled study. A total of 70 men with ED were enrolled at Odense University Hospital, Denmark. Patients received one intracavernous bolus of ADRCs (n = 35) or placebo (n = 35). The primary endpoint w…
Rank97.2
Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer.
European urology focus · 2026 · PMID 41826123
Continuous treatment with an androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in low-volume metastatic castration-sensitive prostate cancer (mCSPC) may lead to overtreatment, resulting in increased toxicity and higher costs. Evidence to guide a shorter duration of ARPI therapy is currently lacking. The Apa/Enza-short trial evaluates whether a 12-mo course of apalutamide or enzalutamide is noninferior to continuous treatment in low-volume mCSPC. This randomized, open-label, noninfer…
Rank96.0
Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy.
The Prostate · 2026 · PMID 42542970
BACKGROUND: Hot flashes are common and often debilitating side effects of castration therapy; a cornerstone in the treatment of metastatic prostate cancer (PCa) as well as in localized or locally advanced PCa when combined with radiotherapy. The evidence for relieving vasomotor symptoms is limited. This systematic review presents both pharmacological and non-pharmacological interventions for treating hot flashes in men with PCa undergoing castration therapy, primarily androgen deprivation therapy (ADT). METHODS: a …
Rank94.7
Assessing the Feasibility of a Self-Management Intervention for Individuals With Advanced Prostate Cancer and Comorbid Type II Diabetes Mellitus.
Cancer medicine · 2026 · PMID 42521319
BACKGROUND: Many older adults with cancer have at least one comorbidity. Type II diabetes mellitus (T2DM) is a common comorbidity among patients with prostate cancer (PC) and represents an important consideration in this population. Comorbid T2DM can negatively impact cancer-specific outcomes for patients, suggesting the need for better glycemic management, especially for patients on active cancer treatment. The goal of this modified Diabetes Self-Management Education Services (mDSMES) pilot study was to provide pa…
Rank93.7
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration).
European urology focus · 2026 · PMID 41714204
BACKGROUND AND OBJECTIVE: This study aimed to develop and validate a prognostic model for overall survival (OS) in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC), using clinical factors from phase 3 trials to improve survival prediction, guide clinical decision-making, and optimize trial design. METHODS: We analyzed individual patient data from three randomized phase 3 trials (four comparisons) of androgen deprivation therapy ± docetaxel: CHAARTED (n = 575), GETUG-15 (n = 272), and STAMPEDE (…
Rank93.0
Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41587107
PURPOSE: Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis. EXPERIMENTAL DESIGN: We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumor-derived genomic alterations …
Rank92.9
Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
The Prostate · 2026 · PMID 42542966
BACKGROUND: Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone-sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second-generation androgen receptor antagonist-based doublet therapy. Although triplet therapy with darolutamide and docetaxel is available, its added clinical value over apalutamide- or enzalutamide-based doublet therapy in real-world practic…
Rank91.2
Acute Toxicity and Quality of Life With Stereotactic Body Radiation Therapy Versus Conventional Fractionated Intensity Modulated Radiation Therapy to the Prostate and Pelvis in High-Risk Prostate Cancer: A Randomized Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 42431329
PURPOSE: Stereotactic body radiation therapy (SBRT) to the prostate and pelvis in high-risk prostate cancer (HR-PC) may shorten treatment, but acute toxicity and quality of life (QoL) outcomes compared with conventional fractionated intensity modulated radiation therapy (IMRT) remain uncertain. We report acute toxicity and early QoL outcomes from a randomized phase 2 trial. METHODS AND MATERIALS: Between 2019 and 2024, 121 patients with node-negative HR-PC were randomized to SBRT (40 Gy in 5 weekly fractions to pro…
Rank91.2
Mediation analysis of adherence to pelvic floor muscle training and weekly self-monitoring on urinary symptoms in men with localized prostate cancer A secondary analysis of the Prostate Cancer-Patient Empowerment Program (PC-PEP) randomized controlled trial.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026 · PMID 41941257
INTRODUCTION: Men treated curatively for localized prostate cancer often experience urinary complications that impair quality of life. The Prostate Cancer-Patient Empowerment Program (PC-PEP) is a six-month, digital intervention integrating pelvic floor muscle training (PFMT), fitness, nutrition, and intimacy support. While early initiation of PC-PEP improves urinary outcomes, the influence of adherence remains unclear. This mediation analysis examined whether reported PFMT duration and engagement with self-monitor…
Rank89.3
EMPTY-RT: A Phase 2 Trial of Prostate Stereotactic Body Radiotherapy with an Empty Bladder Approach.
International journal of radiation oncology, biology, physics · 2026 · PMID 42537851
PURPOSE: To evaluate the feasibility and dosimetric safety of prostate stereotactic radiotherapy (SBRT) with an empty bladder approach. METHODS: Eligible patients had histologically confirmed prostate cancer and planned for SBRT (35-36.25 Gy/5# to prostate ± 25 Gy to pelvic nodes, alternate days or once-weekly). Participants voided immediately before planning CT scan and each SBRT fraction. Interfraction bladder volume variability was evaluated with on-board cone beam CT. Primary endpoint was the rate of acute urin…
Rank85.0
Pelvic lymph node dissection in prostate cancer: current evidence, controversies, and future directions.
Annals of medicine · 2026 · PMID 41999318
BACKGROUND: Pelvic lymph node dissection (PLND) remains controversial in the management of prostate cancer. Although it provides the most accurate pathological staging, its therapeutic value beyond staging has long been debated due to conflicting evidence and concerns regarding procedure-related morbidity. OBJECTIVE: To critically evaluate the contemporary role of PLND, particularly extended pelvic lymph node dissection (ePLND), in prostate cancer management in the context of modern imaging, risk stratification too…
Rank85.0
Therapy Optimization in mHSPC: Insights from a Multidisciplinary Uro-Oncology Expert Panel.
Advances in therapy · 2026 · PMID 42176182
Metastatic hormone-sensitive prostate cancer (mHSPC) is a disease state characterized by the presence of distant metastases detectable on conventional imaging while the tumor remains responsive to androgen deprivation therapy (ADT). It represents an earlier, treatment-sensitive phase that precedes the development of metastatic castration-resistant prostate cancer (mCRPC), the terminal stage of the disease. The addition of therapies beyond traditional ADT to achieve more sustained tumor regression by combining diffe…
Rank85.0
Outcome adaptive propensity score methods for handling censoring and high-dimensionality: Application to insurance claims.
Statistical methods in medical research · 2025 · PMID 40013476
Propensity scores are commonly used to reduce the confounding bias in non-randomized observational studies for estimating the average treatment effect. An important assumption underlying this approach is that all confounders that are associated with both the treatment and the outcome of interest are measured and included in the propensity score model. In the absence of strong prior knowledge about potential confounders, researchers may agnostically want to adjust for a high-dimensional set of pre-treatment variable…
Rank85.0
Apalutamide-induced prostate-specific antigen response and its association with clinical outcomes in metastatic castration sensitive prostate cancer (Review).
Molecular and clinical oncology · 2026 · PMID 42534213
Prostate-specific antigen (PSA) kinetics in metastatic castration-sensitive prostate cancer (mCSPC) have been evaluated as prognostic markers in relation to clinical outcomes under apalutamide plus androgen deprivation therapy (ADT). A literature search was conducted via PubMed, Scopus and Google Scholar. Randomized controlled trials, post hoc analyses, and real-world and retrospective cohort studies were included. Early and deep PSA responses (for example, PSA50, PSA90, PSA ≤0.2 ng/ml, ultralow PSA) were found to …
Rank80.5
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
JCO precision oncology · 2025 · PMID 40865033
PURPOSE: PTEN loss contributes to aberrant signaling of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin pathway and may confer sensitivity to therapies targeting the PI3K pathway. The PIK3CB inhibitor GSK2636771 demonstrated efficacy in tumors with PIK3CB mutations and may similarly show efficacy in patients with PTEN loss. METHODS: Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with ad…
Preclinical Research77 records
Rank45.0
Biodistribution of PET radiotracers in tumor-bearing TRAMP mice administered by retroorbital or jugular vein injections.
Scientific reports · 2024 · PMID 39215130
Nuclear medicine is an important tool for use in molecular imaging of important biological processes. Methods for intravenous delivery of radiotracers remains a challenge, with tail vein injections demonstrated to be technically difficult and lacking in reproducibility. Other intravenous methods include jugular vein (JV) injection, which requires a more invasive and precise microsurgical technique. Although the retroorbital (RO) sinus drains directly into the JV, and RO injections are minimally invasive and simpler…
Rank45.0
The establishment of prostate-specific, SKP2 humanized mice by CRISPR knock-in method reveals neoplastic initiation and microenvironmental reprogramming.
Oncogene · 2026 · PMID 42538409
Genetic inactivation of SKP2 has been shown to effectively prevent cancer initiation and block tumorigenesis. However, direct in vivo evidence for SKP2 on cancer initiation and prostatic microenvironment is still lacking and a SKP2 humanized mouse model is critical for developing prostate cancer immunoprevention approaches through targeting SKP2. We therefore have established a prostate-specific human SKP2 knock-in mouse model driven by an endogenous mouse probasin promoter. Overexpression of hSKP2 induces PIN and …
Rank45.0
The effects of long-term aerobic exercise on prostate cancer-induced adipose tissue wasting: Browning to the rescue?
Cellular signalling · 2026 · PMID 42349705
The loss of adipose tissue has been emerging as a key component of cancer-related body wasting. One of the underlying causes suggested for this loss is the browning of the white adipose tissue. However, exercise, a promising therapeutic strategy for cancer-related body wasting, might also promote white adipose tissue browning. It remains unclear how similar or distinct the browning process and its effects are when triggered by exercise in cancer compared to cancer alone. This study investigated the retroperitoneal …
Rank33.8
Incomplete thermal ablation accelerates local and systemic tumor progression in an immunocompetent prostate cancer model.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 41813588
BACKGROUND: This study aims to evaluate the effects of sublethal hyperthermia on tumor growth of residual tumors in an immune-competent mouse model of prostate cancer. MATERIALS AND METHODS: The study progressed through sequential experiments to assess the effects of incomplete thermal ablation, starting with in vitro tests of sublethal heat on Myc-CaP cell growth, followed by in vivo tumor growth studies on FVB mice (n = 84), proteomic analysis of residual tumors, immunohistochemical evaluation of markers of cellu…
Rank33.0
Identification and verification of immunogenic cell death-related signatures derived from bone metastasis of prostate cancer based on multi-omics and machine learning algorithms.
Computational biology and chemistry · 2026 · PMID 42419189
BACKGROUND: Prostate cancer (PCa) is a prevalent urological malignancy in men, with bone metastasis occurring in the majority of patients, often leading to poor clinical outcomes. Despite its clinical significance, reliable prognostic biomarkers for metastatic PCa remain limited. Immunogenic cell death (ICD), a regulated form of cell death, has emerged as a key modulator of the tumor immune microenvironment (TIME) and a potential determinant of the immunotherapy response. However, the functional role of ICD in PCa …
Rank31.4
NBPF1 acts as a tumor suppressor in prostate cancer by regulating the PI3K/AKT pathway.
Archives of medical science : AMS · 2026 · PMID 42540611
INTRODUCTION: Prostate cancer (PCa) is a leading malignancy in men, yet the roles of many candidate regulators remain unclear. Neuroblastoma breakpoint family member 1 (NBPF1) has been implicated as a tumor suppressor in other cancers; however, its function and clinical relevance in PCa remain undefined. MATERIAL AND METHODS: NBPF1 expression was examined in tissue microarrays (TMAs) comprising 77 PCa tumors and 73 normal prostate tissues using immunohistochemistry, and its correlation with clinicopathological feat…
Rank30.0
Structural and biological insights into obscurolides: obscurolide A2 induces apoptosis in prostate cancer cells.
Natural product research · 2026 · PMID 42489475
We isolated and characterised seven obscurolides: obscurolide A2 (1), B2α (2), B2β(3), A1 (4), streptalbonin G (5), streptalbonin F (6), and (3 R)-obscurolide A (7), from Streptomyces chartreusis SA-7, a soil actinomycete from the Northwestern Himalayas, India. Preliminary screening revealed that obscurolide A2 (1) exhibited better cytotoxicity against prostate cancer (PC-3) cells (IC50: 12.16 ± 2.12 μM). Mechanistic studies confirmed that A2 (1) significantly inhibits PC-3 cells' clonogenic formation and induces m…
Rank30.0
PAX5 modulates vascularization and contributes to neuroendocrine lineage transition during carcinoma progression.
The Journal of clinical investigation · 2026 · PMID 42490143
Human carcinomas often gain aggressive characteristics and escape cell-type specific treatment regimens through cryptic shifts in lineage states. However, the underlying mechanisms that govern lineage plasticity in carcinomas are undefined. Here in this study, we found that PAX5, a neural/lymphatic transcription factor, contributed to neuroendocrine (NE) lineage transition. PAX5 was highly expressed in aggressive human NE carcinoma cells and tissues but not in non-NE cancer cells and tissues. Deletion of Pax5 in Rb…
Rank30.0
Innate immune activity in radiation Proctitis.
Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology · 2026 · PMID 42498560
BACKGROUND AND STUDY AIMS: Radiation proctitis is a common and morbid complication of pelvic radiotherapy, yet its pathophysiological mechanisms remain incompletely understood. Preclinical models suggest that activation of the innate immune system, particularly the NF-kappaB signaling pathway, plays a key role in regulating intestinal responses to ionizing radiation. This study aimed to investigate the activation of innate immune responses in rectal mucosa during prostate radiotherapy and examine correlations with …
Rank30.0
Targeting the NR3C1-ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer.
Cancer science · 2026 · PMID 42492013
Radioresistance in prostate cancer demands innovative sensitization strategies. We identified the glucocorticoid receptor nuclear receptor subfamily 3 group C member 1 (NR3C1) as a key negative regulator of radiosensitivity linked to poor prognosis. NR3C1 transcriptionally upregulates the lipid-metabolizing enzyme, acyl-CoA synthetase long-chain family member 4 (ACSL4), thereby enhancing cell proliferation, migration, and radioresistance. High ACSL4 expression sensitizes cells to ferroptosis inducers that amplify l…
Rank30.0
RON receptor tyrosine kinase regulates abiraterone resistance in prostate cancer via the methylation-dependent and independent dual functions of DNMT1.
Oncogene · 2026 · PMID 42498731
Acquired resistance to the CYP17 inhibitor abiraterone is a critical challenge in the clinical treatment of metastatic prostate cancer; however, the mechanisms driving this resistance remain elusive. This study suggests that aberrant RON expression plays an important role in the development of acquired abiraterone resistance in prostate cancer cells. Increased RON expression was observed in most clinical tumor samples with an abiraterone-insensitive phenotype. In established prostate cancer cell lines, aberrant RON…
Rank30.0
ERRγ impedes neuroendocrine prostate cancer development.
Genes & development · 2026 · PMID 41162153
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (CRPC). The molecular mechanisms underlying the progression of CRPC toward NEPC remain incompletely understood, and effective treatments remain to be discovered. Here, we report that loss of the nuclear receptor ERRγ promotes neuroendocrine differentiation in a Pten-deficient mouse model of prostate adenocarcinoma. These findings were recapitulated in advanced cellular and xenograft models of human prostate cancer. Cri…
Rank30.0
Targeting regulatory T cells in the prostate cancer microenvironment: From mechanisms to therapeutics (Review).
Molecular medicine reports · 2026 · PMID 42246166
Prostate cancer (PCa) is a heterogeneous cancer. Regulatory T cells (Tregs) within the tumor microenvironment play a pivotal role in promoting immune evasion and disease progression. This review systematically outlines the development, functional characteristics and regulatory networks of Tregs in this environment. Synthesis of recent spatial transcriptomic and single‑cell RNA‑sequencing data revealed that the functional heterogeneity and spatial distribution of Tregs within the tumor stroma, rather than their abso…
Rank30.0
Selective anticancer activity of imidazolium salts in prostate cancer cells via ROS-mediated mechanisms.
Bioorganic chemistry · 2026 · PMID 42520517
Prostate cancer remains a major therapeutic challenge, particularly in advanced and treatment-resistant disease. Imidazolium salts (IS) are tunable compounds with reported biological activity and potential anticancer applications. In this study, a series of structurally tailored IS, including C10MImCl, C16MImCl, C16BnImCl, and related analogues, was synthesized and evaluated in androgen-independent prostate cancer cells (PC-3 and DU145), androgen-responsive LNCaP cells, and non-tumorigenic prostate epithelial cells…
Rank30.0
Differential Effects of a First-in-Class IKKα Inhibitor on Trabecular and Cortical Bone in a Human Prostate Cancer Xenograft Model.
Calcified tissue international · 2026 · PMID 42501125
IKKα, a key component of canonical and non-canonical NFκB signalling, is implicated in prostate cancer and bone metabolism. Here, we validated the anti-proliferative effects of selected molecules from a series of first-in-class IKKα inhibitors against a panel of human prostate cancer models and then showed that the potent anti-tumour and highly IKKα-selective SU1349 reduced the ability of human PC3 cells to migrate and invade in vitro, induce osteolysis ex vivo, and cause trabecular bone loss in mice. Paradoxically…
Rank30.0
Vitamin D deficiency alters prostate epithelial differentiation and increases prostate cancer aggressiveness in ex vivo and in vivo models.
Cancer letters · 2026 · PMID 42537900
Here, we examined the consequences of biologically relevant vitamin D deficiency, a known risk factor for aggressive prostate cancer, using ex vivo and in vivo models. Phenotypic and single-cell RNA sequencing of mouse prostate organoids showed that vitamin D deficiency stunted luminal cell differentiation more than androgen deficiency, which is a known driver of prostate development. Mice fed a vitamin D-deficient diet showed significantly altered expression of androgen-responsive genes in their prostate luminal c…
Rank30.0
Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis.
Oncogene · 2026 · PMID 42509416
Immune checkpoint B7-H3 is an emerging target for immunotherapy. DS-7300a is an advanced B7-H3-targeting antibody-drug conjugate (ADC) warheaded with the topoisomerase I inhibitor DXd. DS-7300a has demonstrated clinical activity, but molecular biomarkers to predict its therapeutic response remain elusive. TP53 is one of the most mutated tumor suppressor genes across cancers, and effective therapies are urgently needed for TP53-deficient cancers. Using prostate cancer (PCa) as a model system, we reported that DS-730…
Rank30.0
Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation.
Frontiers in oncology · 2026 · PMID 42535062
BACKGROUND: Novel, radiohybrid, beta-particle-emitting, PSMA-targeted radiopharmaceutical therapy [177Lu]Lu-rhPSMA-10.1 shows promising preclinical and clinical efficacy in prostate cancer. Here, we evaluated [225Ac]Ac-rhPSMA-10.1 as a potential alpha-particle-emitting, PSMA-targeted radiopharmaceutical therapy for prostate cancer. METHODS: Lipophilicity of [225Ac]Ac-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.1 (0.1-0.3 MBq) was assessed by shake-flask method. PSMA-binding affinity (IC50) was evaluated in a competitive bi…
Rank30.0
Balancing Stability and Payload Release in Glutathione-Responsive PROTAC Prodrugs Targeting Prostate Cancer.
JACS Au · 2026 · PMID 42529413
BET-targeting PROteolysis TArgeting Chimeras (PROTACs) outperform their parent inhibitors in preclinical prostate cancer (PCa) models, yet their enhanced potency is expected to amplify dose-limiting on-target toxicities. To widen the therapeutic window, we designed a two-tier selective prodrug strategy enabling glutathione (GSH)-responsive and PCa-targeted delivery of the BET PROTAC MZ1 caged via a carbonate moiety. Our design integrates a prostate-specific membrane antigen (PSMA) ligand with a GSH-cleavable disulf…
Rank30.0
3beta-HSD1-mediated steroid back-conversion maintains androgen signaling in prostate cancer.
Molecular cancer research : MCR · 2026 · PMID 42518214
Dihydrotestosterone (DHT), the principal driver of prostate cancer, is inactivated via reduction of its 3-keto group to a 3β-hydroxyl (3β-OH). 3β-Hydroxysteroid dehydrogenase type 1 (3β-HSD1), encoded by HSD3B1, catalyzes 3β-OH oxidation and is stabilized by an adrenal-permissive germline variant, thereby enhancing androgen biosynthesis. Here, we tested whether 3β-HSD1 maintains androgen receptor (AR) signaling by back-converting the inactive metabolite 3β-androstanediol (3β-diol) to DHT, and whether it similarly o…
Rank30.0
Super enhancer-driven transcriptional reprogramming promotes abiraterone resistance via neuroendocrine transition and ferroptosis evasion in castration-resistant prostate cancer.
Oncogene · 2026 · PMID 42527507
Abiraterone resistance represents a major clinical challenge in the management of castration-resistant prostate cancer (CRPC), yet the epigenetic mechanisms that sustain this resistance remain poorly understood. In particular, how super enhancers (SEs) reprogram transcriptional networks to promote this therapy resistance has not been fully elucidated. Here, by integrating chromatin immunoprecipitation sequencing and transcriptome profiling, we identified aberrantly activated oncogenic SEs that drive the transcripti…
Rank30.0
Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated γ-Sensor Network.
International journal of radiation oncology, biology, physics · 2026 · PMID 41713513
PURPOSE: 177Lu-based radiopharmaceutical therapy (RPT) has shown increasing promise in the treatment of neuroendocrine and metastatic prostate cancer. Delivering optimal radiation dose to tumors while minimizing dose to organs-at-risk (OAR) remains an unmet need because of significant patient-to-patient heterogeneity in treatment response, necessitating multiple snapshots of the in vivo activity distribution. Toward this goal, here we present a high temporal resolution activity reconstruction method demonstrated on…
Rank30.0
From veterinary antibiotic to cancer therapy: revisiting anticancer potential of Monensin.
Molecular biology reports · 2026 · PMID 42530725
Monensin, a polyether ionophore widely used in veterinary medicine, has recently emerged as a multimodal anticancer candidate. This review provides a comprehensive overview of preclinical studies showing that monensin exerts selective cytotoxic and anti-progression effects across a wide range of malignancies. Its activity spans breast cancer to leukemia, reflecting both versatility and significant therapeutic potential. In breast cancer, monensin reduces proliferation, induces apoptosis, and enhances chemosensitivi…
Rank30.0
DNMT3B drives neuroendocrine lineage plasticity and aggressive progression in prostate cancer.
Molecular cancer research : MCR · 2026 · PMID 42530436
Neuroendocrine prostate cancer (NEPC) is an aggressive and therapy-resistant subtype of advanced prostate cancer characterized by poor prognosis and limited treatment options. Enzalutamide, an androgen receptor (AR) pathway inhibitor, is a standard second-line therapy for prostate adenocarcinoma (PrAd). However, enzalutamide resistance (EnzR) promotes not only neuroendocrine differentiation (NED) but also the induction of stemness-associated programs in PrAd cells. We identified the de novo DNA methyltransferase DN…
Rank30.0
Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.
International journal of biological sciences · 2025 · PMID 39990653
Conventional immunotherapy has emerged as a key option for cancer treatment. However, its efficacy has been limited in urological cancers, especially prostate cancer, because of the immunosuppressive tumor microenvironment (TME), difficulty in drug delivery, aberrant immune response, and damage to normal cells. Bispecific antibodies (BsAbs) are engineered proteins with two different antigen-binding domains, designed using different technologies and in various formats. BsAb-based tumor immunotherapy has yielded opti…
Promising Experimental Therapies62 records
Rank99.2
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42096662
PURPOSE: Radium-223 is an α-emitting radiopharmaceutical that improves survival in metastatic castration-resistant prostate cancer (mCRPC). Preclinical data suggest synergy between poly(ADP-ribose) polymerase (PARP) inhibition and radiation. After phase I dose-finding, we conducted a randomized phase II trial to assess efficacy and safety of this combination versus radium-223. PATIENTS AND METHODS: Men with mCRPC and ≥2 bone metastases (BM) were randomly assigned 1:1 to olaparib (200 mg twice daily) plus radium-223…
Rank98.2
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.
Cancer · 2026 · PMID 42319132
BACKGROUND: The combination of olaparib plus radium-223 improved progression-free survival in patients with metastatic castration-resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient-reported outcome (PRO) analysis of this trial is reported. METHODS: Patients were randomized 1:1 to olaparib plus radium-223 (arm A) or radium-223 alone (arm B). PROs were assessed via the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and …
Rank97.0
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.
The Lancet. Oncology · 2026 · PMID 42269655
BACKGROUND: MRI is recommended for men with clinical suspicion of significant prostate cancer. Those with high clinical risk but non-suspicious or equivocal MRI often undergo prostate biopsy, but have a low likelihood of clinically significant prostate cancer, and a high incidence of clinically insignificant prostate cancer. We aimed to investigate whether gallium-68 ([68Ga]Ga)-prostate-specific membrane antigen (PSMA)-11 PET-CT could reduce the number of people requiring prostate biopsy and limit biopsy to targete…
Rank96.5
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41649873
PURPOSE: Clonal hematopoiesis (CH) is a precursor state linked to risk of hematologic neoplasms and may be exacerbated by radiation exposure. We aimed to compare CH prevalence after the new radioligand therapy 177Lu-PSMA-617 versus the alternative standard-of-care cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). EXPERIMENTAL DESIGN: This post hoc correlative analysis used serial blood samples from TheraP (ANZUP 1603), a randomized phase II trial in docetaxel-refractory mCRPC. Cel…
Rank96.4
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.
The Lancet. Oncology · 2026 · PMID 42372744
BACKGROUND: The ARTO trial showed improved early clinical outcomes by adding metastasis-directed therapy (MDT), through stereotactic body radiotherapy (SBRT), to abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer. The aim of this analysis is to explore the long-term impact of MDT on overall survival. METHODS: ARTO was a multicentre, phase 2, randomised trial conducted in 16 academic and community centres across Italy. All patients included were aged 18 years or older and had a diagnos…
Rank95.9
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.
Journal for immunotherapy of cancer · 2026 · PMID 42493213
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is among the leading causes of cancer-related mortality in men worldwide. Treatment options for mCRPC typically include chemotherapy and androgen receptor pathway inhibitors. Immune checkpoint inhibitors (ICIs) have demonstrated a limited effect in mCRPC. We hypothesized that the addition of stereotactic body radiation therapy (SBRT) could enhance immune responses and improve treatment outcomes. METHODS: Patients with mCRPC who had received at leas…
Rank95.8
Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 41927282
The phase 2 LUNAR trial randomized (1:1) patients with oligorecurrent hormone-sensitive prostate cancer to neoadjuvant [177Lu]Lu-PSMA-I&T (2 cycles, 6.8 GBq) followed by stereotactic body radiotherapy (SBRT) versus SBRT alone. [177Lu]Lu-PSMA-I&T before SBRT was well tolerated and significantly improved PSMA PET/CT-based progression-free survival compared with SBRT alone. Here, we report the estimated absorbed doses (AD) of [177Lu]Lu-PSMA-I&T to organs at risk and lesions. Methods: This analysis was conducted on all…
Rank95.5
Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo.
Clinical genitourinary cancer · 2026 · PMID 42303538
BACKGROUND: We previously reported results from a randomized phase 2 trial evaluating a DNA vaccine (pTVG-HP) encoding prostatic acid phosphatase (PAP) versus placebo (GM-CSF vaccine adjuvant alone) in patients with PSA-recurrent, nonmetastatic, noncastrate prostate cancer (NCT01341652). The primary endpoint of 2-year metastasis-free survival (MFS) was not different between the treatment arms. This trial was reopened for long-term evaluation. METHODS AND RESULTS: The median follow-up for long-term overall survival …
Rank94.3
Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.
JAMA internal medicine · 2026 · PMID 42113507
IMPORTANCE: A majority of men with prostate cancer have low-grade cancer and an excellent prognosis after radical prostatectomy. Hypogonadism and associated symptoms impair quality of life in prostate cancer survivors. Many guidelines, citing a lack of randomized clinical trials showing safety and efficacy of testosterone replacement therapy (TRT), consider a history of prostate cancer a contraindication for TRT. OBJECTIVE: To evaluate the short-term safety and efficacy of TRT in prostate cancer survivors with symp…
Rank93.0
Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41587107
PURPOSE: Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis. EXPERIMENTAL DESIGN: We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumor-derived genomic alterations …
Rank92.0
Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation + enzalutamide ± zoledronic acid (BonEnza study).
Bone · 2026 · PMID 42035902
Androgen deprivation therapy has a negative effect on bone mineral density and trabecular bone score in prostate cancer patients. The addition of androgen receptor pathway inhibitors can result in worsened skeletal fragility. BonEnza is a prospective phase II trial in which metastatic hormone sensitive prostate cancer patients were randomized to receive androgen deprivation therapy plus enzalutamide with (EZ arm) or without (E arm) the addition of zoledronic acid. Bone quantity and quality parameters were evaluated…
Rank92.0
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.
Journal for immunotherapy of cancer · 2026 · PMID 42498485
BACKGROUND: Immune checkpoint blockade is minimally active in unselected castration-resistant prostate cancer (CRPC) and does not reproducibly yield durable decreases in prostate-specific antigen (PSA) levels. METHODS: The Quick Efficacy Seeking Trial was designed to employ a combination of agents to initiate an immune response (with BN-Brachyury vaccine), potentiate that response (with nogapendekin-alfa inbakicept (NAI), an interleukin (IL)-15 receptor superagonist), and reduce or eliminate immunosuppressive entit…
Rank90.6
Theory-based dyadic co-learning intervention to enhance family resilience in men with prostate cancer and their spouses in Taiwan: protocol for a randomised controlled trial.
BMJ open · 2026 · PMID 42366001
INTRODUCTION: The diagnosis and treatment of prostate cancer often disrupt patients' and their spouses' established family lives, requiring them to reestablish a sense of balance. This study aims to develop and evaluate a dyadic co-learning intervention derived from the activation-reinforcement-adjustment theory of family resilience for patients with prostate cancer and their spouses. METHODS AND ANALYSIS: An experimental study design was employed. Prostate cancer patients and their spouses (n=60 pairs) will be rec…
Rank85.0
Single-session pelvic prehabilitation improves continence recovery after robot-assisted radical prostatectomy: a prospective comparative study.
Journal of robotic surgery · 2026 · PMID 42474612
Post-robot-assisted radical prostatectomy (RARP) urinary incontinence (PPI) represents the functional complication with the greatest negative impact on the patient's global quality of life (QoL). Although the role of Pelvic Floor Muscle Training (PFMT) is widely established in perioperative clinical management, it is mostly delivered on demand after surgery. This study primarily assesses the clinical efficacy of pelvic prehabilitation when systematically implemented compared with usual care. This is a prospective, …
Rank85.0
Clinical trials in cancer theranostics with potential near-term impact on clinical practice.
The British journal of radiology · 2026 · PMID 39873742
Theranostics has its roots with the first radioiodine therapy for thyroid diseases in about 80 years ago. More recently the field has experienced a remarkable renascence with the regulatory approval of paired imaging and radiopharmaceutical therapy agents in gastroenteropancreatic neuroendocrine tumours and metastatic castration-resistant prostate cancer that are now employed in routine clinical practice. The momentum is strong for identification and testing of new theranostic agents for use in various cancers and …
Rank83.0
Focal therapy using a novel cooled laser device for prostate cancer: early trial results.
BJU international · 2026 · PMID 41601270
OBJECTIVES: To determine the short-term oncological results and safety of the ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT-PC) trial, the first phase II clinical trial of ProFocal® (Medlogical Innovations, Sydney, Australia), a novel, cooled laser focal therapy (cLFT) device for prostate cancer (PCa) treatment. PATIENTS AND METHODS: Men with localised PCa, prostate-specific antigen (PSA) level ≤15 ng/mL, T stage ≤T2c, International Society of Urological Pathology (ISUP) score 2-3 concordant with multip…
Rank81.0
Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42177994
PURPOSE: To evaluate the safety of moderately hypofractionated radiotherapy to the prostate and pelvic elective nodal irradiation (ENI) with intraprostatic and nodal boost in patients with high-risk prostate cancer. METHODS: In this prospective phase 2 single-arm study, patients with high-risk or node-positive prostate cancer received external beam radiotherapy to the prostate and ENI with moderate hypofractionation (60 Gy in 20 fractions to the prostate; 48 Gy ENI) with ADT. Simultaneous integrated boosts were all…
Rank80.6
Hypofractionated versus conventional IMRT in unfavorable intermediate- and high-risk prostate cancer: A phase II comparative study of PSA kinetics, dosimetric and toxicity outcomes.
The French journal of urology · 2026 · PMID 41967586
BACKGROUND: Prostate cancer (PCa) is a leading global malignancy, with unfavorable intermediate-risk (UIR) and high-risk (HR) disease requiring optimized treatment strategies. Hypofractionated intensity-modulated radiotherapy (HF IMRT) has gained attention due to the low α/β ratio of prostate cancer, suggesting enhanced sensitivity to larger fraction sizes. This study compares PSA kinetics, dosimetric and toxicity outcomes between HF IMRT and conventional fractionated IMRT (CF IMRT). METHODS: In this prospective ph…
Rank80.5
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
JCO precision oncology · 2025 · PMID 40865033
PURPOSE: PTEN loss contributes to aberrant signaling of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin pathway and may confer sensitivity to therapies targeting the PI3K pathway. The PIK3CB inhibitor GSK2636771 demonstrated efficacy in tumors with PIK3CB mutations and may similarly show efficacy in patients with PTEN loss. METHODS: Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with ad…
Rank80.5
Safety and efficacy of moderately hypofractionated radiotherapy after radical prostatectomy: A phase II trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42035917
BACKGROUND AND PURPOSE: This single-arm phase II study evaluated the safety and efficacy of moderately hypofractionated radiotherapy (RT) after radical prostatectomy (RP) for prostate cancer in the adjuvant or salvage setting. MATERIALS AND METHODS: Eligible patients were men aged ≥ 20 years who had undergone RP and were scheduled for adjuvant or salvage RT, with an Eastern Cooperative Oncology Group performance status of 0-2 and no prior pelvic RT or distant metastasis. RT consisted of 54 Gy in 18 fractions delive…
Rank80.4
Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
European urology · 2026 · PMID 41904043
BACKGROUND AND OBJECTIVE: Prostate-specific membrane-antigen positron emission tomography (PSMA-PET) has transformed management of prostate cancer biochemical recurrence (BCR) with higher diagnostic accuracy than previous imaging modalities. 64Cu-SAR-bisPSMA PET/computed tomography (CT) (64Cu-bisPSMA) is a bivalent-PSMA-peptide with 12.7-hr half-life. The study objective was detection rate (per-patient) comparison between 64Cu-bisPSMA and 68GaPSMA-11 PET/CT (68Ga-PSMA) in BCR post radical prostatectomy (RP) (NCT069…
Rank80.0
Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41880596
PURPOSE: This multicenter, single-arm, phase II trial evaluated the safety and efficacy of cabazitaxel and carboplatin followed by abiraterone, plus androgen deprivation therapy (ADT), in patients with high-volume metastatic castration-sensitive prostate cancer (mCSPC). PATIENTS AND METHODS: Eligible patients had high-volume mCSPC and ≤3 months of prior ADT. Patients received six 21-day cycles of cabazitaxel (20 mg/m2) and carboplatin (AUC 4) with continuous ADT, followed by maintenance abiraterone (1,000 mg daily)…
Rank80.0
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.
Cancer research communications · 2026 · PMID 42219553
PURPOSE: Ceralasertib is an oral ataxia telangiectasia and Rad3-related (ATR) inhibitor with preclinical activity in ataxia-telangiectasia mutated (ATM)-altered cancers. The phase IIa PLANETTE study evaluated ceralasertib in previously treated advanced solid tumors (cohort A) or metastatic castration-resistant prostate cancer (cohort B) with ATM alterations (ATM mutations and/or ATM protein deficiency). PATIENTS AND METHODS: Patients received ceralasertib 160 mg twice daily on days 1 to 14 of a 28-day cycle. Effica…
Rank79.8
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42208277
BACKGROUND: This phase 1/2 trial evaluated safety, tolerability, pharmacokinetics, and antitumour activity of DEP-cabazitaxel (CTX-SPL9111), a dendrimer-cabazitaxel nanoparticle, in solid tumours. METHODS: Adult patients received DEP-cabazitaxel once every 3 weeks. The primary phase 1 objective was to establish the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). Secondary objectives were to assess safety and tolerability, define the recommended phase 2 dose (RP2D), and evaluate pharmacokinetics an…
Rank77.0
Single-fraction HDR brachytherapy combined with SBRT for intermediate and high-risk prostate cancer: Oncologic and patient-reported outcomes from a prospective phase II study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42264093
PURPOSE: Brachytherapy boost is an established dose-escalation strategy in intermediate- and high-risk prostate cancer, while stereotactic body radiotherapy (SBRT) offers treatment efficiency with favourable radiobiology. We report mature results of a prospective phase II trial combining single-fraction high-dose-rate (HDR) brachytherapy with prostate-only SBRT. MATERIALS AND METHODS: Seventy-six patients with intermediate- or high-risk prostate cancer were enrolled between 2019 and 2021. Treatment consisted of MRI…
Prospective Cohort Studies60 records
Rank107.3
Perirectal spacers and endorectal balloons in external beam radiotherapy for prostate cancer: a review of prospective studies.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026 · PMID 42171762
PURPOSE: Endorectal balloons (ERB) and perirectal spacers (RS) were developed to minimize rectal toxicity in prostate cancer radiotherapy. We conducted a review to assess available data. METHODS AND MATERIALS: Literature search was conducted on 20th May, 2025, using PubMed. Prospective studies and meta-analyses assessing the efficacy of ERB and PRS on rectal toxicity were included. Risk of bias was evaluated (MINORS and Cochrane Risk of Bias). Other relevant publications, guideline recommendations and cost-effectiv…
Rank106.4
Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.
The lancet. Healthy longevity · 2026 · PMID 42320510
BACKGROUND: Whether differences in sex hormones influence cancer risk in men remains uncertain. We aimed to clarify the association of circulating testosterone, sex hormone-binding globulin (SHBG), and related hormones with risks of cancer death, incident cancer, and incident prostate cancer by means of individual participant data (IPD) meta-analyses. METHODS: A systematic review of the literature using MEDLINE, Embase, OpenGrey, and Mednar was conducted from date of database inception till July 22, 2019, with brid…
Rank101.2
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trial.
Contemporary clinical trials · 2026 · PMID 41990428
INTRODUCTION AND OBJECTIVES: Active surveillance is heterogenous using combinations of prostate specific antigen (PSA), digital rectal exam (DRE), magnetic resonance imaging (MRI) and biopsy. Using serial prostate MRI scans during active surveillance to inform when to conduct repeat biopsies might be effective to balance the burden of testing and detecting cancer progression early. IP9-ATLAS aims to determine whether regular MRI scans during active surveillance, compared to current standard of care (clinically-indi…
Rank99.8
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42140755
PURPOSE: /objective: Limited pelvic/para-aortic nodal relapse of prostate cancer after radical local treatment remains a major challenge for locoregional salvage strategies. Salvage Elective Nodes radiotherapy (ENRT) is an appealing option, but concerns persist regarding its toxicity. This study evaluates the 18-months toxicity profile of salvage ENRT combined with intermittent androgen deprivation therapy (iADT) in patients with pelvic and para-aortic oligometastatic disease, compared with iADT alone. MATERIAL: /M…
Rank95.7
The Effect of Virtual Reality Glasses Application on Anxiety, Comfort, and Complication Development During Transrectal Ultrasound-Guided Prostate Biopsy: A Randomized Controlled Study.
Seminars in oncology nursing · 2026 · PMID 41956882
OBJECTIVES: The objective of this investigation was to assess how the implementation of virtual reality glasses (VRG) influences anxiety levels, patient comfort, and the occurrence of complications among individuals undergoing transrectal ultrasound-guided prostate biopsy (TRUS-PB). METHODS: This prospective randomized controlled trial with two parallel arms (1:1 allocation) enrolled 70 TRUS-PB patients. Participants were allocated randomly into VRG (n = 35) and control (n = 35) groups. The VRG group viewed three-d…
Rank95.7
18F-Fluciclovine or 68Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial.
Radiology · 2026 · PMID 42377125
Background PET with gallium 68 (68Ga) prostate-specific membrane antigen (PSMA)-11 and fluorine 18 (18F) fluciclovine has influenced salvage radiation therapy (sRT) planning in postprostatectomy biochemical recurrence. Purpose To assess the comparative impact of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT on sRT changes in postprostatectomy biochemical recurrence. Materials and Methods In this secondary analysis of a prospective randomized controlled trial, men with detectable prostate-specific antigen (PSA) levels af…
Rank92.0
Effect of Transcutaneous Electrical Nerve Stimulation in Transrectal Prostate Biopsy: Randomized Trial.
Pain management nursing : official journal of the American Society of Pain Management Nurses · 2026 · PMID 41702754
PURPOSE: This study aimed to assess the impact of transcutaneous electrical nerve stimulation (TENS) on pain, analgesic consumption, complications and comfort in patients having transrectal ultrasound-guided prostate biopsy (TRUSG-PBx). DESIGN AND METHODS: The study population comprised eighty patients who fulfilled the selection criteria in a two-group, single-blind, single-center, prospective, parallel design of a randomized controlled intervention conducted at a university hospital from January 2021 to March 202…
Rank89.0
Margin evaluation with fluorescence confocal microscopy during minimally invasive radical prostatectomy.
BJU international · 2026 · PMID 41915450
OBJECTIVES: To demonstrate the reliability and diagnostic accuracy of fluorescence confocal microscopy (FCM) analysis of surgical margins during minimally invasive radical prostatectomy (RP). PATIENTS AND METHODS: From January 2022 to February 2023, we enrolled 100 consecutive patients in this single-centre, prospective, non-randomised trial (C2021/32). The VivaScope® 2500M-G4 microscope (Mavig GmbH, Munich, Germany), a laser scanning microscope designed for rapid acquisition of high-resolution digital images, was …
Rank85.0
Single-session pelvic prehabilitation improves continence recovery after robot-assisted radical prostatectomy: a prospective comparative study.
Journal of robotic surgery · 2026 · PMID 42474612
Post-robot-assisted radical prostatectomy (RARP) urinary incontinence (PPI) represents the functional complication with the greatest negative impact on the patient's global quality of life (QoL). Although the role of Pelvic Floor Muscle Training (PFMT) is widely established in perioperative clinical management, it is mostly delivered on demand after surgery. This study primarily assesses the clinical efficacy of pelvic prehabilitation when systematically implemented compared with usual care. This is a prospective, …
Rank85.0
The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol.
BMJ open · 2026 · PMID 42315278
INTRODUCTION: Prostate cancer (PCa) represents a major global health concern due to biological heterogeneity and the complexity of its underlying molecular pathways, which contribute to substantial morbidity and mortality. Ongoing research continues to elucidate distinct molecular mechanisms that may inform diagnostic and therapeutic strategies. Among these, the prostate-specific membrane antigen (PSMA) has emerged as a pivotal biomarker and therapeutic target in PCa. PSMA is indirectly modulated by androgen signal…
Rank82.0
[Early Detection of Prostate Cancer: Current Real-World Data from the VERSUS Study by d-uo].
Aktuelle Urologie · 2026 · PMID 41875916
INTRODUCTION: Since 2018, members of Deutsche Uro-Onkologen (d-uo) have been documenting urological malignancies as part of the prospective VERSUS study. The cancer registry reporting system introduced in Germany in 2015 also includes an additional item for documenting the diagnostic context. We investigated whether differences exist between patients with early-detected and otherwise detected prostate cancer with respect to clinical parameters such as age, PSA, tumor stage, and ISUP grade groups at diagnosis. MATER…
Rank81.0
Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42177994
PURPOSE: To evaluate the safety of moderately hypofractionated radiotherapy to the prostate and pelvic elective nodal irradiation (ENI) with intraprostatic and nodal boost in patients with high-risk prostate cancer. METHODS: In this prospective phase 2 single-arm study, patients with high-risk or node-positive prostate cancer received external beam radiotherapy to the prostate and ENI with moderate hypofractionation (60 Gy in 20 fractions to the prostate; 48 Gy ENI) with ADT. Simultaneous integrated boosts were all…
Rank80.6
Hypofractionated versus conventional IMRT in unfavorable intermediate- and high-risk prostate cancer: A phase II comparative study of PSA kinetics, dosimetric and toxicity outcomes.
The French journal of urology · 2026 · PMID 41967586
BACKGROUND: Prostate cancer (PCa) is a leading global malignancy, with unfavorable intermediate-risk (UIR) and high-risk (HR) disease requiring optimized treatment strategies. Hypofractionated intensity-modulated radiotherapy (HF IMRT) has gained attention due to the low α/β ratio of prostate cancer, suggesting enhanced sensitivity to larger fraction sizes. This study compares PSA kinetics, dosimetric and toxicity outcomes between HF IMRT and conventional fractionated IMRT (CF IMRT). METHODS: In this prospective ph…
Rank80.4
Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
European urology · 2026 · PMID 41904043
BACKGROUND AND OBJECTIVE: Prostate-specific membrane-antigen positron emission tomography (PSMA-PET) has transformed management of prostate cancer biochemical recurrence (BCR) with higher diagnostic accuracy than previous imaging modalities. 64Cu-SAR-bisPSMA PET/computed tomography (CT) (64Cu-bisPSMA) is a bivalent-PSMA-peptide with 12.7-hr half-life. The study objective was detection rate (per-patient) comparison between 64Cu-bisPSMA and 68GaPSMA-11 PET/CT (68Ga-PSMA) in BCR post radical prostatectomy (RP) (NCT069…
Rank80.2
Utility of PSMA PET/CT After an Initial Negative Scan: Results from a Prospective Multicenter PSMA PET Registry.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 41991335
There is a paucity of data on the utility of a second prostate-specific membrane antigen (PSMA) PET/CT scan after an initial negative scan in patients with recurrent prostate cancer. The purpose of this study was to assess the utility of a second PSMA PET/CT scan in these patients. Methods: This cohort comprised patients in the PSMA PET Registry for Recurrent Prostate Cancer in Ontario, Canada, who were recruited in 1 of 6 predefined clinical cohorts between October 2018 and September 2022 who had more than 1 PSMA …
Rank80.0
Cumulative dose analysis following elective pelvis re-irradiation at junction with primary prostate radiotherapy from the OLIGOPELVIS GETUG P07 trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 41825803
OBJECTIVE: Re-irradiation for pelvic lymph node recurrences at junction with primary prostate radiotherapy remains challenging due to the risk of adverse events from excessive cumulative doses. Clear dosimetric constraints for pelvic OAR are currently lacking in this situation. METHODS: The OLIGOPELVIS GETUG P07 prospective Phase 2 trial evaluated elective nodal radiotherapy combined with androgen deprivation therapy in patients with oligorecurrent pelvic lymph nodes. We focused on patients with prior prostate radi…
Rank78.5
Local control in oligometastatic cancer patients following metastasis-directed stereotactic ablative radiotherapy: An interim analysis of ESTRO EORTC E2-RADIatE OligoCare cohort.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42019680
AIM: To evaluate real-world local control outcomes and identify clinical and dosimetric determinants of local progression following metastasis-directed stereotactic ablative radiotherapy (SABR) within the international OligoCare cohort. METHODS: OligoCare is a prospective observational registry (EORTC-ESTRO E2-RADIatE) evaluating SABR for oligometastatic prostate, breast, colorectal, and non-small cell lung cancer (NSCLC). The secondary endpoint, local progression, was defined as recurrence within the planning targ…
Rank78.5
Magnetic resonance imaging-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial.
Cancer · 2026 · PMID 42319125
BACKGROUND: Index lesion-focused ipsilateral systematic biopsy (iSB) has been proposed as a core-reduction alternative to MRI-targeted biopsy combined with systematic biopsy (TB + SB) for prostate cancer, but prospective multicenter validation is limited. METHODS: This prospective multicenter trial (NCT06584279) enrolled biopsy-naive men with Prostate Imaging Reporting and Data System (PI-RADS) ≥4 lesions or PI-RADS 3 plus prostate-specific antigen (PSA) density ≥0.15 ng/mL/cm3. All underwent MRI-targeted biopsy (≥…
Rank78.3
Fat quality, not quantity, linked to reduced risk of advanced and lethal prostate cancer in US populations: a large prospective multicenter study.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 · PMID 41562707
BACKGROUND: Epidemiological evidence on dietary fat intake and advanced prostate cancer (PCa) risk is limited and inconclusive; moreover, no prospective study has been conducted to investigate the association between fat quality and quantity and advanced and lethal PCa risk. METHODS: This prospective cohort included 49 424 men from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. The fat quality index (FQI) and low-fat diet score (LFDs) were used to evaluate the quality and quantity separately, w…
Rank78.1
Volume-adjusted p2PSA-derived indices for predicting prostate cancer: the PROPHET study.
International journal of clinical oncology · 2026 · PMID 42262690
BACKGROUND: This study aimed to assess the diagnostic value of prostate and transition zone (TZ) volume-adjusted p2PSA-derived indices for detecting any and clinically significant prostate cancer (PCa) in the prospective multicenter PROPHET study. METHODS: Among 363 men (median age 68 years, PSA 5.96 ng/mL), total PSA, free PSA, and p2PSA were measured to calculate %p2PSA, p2PSA/%fPSA, and the Prostate Health Index (PHI). Each index was adjusted by prostate or TZ volume. Diagnostic accuracy for any PCa and clinical…
Rank77.1
Comparison of three-lobe and en-bloc techniques during the holmium laser enucleation of the prostate learning curve: a prospective, multicenter, cohort study.
Revista da Associacao Medica Brasileira (1992) · 2026 · PMID 42385050
OBJECTIVE: The aim of this study was to compare the safety and effectiveness of the three-lobe and en-bloc techniques during the learning curve of holmium laser enucleation of the prostate. METHODS: We conducted a prospective, parallel-group, multicenter study that included patients who underwent holmium laser enucleation of the prostate between February and December 2024 at two tertiary urology departments. Patients with prostate volumes ≥80 cm3 scheduled for holmium laser enucleation of the prostate were alternat…
Rank77.0
Single-fraction HDR brachytherapy combined with SBRT for intermediate and high-risk prostate cancer: Oncologic and patient-reported outcomes from a prospective phase II study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42264093
PURPOSE: Brachytherapy boost is an established dose-escalation strategy in intermediate- and high-risk prostate cancer, while stereotactic body radiotherapy (SBRT) offers treatment efficiency with favourable radiobiology. We report mature results of a prospective phase II trial combining single-fraction high-dose-rate (HDR) brachytherapy with prostate-only SBRT. MATERIALS AND METHODS: Seventy-six patients with intermediate- or high-risk prostate cancer were enrolled between 2019 and 2021. Treatment consisted of MRI…
Rank76.9
Circulating Tumor DNA Genomic Profiling in 223Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 41991340
Circulating tumor DNA (ctDNA) testing has emerged as a cancer precision medicine approach. We investigated the genomic landscape and clinical utility of ctDNA in patients receiving 223Ra dichloride for bone metastatic castration-resistant prostate cancer (mCRPC). Methods: This prospective, observational, multicenter study enrolled patients treated with 223Ra for bone mCRPC. Targeted sequencing of cell-free DNA from plasma at baseline and end of treatment (EOT), along with paired leukocyte DNA, was performed using a…
Rank75.2
Diagnostic accuracy of a 'stage-gated' approach for reporting prostate screening MRI: "Is less more?".
European radiology · 2026 · PMID 41711881
OBJECTIVES: To evaluate whether a two-step, 'stage-gated' reporting approach could improve the positive predictive value (PPV) of biparametric (bp)MRI for prostate cancer (PCa) screening compared to conventional Likert/PI-RADS scoring. MATERIALS AND METHODS: This retrospective secondary analysis utilised data from IP1-PROSTAGRAM-a prospective, population-based study of men aged 50-69 years who underwent PCa screening with bpMRI, ultrasound and prostate-specific antigen (PSA) testing between October 2018 and May 201…
Rank75.0
The Multiethnic Cohort: A Resource for the Study of Genetic and Nongenetic Cancer Risk across Populations.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · PMID 42065926
BACKGROUND: The Multiethnic Cohort Study (MEC) is a US prospective cohort of more than 215,000 participants, designed to investigate variation in risk factors and disease across diverse racial and ethnic groups. More than 74,000 participants contributed biospecimens for genetic studies. We describe this subcohort and demonstrate the types of analyses it enables. METHODS: The MEC recruited adults aged 45 to 75 in California and Hawaii between 1993 and 1996. Cancer diagnoses were identified via state tumor registries…
Quality Of Life67 records
Rank104.9
Postoperative survival in patients undergoing surgery for long bone metastases: a systematic review and Meta-analysis of outcomes across primary tumor types.
Journal of bone oncology · 2026 · PMID 42388270
BACKGROUND: Surgery for long bone metastases is performed to alleviate pain, restore function, and improve quality of life. Accurate postoperative survival estimates are essential for surgical planning and shared decision-making, yet no comprehensive synthesis exists across primary tumor types. This systematic review aimed to characterize postoperative survival and its temporal trend in patients undergoing surgery for long bone metastases. METHODS: A systematic literature search was performed in PubMed, EMBASE, and…
Rank102.0
Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.
International journal of cancer · 2026 · PMID 42015666
Prostate cancer overdiagnosis is detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime. It is a major concern to policymakers due to its impact on quality of life. We used long-term follow-up data from the CAP randomised trial of a one-off screen, and English male competing mortality rates (2021-23), to estimate the impact of age on excess prostate cancer incidence within 15 years ('overdiagnosis') using competing-risks methods. In total, 2249 (1…
Rank100.0
Magnetic resonance-guided radiotherapy (MRgRT) and clinical outcomes: A systematic review.
Radiography (London, England : 1995) · 2026 · PMID 42361614
INTRODUCTION: Magnetic resonance-guided radiotherapy (MRgRT) offers potential advantages over conventional computed tomography-guided radiotherapy (CTgRT), however its impact on clinical outcomes remains unclear. METHODS: We systematically reviewed the clinical effectiveness and safety of MRgRT searching three databases and three trial registries through 9 December 2024. Comparative studies were assessed for risk of bias and the certainty of evidence was evaluated. An evidence and gap map was used to visualise avai…
Rank99.0
Radiation-induced erectile dysfunction in prostate cancer: A systematic review of pathophysiology, clinical radiobiology, and predictive modeling.
Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · 2026 · PMID 42468493
BACKGROUND: Radiation-induced erectile dysfunction (RIED) remains one of the most prevalent and distressing late toxicities among prostate cancer survivors. Despite advances in radiation therapy techniques, its underlying mechanisms, dose-response relationships, and predictive modeling strategies are not yet fully understood. METHODS: We searched PubMed/MEDLINE, Web of Science, Scopus, Embase and Cochrane Library from inception to November 10, 2025. Eligible English-language studies included adult prostate cancer p…
Rank98.2
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.
Cancer · 2026 · PMID 42319132
BACKGROUND: The combination of olaparib plus radium-223 improved progression-free survival in patients with metastatic castration-resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient-reported outcome (PRO) analysis of this trial is reported. METHODS: Patients were randomized 1:1 to olaparib plus radium-223 (arm A) or radium-223 alone (arm B). PROs were assessed via the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and …
Rank98.0
Integrative Traditional East Asian Medicine-Based Adjunctive Therapies for Patients With Prostate Cancer Undergoing Standard Cancer Treatment: Protocol for a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
JMIR research protocols · 2026 · PMID 42398929
BACKGROUND: Prostate cancer treatment increasingly emphasizes quality-of-life maintenance alongside oncological control. Integrative Traditional East Asian Medicine (TEAM), including traditional Chinese medicine, traditional Korean medicine, and Kampo medicine, has been used as an adjunctive approach for symptom management during cancer treatment. However, evidence regarding its effectiveness and safety across different disease stages remains heterogeneous and has not been comprehensively synthesized. OBJECTIVE: Th…
Rank97.7
A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy.
European urology focus · 2026 · PMID 41760422
BACKGROUND AND OBJECTIVE: Erectile dysfunction (ED) following radical prostatectomy (RP) has a negative impact on quality of life. Herein, the aim was to assess the effectiveness of autologous adipose-derived regenerative cells (ADRCs) for treating ED after RP. METHODS: This was a randomized, double-blinded, placebo-controlled study. A total of 70 men with ED were enrolled at Odense University Hospital, Denmark. Patients received one intracavernous bolus of ADRCs (n = 35) or placebo (n = 35). The primary endpoint w…
Rank96.9
Evaluating a Tailored Web-Based eHealth Intervention for Symptom Management in Couples Managing Prostate Cancer During the COVID-19 Pandemic: Randomized Clinical Trial.
Journal of medical Internet research · 2026 · PMID 42430132
BACKGROUND: Prostate cancer (PCa) is the most common nonskin cancer among men. Although treatments achieve excellent survival for localized PCa, long-lasting complications significantly diminish patients' quality of life (QOL) across physical, sexual, psychosocial, and general symptom domains. Because these effects also profoundly impact intimate partners, often reducing partners' QOL as much as or more than patients' QOL, supportive care must address the needs of both members of the couple. OBJECTIVE: This study e…
Rank96.3
Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42134662
PURPOSE: Ultra-hypofractionation (UHF) has emerged as a safe and effective strategy; however, its role in prostate cancer (PCa) pelvic nodal irradiation combined with high-dose-rate brachytherapy (HDR-BT) and androgen deprivation therapy (ADT) remains insufficiently defined. PCS-XI (NCT05820633) is a multicentre, phase III randomized trial evaluating pelvic UHF versus conventionally fractionated (CF) radiotherapy. We report a prespecified interim analysis focusing on toxicity and patient-reported outcomes (PROs). M…
Rank96.0
Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy.
The Prostate · 2026 · PMID 42542970
BACKGROUND: Hot flashes are common and often debilitating side effects of castration therapy; a cornerstone in the treatment of metastatic prostate cancer (PCa) as well as in localized or locally advanced PCa when combined with radiotherapy. The evidence for relieving vasomotor symptoms is limited. This systematic review presents both pharmacological and non-pharmacological interventions for treating hot flashes in men with PCa undergoing castration therapy, primarily androgen deprivation therapy (ADT). METHODS: a …
Rank93.9
Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Prostate Biopsy in the Era of Lesion-focused Sampling.
European urology focus · 2026 · PMID 42399176
BACKGROUND AND OBJECTIVE: The transperineal (TP) route is recommended for prostate biopsy due to its superior safety profile. However, randomized evidence comparing the TP and the transrectal (TR) routes was generated through combined targeted and systematic biopsy frameworks, now challenged by lesion-focused strategies, defined as the combination of targeted (TB) and perilesional (PB) sampling without distant systematic cores. This study aimed to reassess the diagnostic performance of TP versus TR biopsy with the …
Rank91.9
Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.
Clinical genitourinary cancer · 2026 · PMID 42509097
BACKGROUND: Head-to-head comparisons between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) have shown comparable survival benefits in patients with castration-resistant prostate cancer (CRPC). However, the quality of life (QoL) associated with these agents has not been directly compared. We conducted a sub-analysis to evaluate longitudinal changes in QoL within each treatment arm. METHODS: The ENABLE study for PCa, an investigator-initiated, multicenter, randomized controlled trial, was performed. Pati…
Rank91.2
Acute Toxicity and Quality of Life With Stereotactic Body Radiation Therapy Versus Conventional Fractionated Intensity Modulated Radiation Therapy to the Prostate and Pelvis in High-Risk Prostate Cancer: A Randomized Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 42431329
PURPOSE: Stereotactic body radiation therapy (SBRT) to the prostate and pelvis in high-risk prostate cancer (HR-PC) may shorten treatment, but acute toxicity and quality of life (QoL) outcomes compared with conventional fractionated intensity modulated radiation therapy (IMRT) remain uncertain. We report acute toxicity and early QoL outcomes from a randomized phase 2 trial. METHODS AND MATERIALS: Between 2019 and 2024, 121 patients with node-negative HR-PC were randomized to SBRT (40 Gy in 5 weekly fractions to pro…
Rank91.2
Mediation analysis of adherence to pelvic floor muscle training and weekly self-monitoring on urinary symptoms in men with localized prostate cancer A secondary analysis of the Prostate Cancer-Patient Empowerment Program (PC-PEP) randomized controlled trial.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026 · PMID 41941257
INTRODUCTION: Men treated curatively for localized prostate cancer often experience urinary complications that impair quality of life. The Prostate Cancer-Patient Empowerment Program (PC-PEP) is a six-month, digital intervention integrating pelvic floor muscle training (PFMT), fitness, nutrition, and intimacy support. While early initiation of PC-PEP improves urinary outcomes, the influence of adherence remains unclear. This mediation analysis examined whether reported PFMT duration and engagement with self-monitor…
Rank90.6
Quality of life results of addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy: NRG Oncology/RTOG 0534 SPPORT.
International journal of radiation oncology, biology, physics · 2026 · PMID 42448001
BACKGROUND: This is the quality of life (QOL) analysis of the SPPORT trial of men with a detectable prostate specific antigen (PSA) after prostatectomy for prostate cancer. Primary analysis established a benefit of adding pelvic lymph node radiotherapy (PLNRT) and short-term androgen deprivation therapy (STADT) to salvage prostate bed radiotherapy (PBRT) for biochemical progression-free survival. METHODS: Subjects were randomized to Arm 1, PBRT, Arm 2, 4-6 months of STADT + PBRT, and Arm 3, PLNRT + STADT + PBRT. QO…
Rank90.1
(Cost-)effectiveness of focal therapy versus radical therapy (standard of care) in the treatment of men with intermediate-risk prostate cancer: study protocol for the ENFORCE focal randomised controlled trial.
BMJ open · 2026 · PMID 42419881
BACKGROUND: Intermediate-risk prostate cancer (PCa) is currently managed with radical whole-gland therapies, such as radical prostatectomy (RP) or radiotherapy (RT). While effective, these treatments can significantly impact quality of life (QoL), particularly in relation to urinary incontinence and erectile dysfunction. Focal therapy poses a promising alternative for whole-gland treatment in this specific patient population; however, current evidence has primarily been limited to phase I and II studies. Robust pro…
Rank89.4
Quality of Life After Postprostatectomy Radiotherapy: A TROG 08.03 RAVES Randomized Controlled Trial Substudy.
European urology oncology · 2026 · PMID 42425869
BACKGROUND AND OBJECTIVE: There is continued uncertainty about whether the timing of radiotherapy (RT) after radical prostatectomy (RP) affects toxicity. This study assesses differences in patient-reported quality of life (QOL) for patients randomized to adjuvant RT (aRT) or salvage RT (sRT) after RP. METHODS: This is a planned secondary analysis of a randomized trial comparing aRT with sRT delivered if prostate-specific antigen increased to >0.2 ng/ml. QOL was measured using the EORTC (European Organization for Re…
Rank88.4
Evaluation of [225Ac]Ac-PSMA-617 vis-a-vis Rechallenge [177Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.
The Prostate · 2026 · PMID 42503230
INTRODUCTION: A subset of prostate cancer progresses to aggressive state of metastatic castration-resistant prostate cancer (mCRPC), wherein multiple therapeutic options demonstrate limited success rates. In this observational study, we aimed to evaluate the efficacy, toxicity, and survival outcomes of (a) [225Ac]Ac-PSMA-617, (b) rechallenge [177Lu]Lu-PSMA-617, (c) cabazitaxel, and (d) oral metronomic cyclophosphamide treatments in postdocetaxel mCRPC patients with progressive disease following initial course of [1…
Rank88.0
Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.
Clinical and translational radiation oncology · 2026 · PMID 42205730
Definitive radiotherapy (RT) for prostate cancer (PC) with dose intensification and/or focal boosting has excellent oncologic outcomes, but many patients experience adverse events. Dose escalation to the whole prostate improves outcomes at the expense of increased late adverse events. Intraprostatic recurrence after definitive RT typically occurs at the site of the primary tumor, suggesting that dose to the site of the dominant lesion is an important predictor of future failure. The efficacy and safety of tumor-foc…
Rank87.0
Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.
European urology · 2026 · PMID 42476886
Patient-reported outcome measures (PROMs) complement oncological endpoints by capturing what matters most to patients. The TrueNTH surgical collaboration presented 1-yr PROMs following robotic prostatectomy using accessible visual formats. We present 5-yr PROMs from the phase 3, international PACE-B trial, which randomised men with localised prostate cancer to stereotactic body radiotherapy (SBRT) or conventionally fractionated radiotherapy (CRT). PROMs are reported from baseline to 5 yr and presented using waffle …
Rank85.0
Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42435817
PURPOSE: The etiology of the improved long-term sexual function seen following MRI-guided stereotactic body radiotherapy (SBRT) with aggressive margin reduction for prostate cancer remains unknown. METHODS AND MATERIALS: To investigate potential explanatory mechanisms for this finding, we conducted a secondary analysis of data collected for the prospective, randomized phase III MIRAGE trial. Dosimetric data for the structures hypothesized to drive sexual function decline (neurovascular bundles (NVB) and internal pu…
Rank85.0
Single-session pelvic prehabilitation improves continence recovery after robot-assisted radical prostatectomy: a prospective comparative study.
Journal of robotic surgery · 2026 · PMID 42474612
Post-robot-assisted radical prostatectomy (RARP) urinary incontinence (PPI) represents the functional complication with the greatest negative impact on the patient's global quality of life (QoL). Although the role of Pelvic Floor Muscle Training (PFMT) is widely established in perioperative clinical management, it is mostly delivered on demand after surgery. This study primarily assesses the clinical efficacy of pelvic prehabilitation when systematically implemented compared with usual care. This is a prospective, …
Rank85.0
β-Glucans, Triterpenes and Nucleoside Analogs of Edible and Medicinal Mushrooms as Complementary Treatment in Diabetes and Cancer-A Review of Evidence from Clinical Trials.
Cancers · 2026 · PMID 42512356
There is a growing interest in preventive and complementary therapies to support health, increase the effectiveness of conventional medical treatments, and improve quality of life (QoL). This review summarizes the effects of β-glucans, triterpenes and nucleoside analogs of edible and/or medicinal mushrooms with results of clinical trials that investigated these effects in diabetes, breast-, prostate-, lung- and colorectal cancer patients. The results support that these components effectively alleviate symptoms and …
Rank81.0
Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42177994
PURPOSE: To evaluate the safety of moderately hypofractionated radiotherapy to the prostate and pelvic elective nodal irradiation (ENI) with intraprostatic and nodal boost in patients with high-risk prostate cancer. METHODS: In this prospective phase 2 single-arm study, patients with high-risk or node-positive prostate cancer received external beam radiotherapy to the prostate and ENI with moderate hypofractionation (60 Gy in 20 fractions to the prostate; 48 Gy ENI) with ADT. Simultaneous integrated boosts were all…
Rank77.0
Single-fraction HDR brachytherapy combined with SBRT for intermediate and high-risk prostate cancer: Oncologic and patient-reported outcomes from a prospective phase II study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42264093
PURPOSE: Brachytherapy boost is an established dose-escalation strategy in intermediate- and high-risk prostate cancer, while stereotactic body radiotherapy (SBRT) offers treatment efficiency with favourable radiobiology. We report mature results of a prospective phase II trial combining single-fraction high-dose-rate (HDR) brachytherapy with prostate-only SBRT. MATERIALS AND METHODS: Seventy-six patients with intermediate- or high-risk prostate cancer were enrolled between 2019 and 2021. Treatment consisted of MRI…
Randomized Controlled Trials64 records
Rank109.7
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.
Targeted oncology · 2026 · PMID 42371314
BACKGROUND: Abiraterone (ABI) and enzalutamide (ENZA) are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, their safety and efficacy have not been directly compared in prospective clinical trials. OBJECTIVE: To directly compare their safety and efficacy in prospective clinical trials. PATIENTS AND METHODS: A systematic search was performed in PubMed, Embase, and Cochrane Library databases (CRD42024608496) on 24 June 2025. Eligibility criteria included studies on patients wit…
Rank107.9
The impact of abiraterone and enzalutamide on hypokalemia incidence in patients with prostate cancer: a systematic review and meta-analysis.
BMC cancer · 2026 · PMID 42387420
OBJECTIVE: To systematically evaluate the incidence of hypokalemia associated with novel androgen receptor axis-targeted therapies (ARATs)-specifically abiraterone, enzalutamide, and their combination-in patients with advanced prostate cancer. METHODS: A comprehensive search of PubMed, Embase, and the Cochrane Library was conducted to identify published randomized controlled trials (RCTs). Risk of bias was assessed using the Cochrane Risk of Bias tool. A random-effects model was employed to pool risk ratios (RRs) a…
Rank107.7
Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.
International journal of radiation oncology, biology, physics · 2026 · PMID 41663033
PURPOSE: The association between late toxicity and biochemical recurrence (BCR) after prostate radiation therapy is unclear. We set out to characterize the relationship between late gastrointestinal (GI) and genitourinary (GU) toxicity and BCR among patients receiving conventionally fractionated (CF) or moderately hypofractionated (MHF) prostate radiation therapy. METHODS AND MATERIALS: This was an individual patient data meta-analysis that identified randomized phase 3 trials of CF or MHF prostate radiation therap…
Rank107.2
Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer Outside of Randomized Controlled Trials: A Systematic Review and Meta-Analysis of Prognostic Factors in Real-World Analyses.
Clinical genitourinary cancer · 2026 · PMID 42191465
We aimed to analyze prognostic factors for overall survival (OS) and progression-free survival (PFS) in real-world patients treated with androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPI) for metastatic hormone-sensitive prostate cancer (mHSPC). A systematic literature search was conducted in MEDLINE, Embase, and Web of Science in October 2025. Eligible studies examined prognostic factors for OS or PFS in patients with mHSPC receiving ARPI plus ADT using real-world data. To…
Rank106.6
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for ARPI-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer: a pooled analysis of KEYNOTE-921 and CheckMate 7DX trials.
International urology and nephrology · 2026 · PMID 41741934
BACKGROUND: The optimal treatment strategy for androgen receptor pathway inhibitor (ARPI)-pretreated and chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) remains unclear. Chemotherapy has limited efficacy as a monotherapy in unselected mCRPC patients. In contrast, the addition of PD-1/PD-L1 inhibitors to chemotherapy (Chemo-IO) may enhance antitumor activity. We conducted a meta-analysis using data from phase 3 randomized controlled trials (RCTs), with the objective of assessing the compar…
Rank102.8
Benefits and harms of antiresorptive therapy in men with non-metastatic prostate cancer on androgen deprivation therapy: A systematic review and meta-analysis of randomized controlled trials.
Metabolism: clinical and experimental · 2026 · PMID 42263846
BACKGROUND: Androgen deprivation therapy (ADT) is used as an adjuvant treatment in men with prostate cancer. It is associated with bone loss and increased fracture risk. In this systematic review and meta-analysis, we evaluated the effects of antiresorptives on bone health in men with non-metastatic prostate cancer (nmPCa) on ADT. METHODS: We searched four databases until October 14th 2024 for randomized controlled trials (RCTs) of antiresorptives in men with non-metastatic prostate cancer on ADT. FINDINGS: We incl…
Rank102.4
Effect of combined lifestyle intervention on cardiometabolic risk in cancer survivors: A systematic review and meta-analysis of randomized controlled trials.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42455364
PURPOSE: Unhealthy lifestyle behaviors are significant and adjustable contributors to cardiometabolic abnormalities among cancer survivors. Combined lifestyle interventions (CLIs), addressing multiple behaviors simultaneously, may offer superior cardioprotective effects. This systematic review and meta-analysis synthesized evidence on existing CLIs and evaluated their effectiveness in reducing cardiometabolic risk. METHODS: A comprehensive search was performed in PubMed, Web of Science, EMBASE, CINAHL, the Cochrane…
Rank102.0
Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.
International journal of cancer · 2026 · PMID 42015666
Prostate cancer overdiagnosis is detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime. It is a major concern to policymakers due to its impact on quality of life. We used long-term follow-up data from the CAP randomised trial of a one-off screen, and English male competing mortality rates (2021-23), to estimate the impact of age on excess prostate cancer incidence within 15 years ('overdiagnosis') using competing-risks methods. In total, 2249 (1…
Rank100.0
Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology- and European Randomized Study of Screening for Prostate Cancer-based strategies.
International journal of cancer · 2026 · PMID 41741956
Prostate cancer (PC) screening reduces PC mortality but also causes burden such as overdiagnosis and unnecessary biopsies. The European Association of Urology (EAU) recently proposed a risk-adapted screening protocol incorporating prostate-specific antigen (PSA)-based intervals, a risk calculator (RC), and magnetic resonance imaging (MRI), though its long-term outcomes remain unquantified. We constructed the MIcrosimulation SCreening Analysis-PSA model by adapting the existing MIcrosimulation SCreening Analysis-PRO…
Rank100.0
Magnetic resonance-guided radiotherapy (MRgRT) and clinical outcomes: A systematic review.
Radiography (London, England : 1995) · 2026 · PMID 42361614
INTRODUCTION: Magnetic resonance-guided radiotherapy (MRgRT) offers potential advantages over conventional computed tomography-guided radiotherapy (CTgRT), however its impact on clinical outcomes remains unclear. METHODS: We systematically reviewed the clinical effectiveness and safety of MRgRT searching three databases and three trial registries through 9 December 2024. Comparative studies were assessed for risk of bias and the certainty of evidence was evaluated. An evidence and gap map was used to visualise avai…
Rank100.0
Micro-ultrasonography- vs MRI-targeted biopsy in prostate cancer: Updated systematic review and meta-analysis.
BJU international · 2026 · PMID 41989063
OBJECTIVE: To refine prostate cancer (PCa) pathways by comparing micro-ultrasonography-targeted biopsy (micro-US-TBx) with magnetic resonance imaging (MRI)-TBx for detecting clinically significant PCa (csPCa) and by evaluating diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value). METHODS: The Medical Literature Analysis and Retrieval System Online (MEDLINE; PubMed), Excerpta Medica dataBASE (EMBASE), and ClinicalTrials.gov were searched on 4 July 2025 and updated 5 Au…
Rank99.8
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42140755
PURPOSE: /objective: Limited pelvic/para-aortic nodal relapse of prostate cancer after radical local treatment remains a major challenge for locoregional salvage strategies. Salvage Elective Nodes radiotherapy (ENRT) is an appealing option, but concerns persist regarding its toxicity. This study evaluates the 18-months toxicity profile of salvage ENRT combined with intermittent androgen deprivation therapy (iADT) in patients with pelvic and para-aortic oligometastatic disease, compared with iADT alone. MATERIAL: /M…
Rank99.2
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42096662
PURPOSE: Radium-223 is an α-emitting radiopharmaceutical that improves survival in metastatic castration-resistant prostate cancer (mCRPC). Preclinical data suggest synergy between poly(ADP-ribose) polymerase (PARP) inhibition and radiation. After phase I dose-finding, we conducted a randomized phase II trial to assess efficacy and safety of this combination versus radium-223. PATIENTS AND METHODS: Men with mCRPC and ≥2 bone metastases (BM) were randomly assigned 1:1 to olaparib (200 mg twice daily) plus radium-223…
Rank98.2
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.
Cancer · 2026 · PMID 42319132
BACKGROUND: The combination of olaparib plus radium-223 improved progression-free survival in patients with metastatic castration-resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient-reported outcome (PRO) analysis of this trial is reported. METHODS: Patients were randomized 1:1 to olaparib plus radium-223 (arm A) or radium-223 alone (arm B). PROs were assessed via the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and …
Rank98.0
Integrative Traditional East Asian Medicine-Based Adjunctive Therapies for Patients With Prostate Cancer Undergoing Standard Cancer Treatment: Protocol for a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
JMIR research protocols · 2026 · PMID 42398929
BACKGROUND: Prostate cancer treatment increasingly emphasizes quality-of-life maintenance alongside oncological control. Integrative Traditional East Asian Medicine (TEAM), including traditional Chinese medicine, traditional Korean medicine, and Kampo medicine, has been used as an adjunctive approach for symptom management during cancer treatment. However, evidence regarding its effectiveness and safety across different disease stages remains heterogeneous and has not been comprehensively synthesized. OBJECTIVE: Th…
Rank97.8
Artificial intelligence-assisted reading of non-contrast prostate MRI: application and concordance with expert interpretation in a screening population within the PROSA trial.
European radiology · 2026 · PMID 41686238
OBJECTIVES: Non-contrast MRI (bi-parametric MRI-bpMRI) has been investigated as a potential tool to be integrated in clinically significant prostate cancer (csPCa) screening. Moreover, artificial intelligence (AI) is emerging too as a potential support, especially for less-experienced radiologists. Therefore, the aim of this study was to evaluate the effectiveness of an AI-based software in csPCa screening using bpMRI, with a focus on supporting less-experienced radiologists. MATERIAL AND METHODS: A retrospective a…
Rank97.7
Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up.
Annals of internal medicine · 2026 · PMID 42330502
BACKGROUND: Prostate-specific antigen (PSA) testing to screen for prostate cancer is controversial. An alternative approach, Stockholm3, combines PSA, plasma protein biomarkers, polygenic risk, and clinical factors into a multivariable risk score. OBJECTIVE: To compare detection of clinically significant prostate cancer (csPC) using PSA and Stockholm3 in a population-based screening with short-term follow-up. DESIGN: Secondary analysis of the baseline round of the prospective STHLM3-MRI (Prostate Cancer Screening U…
Rank97.7
A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy.
European urology focus · 2026 · PMID 41760422
BACKGROUND AND OBJECTIVE: Erectile dysfunction (ED) following radical prostatectomy (RP) has a negative impact on quality of life. Herein, the aim was to assess the effectiveness of autologous adipose-derived regenerative cells (ADRCs) for treating ED after RP. METHODS: This was a randomized, double-blinded, placebo-controlled study. A total of 70 men with ED were enrolled at Odense University Hospital, Denmark. Patients received one intracavernous bolus of ADRCs (n = 35) or placebo (n = 35). The primary endpoint w…
Rank97.6
Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42502892
OBJECTIVES: Talazoparib plus enzalutamide improved overall survival (OS) in the biomarker-unselected TALAPRO-2 population, but OS benefit was not statistically significant in the homologous recombination repair (HRR) non-deficient or unknown subgroup, whereas radiographic progression-free survival (rPFS) was prolonged. We explored time-dependent patterns in estimated treatment effects in this subgroup. METHODS: Approximate individual-level data for 636 patients were reconstructed from published Kaplan-Meier curves;…
Rank97.2
Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer.
European urology focus · 2026 · PMID 41826123
Continuous treatment with an androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in low-volume metastatic castration-sensitive prostate cancer (mCSPC) may lead to overtreatment, resulting in increased toxicity and higher costs. Evidence to guide a shorter duration of ARPI therapy is currently lacking. The Apa/Enza-short trial evaluates whether a 12-mo course of apalutamide or enzalutamide is noninferior to continuous treatment in low-volume mCSPC. This randomized, open-label, noninfer…
Rank97.2
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.
JCO precision oncology · 2026 · PMID 42418739
PURPOSE: Metastatic hormone-sensitive prostate cancer (mHSPC) is a heterogeneous disease state with multiple treatment options. Biomarkers are needed for risk stratification and to guide treatment intensification or deintensification. We used a computational histology artificial intelligence-based platform (CHAI) to develop and validate a digital image-only prognostic biomarker in mHSPC with participant-level data from two prospective, phase III randomized controlled trials. METHODS: The CHAI platform extracted qua…
Rank97.0
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.
The New England journal of medicine · 2026 · PMID 42223064
BACKGROUND: A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib to enzalutamide significantly improved imaging-based progression-free survival and overall survival, with the greatest benefit observed in the cohort with alterations in homologous recombination repair genes. METHODS: In this ongoing, phase 3, double-blind trial assessing talazoparib in patients with metastatic…
Rank97.0
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.
The Lancet. Oncology · 2026 · PMID 42269655
BACKGROUND: MRI is recommended for men with clinical suspicion of significant prostate cancer. Those with high clinical risk but non-suspicious or equivocal MRI often undergo prostate biopsy, but have a low likelihood of clinically significant prostate cancer, and a high incidence of clinically insignificant prostate cancer. We aimed to investigate whether gallium-68 ([68Ga]Ga)-prostate-specific membrane antigen (PSMA)-11 PET-CT could reduce the number of people requiring prostate biopsy and limit biopsy to targete…
Rank96.9
Evaluating a Tailored Web-Based eHealth Intervention for Symptom Management in Couples Managing Prostate Cancer During the COVID-19 Pandemic: Randomized Clinical Trial.
Journal of medical Internet research · 2026 · PMID 42430132
BACKGROUND: Prostate cancer (PCa) is the most common nonskin cancer among men. Although treatments achieve excellent survival for localized PCa, long-lasting complications significantly diminish patients' quality of life (QOL) across physical, sexual, psychosocial, and general symptom domains. Because these effects also profoundly impact intimate partners, often reducing partners' QOL as much as or more than patients' QOL, supportive care must address the needs of both members of the couple. OBJECTIVE: This study e…
Rank96.5
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41649873
PURPOSE: Clonal hematopoiesis (CH) is a precursor state linked to risk of hematologic neoplasms and may be exacerbated by radiation exposure. We aimed to compare CH prevalence after the new radioligand therapy 177Lu-PSMA-617 versus the alternative standard-of-care cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). EXPERIMENTAL DESIGN: This post hoc correlative analysis used serial blood samples from TheraP (ANZUP 1603), a randomized phase II trial in docetaxel-refractory mCRPC. Cel…
Safety And Adverse Effects83 records
Rank110.0
Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management.
The Journal of urology · 2026 · PMID 42095477
PURPOSE: This Guideline covers the treatment of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). The summary presented herein represents Part II of the three-part series dedicated to Management of LUTS attributed to BPH. Please refer to Parts I and III for additional information on this topic. MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic …
Rank109.7
Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.
Targeted oncology · 2026 · PMID 42371314
BACKGROUND: Abiraterone (ABI) and enzalutamide (ENZA) are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, their safety and efficacy have not been directly compared in prospective clinical trials. OBJECTIVE: To directly compare their safety and efficacy in prospective clinical trials. PATIENTS AND METHODS: A systematic search was performed in PubMed, Embase, and Cochrane Library databases (CRD42024608496) on 24 June 2025. Eligibility criteria included studies on patients wit…
Rank107.3
Perirectal spacers and endorectal balloons in external beam radiotherapy for prostate cancer: a review of prospective studies.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026 · PMID 42171762
PURPOSE: Endorectal balloons (ERB) and perirectal spacers (RS) were developed to minimize rectal toxicity in prostate cancer radiotherapy. We conducted a review to assess available data. METHODS AND MATERIALS: Literature search was conducted on 20th May, 2025, using PubMed. Prospective studies and meta-analyses assessing the efficacy of ERB and PRS on rectal toxicity were included. Risk of bias was evaluated (MINORS and Cochrane Risk of Bias). Other relevant publications, guideline recommendations and cost-effectiv…
Rank106.6
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for ARPI-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer: a pooled analysis of KEYNOTE-921 and CheckMate 7DX trials.
International urology and nephrology · 2026 · PMID 41741934
BACKGROUND: The optimal treatment strategy for androgen receptor pathway inhibitor (ARPI)-pretreated and chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) remains unclear. Chemotherapy has limited efficacy as a monotherapy in unselected mCRPC patients. In contrast, the addition of PD-1/PD-L1 inhibitors to chemotherapy (Chemo-IO) may enhance antitumor activity. We conducted a meta-analysis using data from phase 3 randomized controlled trials (RCTs), with the objective of assessing the compar…
Rank106.4
The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.
Human vaccines & immunotherapeutics · 2026 · PMID 41672480
Some immune checkpoint inhibitors (ICI) has been used for men with specific metastatic castration-resistant prostate cancer (mCRPC). However, inconsistent results of ICI for unselected mCRPC population raise concerns. The primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS), and the secondary outcomes included objective response rate (ORR). Individual patient data (IPD) were reconstructed from reported survival curve, and Kaplan-Meier method was used to evaluate the efficacy.…
Rank103.0
Feasibility and Safety of Same-say Discharge after Robot-assisted Radical Prostatectomy: A Systematic Review and Meta-analysis.
European urology focus · 2026 · PMID 42331644
BACKGROUND AND OBJECTIVE: Same-day discharge (SDD) after robot-assisted radical prostatectomy (RARP) is increasingly adopted as a standard of care. This systematic review and meta-analysis assess the safety and effectiveness of SDD compared with conventional inpatient (IP) management. METHODS: A literature search was conducted in accordance with PRISMA guidelines using PubMed/MEDLINE, Embase, Web of Science, and Scopus databases up to February 2025, including only comparative studies reporting on SDD versus IP RARP…
Rank102.8
Benefits and harms of antiresorptive therapy in men with non-metastatic prostate cancer on androgen deprivation therapy: A systematic review and meta-analysis of randomized controlled trials.
Metabolism: clinical and experimental · 2026 · PMID 42263846
BACKGROUND: Androgen deprivation therapy (ADT) is used as an adjuvant treatment in men with prostate cancer. It is associated with bone loss and increased fracture risk. In this systematic review and meta-analysis, we evaluated the effects of antiresorptives on bone health in men with non-metastatic prostate cancer (nmPCa) on ADT. METHODS: We searched four databases until October 14th 2024 for randomized controlled trials (RCTs) of antiresorptives in men with non-metastatic prostate cancer on ADT. FINDINGS: We incl…
Rank97.7
A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy.
European urology focus · 2026 · PMID 41760422
BACKGROUND AND OBJECTIVE: Erectile dysfunction (ED) following radical prostatectomy (RP) has a negative impact on quality of life. Herein, the aim was to assess the effectiveness of autologous adipose-derived regenerative cells (ADRCs) for treating ED after RP. METHODS: This was a randomized, double-blinded, placebo-controlled study. A total of 70 men with ED were enrolled at Odense University Hospital, Denmark. Patients received one intracavernous bolus of ADRCs (n = 35) or placebo (n = 35). The primary endpoint w…
Rank97.2
Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer.
European urology focus · 2026 · PMID 41826123
Continuous treatment with an androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in low-volume metastatic castration-sensitive prostate cancer (mCSPC) may lead to overtreatment, resulting in increased toxicity and higher costs. Evidence to guide a shorter duration of ARPI therapy is currently lacking. The Apa/Enza-short trial evaluates whether a 12-mo course of apalutamide or enzalutamide is noninferior to continuous treatment in low-volume mCSPC. This randomized, open-label, noninfer…
Rank96.3
Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42134662
PURPOSE: Ultra-hypofractionation (UHF) has emerged as a safe and effective strategy; however, its role in prostate cancer (PCa) pelvic nodal irradiation combined with high-dose-rate brachytherapy (HDR-BT) and androgen deprivation therapy (ADT) remains insufficiently defined. PCS-XI (NCT05820633) is a multicentre, phase III randomized trial evaluating pelvic UHF versus conventionally fractionated (CF) radiotherapy. We report a prespecified interim analysis focusing on toxicity and patient-reported outcomes (PROs). M…
Rank96.0
A narrative review: key evidence from meta-analyses in nuclear medicine.
Annals of nuclear medicine · 2026 · PMID 41944968
Recent progress in nuclear medicine has been driven by continuous advances in radiotracers, imaging technologies, and radiopharmaceutical therapies, leading to an expansion of clinical applications supported by an increasing body of evidence. In particular, systematic reviews and meta-analyses have played an important role in quantitatively evaluating the clinical value of these developments. This narrative review provides an overview of recent meta-analytic evidence in nuclear medicine, with a primary focus on onc…
Rank92.2
Superior cancer detection with transperineal biopsy in patients with an elevated prostate-specific antigen level and a PI-RADS score of 3-4: A retrospective cohort study.
Oncology letters · 2026 · PMID 42416028
The early and accurate detection of prostate cancer remains pivotal for improving clinical outcomes. The present study aimed to compare the cancer detection rates (CDRs) and safety profiles of transperineal (TP) vs. transrectal (TR) prostate biopsy techniques in patients with elevated prostate-specific antigen (PSA) levels and magnetic resonance imaging findings suggestive of malignancy (Prostate Imaging Reporting and Data System score 3 or 4). A retrospective cohort study was conducted on 127 patients who underwen…
Rank92.2
A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 42532645
OPTIMAL-PSMA aims to determine the safety and efficacy of a dose-intensified (intense induction followed by a maintenance period) regimen of [177Lu]Lu-PSMA-597 compared with the standard-of-care regimen (every 6 wk for up to 6 doses) in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: OPTIMAL-PSMA is a phase 2, open-label, 2-arm, multicenter, randomized controlled trial of [177Lu]Lu-PSMA-597, a novel prostate-specific membrane antigen (PSMA) peptide with low nontarget organ dosimetry.…
Rank91.2
Acute Toxicity and Quality of Life With Stereotactic Body Radiation Therapy Versus Conventional Fractionated Intensity Modulated Radiation Therapy to the Prostate and Pelvis in High-Risk Prostate Cancer: A Randomized Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 42431329
PURPOSE: Stereotactic body radiation therapy (SBRT) to the prostate and pelvis in high-risk prostate cancer (HR-PC) may shorten treatment, but acute toxicity and quality of life (QoL) outcomes compared with conventional fractionated intensity modulated radiation therapy (IMRT) remain uncertain. We report acute toxicity and early QoL outcomes from a randomized phase 2 trial. METHODS AND MATERIALS: Between 2019 and 2024, 121 patients with node-negative HR-PC were randomized to SBRT (40 Gy in 5 weekly fractions to pro…
Rank90.0
Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 42532646
This is a dosimetry analysis of the prospective randomized phase 2 trial RESIST-PC which evaluated the efficacy and safety of 2 injected activity regimens of [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer. Methods: This biinstitutional study randomized patients with metastatic castration-resistant prostate cancer to receive either 6.0 or 7.4 GBq of [177Lu]Lu-PSMA-617 per cycle for up to 4 cycles (1:1 randomization). The γ-images were obtained at the first cycle using…
Rank89.3
EMPTY-RT: A Phase 2 Trial of Prostate Stereotactic Body Radiotherapy with an Empty Bladder Approach.
International journal of radiation oncology, biology, physics · 2026 · PMID 42537851
PURPOSE: To evaluate the feasibility and dosimetric safety of prostate stereotactic radiotherapy (SBRT) with an empty bladder approach. METHODS: Eligible patients had histologically confirmed prostate cancer and planned for SBRT (35-36.25 Gy/5# to prostate ± 25 Gy to pelvic nodes, alternate days or once-weekly). Participants voided immediately before planning CT scan and each SBRT fraction. Interfraction bladder volume variability was evaluated with on-board cone beam CT. Primary endpoint was the rate of acute urin…
Rank85.0
Investigation of a prostate cancer radiation response signature in the breast cancer SweBCG91RT randomized trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42531378
PURPOSE: PORTOS is a 24-gene radiation response signature developed and validated in multiple randomized trials in prostate cancer. Given its basis in general radiation and DNA damage response pathways, we sought to evaluate whether PORTOS could also predict RT benefit in breast cancer. METHODS: PORTOS scores were calculated from gene expression profiles of 765 tumor samples from SweBCG91RT, a randomized trial of adjuvant whole-breast RT versus observation following breast-conserving surgery in node-negative stage …
Rank85.0
Therapy Optimization in mHSPC: Insights from a Multidisciplinary Uro-Oncology Expert Panel.
Advances in therapy · 2026 · PMID 42176182
Metastatic hormone-sensitive prostate cancer (mHSPC) is a disease state characterized by the presence of distant metastases detectable on conventional imaging while the tumor remains responsive to androgen deprivation therapy (ADT). It represents an earlier, treatment-sensitive phase that precedes the development of metastatic castration-resistant prostate cancer (mCRPC), the terminal stage of the disease. The addition of therapies beyond traditional ADT to achieve more sustained tumor regression by combining diffe…
Rank85.0
Pelvic lymph node dissection in prostate cancer: current evidence, controversies, and future directions.
Annals of medicine · 2026 · PMID 41999318
BACKGROUND: Pelvic lymph node dissection (PLND) remains controversial in the management of prostate cancer. Although it provides the most accurate pathological staging, its therapeutic value beyond staging has long been debated due to conflicting evidence and concerns regarding procedure-related morbidity. OBJECTIVE: To critically evaluate the contemporary role of PLND, particularly extended pelvic lymph node dissection (ePLND), in prostate cancer management in the context of modern imaging, risk stratification too…
Rank81.0
Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42177994
PURPOSE: To evaluate the safety of moderately hypofractionated radiotherapy to the prostate and pelvic elective nodal irradiation (ENI) with intraprostatic and nodal boost in patients with high-risk prostate cancer. METHODS: In this prospective phase 2 single-arm study, patients with high-risk or node-positive prostate cancer received external beam radiotherapy to the prostate and ENI with moderate hypofractionation (60 Gy in 20 fractions to the prostate; 48 Gy ENI) with ADT. Simultaneous integrated boosts were all…
Rank80.5
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
JCO precision oncology · 2025 · PMID 40865033
PURPOSE: PTEN loss contributes to aberrant signaling of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin pathway and may confer sensitivity to therapies targeting the PI3K pathway. The PIK3CB inhibitor GSK2636771 demonstrated efficacy in tumors with PIK3CB mutations and may similarly show efficacy in patients with PTEN loss. METHODS: Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with ad…
Rank78.0
An interpretable 1⁸F-PSMA PET/CT-MRI model for optimizing prostate biopsy decisions.
European journal of nuclear medicine and molecular imaging · 2026 · PMID 42176196
PURPOSE: Distinguishing indolent from clinically significant prostate cancer (csPCa) in biopsy-naïve men remains a diagnostic challenge, often leading to unnecessary biopsies. This study aimed to develop and externally validate an interpretable multimodal model integrating 18F-PSMA PET/CT, mpMRI, and clinical variables to predict csPCa and optimize biopsy decision-making. METHODS: This multicenter retrospective study analyzed 302 biopsy-naïve patients derived from a prospective multicenter cohort. Radiomic features…
Rank77.9
Transperineal cognitive versus trans-rectal fusion biopsy under local anesthesia: multicenter outcomes in detection rates, complications, and feasibility.
International urology and nephrology · 2026 · PMID 41678101
OBJECTIVE: This multi-center retrospective study aimed to compare the diagnostic efficacy, safety, and procedural feasibility of trans-perineal cognitive biopsy (TPC) and trans-rectal-MRI fusion biopsy (TRF), both performed under local anesthesia, in patients with suspected prostate cancer. MATERIALS AND METHODS: A total of 634 biopsy-naïve patients with PI-RADS ≥3 lesions on multi-parametric MRI were included. Among them, 284 patients underwent TRF and 350 underwent TPC across two tertiary centers between January …
Rank77.8
Efficacy, Safety, and Cost-Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Study.
The Prostate · 2026 · PMID 42190045
BACKGROUND: The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs. Dose reduction has been proposed as a potential strategy to improve tolerability and reduce costs; however, the efficacy, safety, and cost-effectiveness of reduced-dose ARSIs in patients with nmCRPC re…
Rank77.8
Biochemical control and 2-year tolerability following stereotactic body radiotherapy for localized prostate cancer: a multicenter study in Spain.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41653361
PURPOSE: To assess 2-year biochemical control, radiological progression, late side effects, and survival outcomes following stereotactic body radiotherapy (SBRT) for localized prostate cancer in a multicenter Spanish cohort. METHODS: A total of 250 patients with localized prostate cancer treated with SBRT across 12 Spanish centers between January 2020 and December 2023 were analyzed. Biochemical recurrence was defined according to the Phoenix criterion (nadir PSA + 2 ng/mL). Late genitourinary (GU), gastrointestina…
Treatments That Failed Clinical Trials60 records
Rank100.2
Metformin Active Surveillance Trial in Low-Risk Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · PMID 41166665
PURPOSE: Active surveillance (AS) is a standard management strategy for low-risk prostate cancer (PCa), but a significant proportion of patients ultimately experience disease progression. Metformin, a commonly prescribed antidiabetic agent, has demonstrated antitumor activity in preclinical studies and observational data, prompting investigation into its potential to delay PCa progression. PATIENTS AND METHODS: The Metformin Active Surveillance Trial (MAST) was a multicenter, randomized, double-blind, placebo-contr…
Rank99.9
Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy.
Med (New York, N.Y.) · 2026 · PMID 42127891
BACKGROUND: Severe neutropenia (grade ≥3) is a major adverse event in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving triplet therapy. The purpose of this study was to investigate the influence of lead-in androgen-deprivation therapy (ADT) on the incidence of grade ≥3 neutropenia. METHODS: This post hoc analysis of the ARASENS phase 3 trial compared patients with and without lead-in ADT. Inverse probability of treatment weighting (IPTW) balanced baseline characteristics. The primary end…
Rank99.7
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.
The Lancet. Oncology · 2026 · PMID 42061373
BACKGROUND: Serum prostate-specific antigen (PSA) concentrations decrease after hormone therapy for prostate cancer, with the nadir serving as a potentially useful prognostic biomarker. To support clinical use, we evaluated the association between PSA nadir values and survival outcomes, stratified by pre-treatment metastatic volume or, in patients with non-metastatic cancer, stratified by lymph node status. METHODS: As part of the STAMPEDE platform trial, patients with metastatic or very high-risk non-metastatic pr…
Rank99.3
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42161369
OBJECTIVES: The ENABLE study, an investigator-initiated, multicenter, randomized controlled trial, demonstrated comparable survival benefits between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) for castration-resistant prostate cancer (CRPC). Because randomized controlled trials typically exclude patients with a history of other cancers (HOCs), we evaluated the efficacy of these agents in this population. METHODS: This sub-analysis was conducted as a post hoc analysis using data from the ENABLE study.…
Rank99.1
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.
European urology oncology · 2026 · PMID 41033927
BACKGROUND AND OBJECTIVE: Whether cabazitaxel or an androgen receptor pathway inhibitor (ARPI) is the optimal treatment option for poor-prognosis metastatic castration-resistant prostate cancer (mCRPC), progressing on docetaxel, remains unclear. There are limited prospective data supporting a preference for one of these treatments and few candidate biomarkers to inform individual patient management. This study aims to compare the clinical efficacy of cabazitaxel versus ARPIs in patients with poor-prognosis mCRPC wh…
Rank98.6
Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility.
Scandinavian journal of urology · 2026 · PMID 41778764
OBJECTIVE: This study aimed to compare test sensitivity for detecting aggressive prostate cancer and test specificity (measured by reduction in prostate biopsies) between algorithm-triage and standard systematic biopsy in elderly men with suspected prostate cancer. METHODS: This randomised controlled trial enrolled men ≥ 70 years old suspected of prostate cancer and randomised them 1:1 to algorithm-triage or standard systematic biopsies. The algorithm arm used a 10-gene mRNA panel from urine and plasma samples, int…
Rank98.6
The effect of povidone-iodine-enhanced rectal enema on procedure-related infectious complications before transrectal ultrasound-guided prostate biopsy: A prospective randomized study.
Medicine · 2026 · PMID 42152336
BACKGROUND: To prospectively evaluate the effects of rectal cleansing using a povidone-iodine (PI) and PI enhanced rectal enema on procedure-related infectious complications in patients undergoing transrectal prostate biopsy. METHODS: Between September 2023 and March 2024, patients scheduled for their first transrectal ultrasound-guided prostate biopsy due to elevated prostate-specific antigen levels, suspicious multiparametric prostate magnetic resonance imaging findings, or abnormal digital rectal examination wer…
Rank98.6
Functional outcomes of hypothermic robot assisted radical prostatectomy using BELLOCOOL in a randomized controlled trial.
Scientific reports · 2025 · PMID 41291046
Hypothermia during robot-assisted radical prostatectomy (RARP) has been proposed to enhance functional recovery. This study aimed to assess the efficacy of BELLOCOOL-induced hypothermic RARP for improving urinary continence and erectile function. A total of 200 patients with cT1-T3aN0M0 prostate cancer, eligible for bilateral nerve-sparing surgery, were enrolled across three tertiary centers and randomized 1:1. Stratification was based on International Index of Erectile Function (IIEF-5) scores (≥ 12). The primary …
Rank98.4
Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.
JAMA oncology · 2025 · PMID 41100113
IMPORTANCE: Cribriform prostate cancer is associated with poor outcomes; however, its optimal treatment strategy remains unclear in the absence of randomized data. OBJECTIVE: To retrospectively analyze the results of the PROTECT randomized clinical trial to establish the association between cribriform-positive and cribriform-negative prostate cancer and 15-year risk of metastasis in patients who underwent active monitoring, surgery, or radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: Between 1999 and 2009, the PROT…
Rank98.4
Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.
BJU international · 2026 · PMID 41896701
OBJECTIVES: To retrospectively analyse the results of the Prostate Testing for Cancer and Treatment (ProtecT; ClinicalTrials.gov identifier: NCT02044172) trial to establish the association between cribriform-positive and -negative prostate cancer (PCa) and the 15-year risk of metastasis or death from PCa in patients who underwent radical prostatectomy (RP). PATIENTS AND METHODS: Between 1999 and 2009, the ProtecT phase 3 clinical trial enrolled 1643 men with clinically localised PCa who were randomised to receive a…
Rank98.2
Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer.
European urology oncology · 2026 · PMID 40335398
BACKGROUND AND OBJECTIVE: The PROFIT trial was designed to compare moderately hypofractionated (HF) radiotherapy versus conventional fractionation (CF) for patients with intermediate-risk prostate cancer (IR-PC). Similar efficacy and toxicity outcomes were previously reported. The aim of the current analysis was to evaluate differences in long-term patient-reported outcomes (PROs) between the HF and CF arms in PROFIT. METHODS: For the PROFIT phase 3 randomized clinical trial, patients with IR-PC (n = 1206) were enr…
Rank98.2
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.
Cancer · 2026 · PMID 42319132
BACKGROUND: The combination of olaparib plus radium-223 improved progression-free survival in patients with metastatic castration-resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient-reported outcome (PRO) analysis of this trial is reported. METHODS: Patients were randomized 1:1 to olaparib plus radium-223 (arm A) or radium-223 alone (arm B). PROs were assessed via the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and …
Rank98.2
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · PMID 40239134
PURPOSE: Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration. METHODS: A multimodal artificial intelligence (MMAI)-derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data (age, prostate-specific antigen, Gleason, and T stage) from six NRG Oncology phase III randomized rad…
Rank98.1
Cost Effectiveness of Local Anaesthetic Transperineal Versus Transrectal Biopsy: Results from the TRANSLATE Study.
European urology focus · 2026 · PMID 41387023
BACKGROUND AND OBJECTIVE: A local anaesthetic ultrasound-guided transperineal (LATP) prostate biopsy has advantages over transrectal ultrasound (TRUS)-guided biopsy, with improved magnetic resonance imaging (MRI)-guided prostate cancer detection and lower rates of infection-related complications. However, uncertainty remains regarding the cost effectiveness of an LATP biopsy compared with a TRUS biopsy. METHODS: Between December 2021 and September 2023, the TRANSLATE randomised clinical trial allocated 1126 men to …
Rank97.9
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115).
International journal of radiation oncology, biology, physics · 2025 · PMID 40712984
PURPOSE: NRG/RTOG 1115 was a phase 3 trial evaluating the addition of orteronel, a CYP17A1 inhibitor, to radiation therapy (RT) plus androgen deprivation therapy (ADT) in men with high-risk prostate cancer. METHODS AND MATERIALS: The study was designed to evaluate overall survival for 900 men with high-risk prostate cancer (Gleason 9-10, prostate specific antigen (PSA) > 20, or clinical stage T2 or higher with Gleason ≥ 8). Patients were randomized 1:1 to standard of care (SOC) therapy (RT plus 2 years of ADT) or S…
Rank97.7
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.
Clinical and translational science · 2025 · PMID 41346252
Enzalutamide and abiraterone are hormonal treatments that improve survival in metastatic castration-resistant prostate cancer. Identifying genetic variants associated with the clearance of these drugs may aid in improved dosing and outcomes. We performed genetic association studies of enzalutamide and abiraterone oral clearance in the Alliance A031201 clinical trial. Genome-wide genotyping was performed with the primary analysis limited to European-descent participants. Pharmacogene metabolic phenotypes were estima…
Rank97.7
Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up.
Annals of internal medicine · 2026 · PMID 42330502
BACKGROUND: Prostate-specific antigen (PSA) testing to screen for prostate cancer is controversial. An alternative approach, Stockholm3, combines PSA, plasma protein biomarkers, polygenic risk, and clinical factors into a multivariable risk score. OBJECTIVE: To compare detection of clinically significant prostate cancer (csPC) using PSA and Stockholm3 in a population-based screening with short-term follow-up. DESIGN: Secondary analysis of the baseline round of the prospective STHLM3-MRI (Prostate Cancer Screening U…
Rank97.7
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.
JCO precision oncology · 2026 · PMID 42114035
PURPOSE: In the PROpel study (ClinicalTrials.gov identifier: NCT03732820), olaparib plus abiraterone demonstrated statistically significant radiographic progression-free survival benefit versus placebo plus abiraterone in a first-line metastatic castration-resistant prostate cancer (mCRPC) population unselected by homologous recombination repair gene mutation (HRRm) status. From PROpel, we report exploratory biomarker analyses assessing HRRm and BRCA1 and/or BRCA2 (BRCAm) status using tumor tissue and plasma-derive…
Rank97.7
A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy.
European urology focus · 2026 · PMID 41760422
BACKGROUND AND OBJECTIVE: Erectile dysfunction (ED) following radical prostatectomy (RP) has a negative impact on quality of life. Herein, the aim was to assess the effectiveness of autologous adipose-derived regenerative cells (ADRCs) for treating ED after RP. METHODS: This was a randomized, double-blinded, placebo-controlled study. A total of 70 men with ED were enrolled at Odense University Hospital, Denmark. Patients received one intracavernous bolus of ADRCs (n = 35) or placebo (n = 35). The primary endpoint w…
Rank97.2
Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.
The Journal of urology · 2026 · PMID 41270377
PURPOSE: The combined targeted and systematic biopsy (CTSBx) was the standard scheme for patients with visible suspicious lesions on MRI in recent years. 2024 European Association of Urology guideline recommended targeted and perilesional biopsy (TPLBx) for the diagnosis of patients with MRI-visible suspicious lesions. This randomized controlled trial aims to comprehensively evaluate the efficacy and safety profiles of TPLBx and CTSBx schemes. MATERIALS AND METHODS: A single-center noninferiority randomized control…
Rank97.1
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial.
European urology · 2026 · PMID 41494929
We report long-term outcomes from the phase 3 SAKK 09/10 trial that randomly assigned men with biochemical progression after radical prostatectomy to conventional-dose (64 Gy) or dose-intensified (70 Gy) salvage radiotherapy (SRT) to the prostate bed without hormonal therapy. The primary endpoint was freedom from biochemical progression (FFBP). Secondary endpoints included clinical progression-free survival (PFS), time to hormonal treatment, overall survival (OS), and late toxicity. Between February 2011 and April …
Rank97.0
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.
European urology oncology · 2026 · PMID 39613566
BACKGROUND AND OBJECTIVE: There is uncertainty regarding the clinical significance of 68Ga-PSMA-11 positron emission tomography (PET) computed tomography (CT) findings in men with prostate cancer. In this prespecified objective of the proPSMA study, we report the prognostic value of PET-defined nodal involvement. METHODS: Men with intermediate- to high-risk prostate cancer (grade group 3-5, prostate-specific antigen [PSA] ≥20 ng/ml, or clinical stage ≥T3) underwent 68Ga-PSMA-11 PET-CT or CT and bone scanning as fir…
Rank97.0
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.
The Lancet. Oncology · 2026 · PMID 42269655
BACKGROUND: MRI is recommended for men with clinical suspicion of significant prostate cancer. Those with high clinical risk but non-suspicious or equivocal MRI often undergo prostate biopsy, but have a low likelihood of clinically significant prostate cancer, and a high incidence of clinically insignificant prostate cancer. We aimed to investigate whether gallium-68 ([68Ga]Ga)-prostate-specific membrane antigen (PSMA)-11 PET-CT could reduce the number of people requiring prostate biopsy and limit biopsy to targete…
Rank96.9
Evaluating a Tailored Web-Based eHealth Intervention for Symptom Management in Couples Managing Prostate Cancer During the COVID-19 Pandemic: Randomized Clinical Trial.
Journal of medical Internet research · 2026 · PMID 42430132
BACKGROUND: Prostate cancer (PCa) is the most common nonskin cancer among men. Although treatments achieve excellent survival for localized PCa, long-lasting complications significantly diminish patients' quality of life (QOL) across physical, sexual, psychosocial, and general symptom domains. Because these effects also profoundly impact intimate partners, often reducing partners' QOL as much as or more than patients' QOL, supportive care must address the needs of both members of the couple. OBJECTIVE: This study e…
Rank96.7
Two Versus Five-Fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial.
Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026 · PMID 41548387
AIMS: DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2) is a phase II randomised controlled trial comparing two ultra-hypofractionated radiotherapy with dominant intraprostatic lesion (DIL) boost: 26 Gy/2F, 32 Gy to DIL vs 36.25 Gy/5F, 40 Gy to DIL, without androgen deprivation therapy (ADT), for prostate cancer. MATERIALS AND METHODS: Patients with low- to favourable-intermediate-risk prostate cancer were randomly assigned to receive either 2 fractions or 5 fractions. Magnetic resonance-guided adaptive…
i
Research information notice
Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.